The undersigned hereby certify that they have read and recommend to the Faculty of Graduate Studies for acceptance a thesis entitled “CANNABINOIDS REGULATE TYPE 1 CANNABINOID RECEPTOR EXPRESSION IN CELL CULTURE MODELS OF HUNTINGTON’S DISEASE” by Robert Laprairie in partial fulfilment of the requirements for the degree of Master of Science.

Dated: July 30 2012

Supervisor: ________________________________

Readers: ________________________________

______________________________

______________________________
DALHOUSIE UNIVERSITY

DATE: July 30 2012

AUTHOR: Robert Laprairie

TITLE: CANNABINOIDS REGULATE TYPE 1 CANNABINOID RECEPTOR EXPRESSION IN CELL CULTURE MODELS OF HUNTINGTON’S DISEASE

DEPARTMENT OR SCHOOL: Department of Pharmacology

DEGREE: MSc. CONVOCATION: October YEAR: 2012

Permission is herewith granted to Dalhousie University to circulate and to have copied for non-commercial purposes, at its discretion, the above title upon the request of individuals or institutions. I understand that my thesis will be electronically available to the public.

The author reserves other publication rights, and neither the thesis nor extensive extracts from it may be printed or otherwise reproduced without the author’s written permission.

The author attests that permission has been obtained for the use of any copyrighted material appearing in the thesis (other than the brief excerpts requiring only proper acknowledgement in scholarly writing), and that all such use is clearly acknowledged.

_______________________________
Signature of Author
# TABLE OF CONTENTS

- List of Tables .......................................................................................................................... vii
- List of Figures ........................................................................................................................... viii
- Abstract ..................................................................................................................................... xi
- List of Abbreviations Used ...................................................................................................... xii
- Acknowledgements .................................................................................................................. xvi

## Chapter 1: Introduction ............................................................................................................. 1

1.1. Clinical characteristics and management of Huntington’s disease (HD) .......... 1
   1.1.1. Genetics of HD ............................................................................................................. 4
1.2. Cellular Effects of Mutant Huntingtin Protein ......................................................... 8
   1.2.1. Treatment of HD ........................................................................................................ 12
1.3. The type 1 Cannabinoid Receptor ................................................................................. 13
   1.3.1. Architecture, Splice Variants, and Isoforms of the *CNRI* Gene .................. 14
   1.3.2. *CB1*-mediated Signal Transduction ................................................................. 18
   1.3.3. The *When* and *Where* of *CB1* Expression .................................................. 21
   1.3.4. *CB1* mRNA Expression is Induced by Inflammation ..................................... 24
   1.3.5. *CB1* Expression is Reduced in the Presence of mHtt ....................................... 25
   1.3.6. *CB1* mRNA Level is Modulated by Cannabinoids ........................................... 27
1.4. Objectives of this Study ....................................................................................................... 29

## Chapter 2: Materials and Methods ......................................................................................... 31

2.1. Animal Care, Tissue Collection, and Preparation ......................................................... 31
2.2. *In situ* Hybridization ....................................................................................................... 33
2.3. STHdh Cell Culture ............................................................................................................ 36
   2.3.1 Serum Deprivation and Drug Treatments .............................................................. 36
2.4. Plasmid Manipulation and Cloning .................................................................................... 39
   2.4.1. pLight_Switch *CNRI* Promoter-*Renilla* Luciferase Construct .................. 40
   2.4.2. Firefly Luciferase Constructs .................................................................................. 41
   2.4.3. pEGFP Construct ..................................................................................................... 42
2.5. Transfection of Vectors into Cells and the Dual Luciferase Assay ............................. 42
2.6. Quantitative Reverse Transcriptase (qRT)-Polymerase Chain Reaction (PCR) ....... 45
   2.6.1. Trizol Harvest of RNA from Cell Culture ............................................................ 45
Chapter 3: Results

3.1. CB₁, Fatty Acid Amide Hydrolase (FAAH), and CB₂ mRNA Levels were Dysregulated in R6/1 and R6/2 HD Transgenic Mice ........................................54
3.2. CNR1 Promoter Activity was Lower in 7/111 and 111/111 Cells Expressing mHtt .65
3.3. CB₁ mRNA Levels were Lower in 7/111 and 111/111 Cells Expressing mHtt ......67
3.4. CB₁ Protein Levels were Lower in 7/111 and 111/111 Cells Expressing mHtt ......71
3.5. Cannabinoid Agonists Increased CB₁ Promoter Activity, mRNA and Protein Levels in 7/7, 7/111, and 111/111 cells ...........................................73
3.6. CB₁ Receptor Localization and Trafficking were Altered in 7/111 and 111/111 Cells Expressing mHtt ..........................................................77
3.7. Cannabinoid Agonists Induced CB₁ Levels Via Functional CB₁ Receptors........83
3.8. Activated CB₁ Receptors Signal Through Akt and NF-κB to Induce CB₁ mRNA Transcription .................................................................93
3.9. Transcriptional Dysregulation in Heterozygous CB₁ Knock-out Mice (CB₁⁺⁻) did not Recapitulate HD Transcriptional Dysregulation .........................96
3.10. Cannabinoid Agonism Improved Cell Functionality and Viability.................103

Chapter 4: Discussion ......................................................................................112
4.1. Hypotheses of this Research ......................................................................112
4.2. The Endocannabinoid System was Dysregulated During HD Progression ........112
4.3. CB₁ mRNA Abundance and Distribution were Developmental Stage-specific .....113
4.4. Cannabinoid Treatment Induced CB₁ Expression in the Presence of mHtt ........115
   4.4.1 Cannabinoid Treatment was Associated with Elevated CB₁ Promoter Activity, mRNA and Protein Levels .............................................115
4.4.2 CB1 Receptor Localization was Altered in the Presence of mHtt............. 116
4.4.3 Cannabinoid Treatment Induced CB1 Expression Via Functional CB1
Receptors ............................................................................................................... 118
4.4.4 CB1 Promoter Activity was Induced by Akt-dependent Activation of
NF-κB .................................................................................................................. 120
4.5. Cannabinoid Treatment Improved Cellular Function ................................. 121
4.6. Elevated CB1 Levels Could Affect GPCR Signaling and Pharmacology ....... 124
4.7 Cannabinoid-mediated Induction of CB1 Receptors may Negatively Feedback onto
Neurotransmitter Release ...................................................................................... 125
4.8 Cannabinoid-mediated Induction of CB1 may Hold Therapeutic Benefit for HD .... 125
4.9 Conclusions and Future Research................................................................. 126

References ............................................................................................................... 129
LIST OF TABLES

Table 1. Sequence, annealing temperatures, and target PCR products of primers used in RT-PCR and qRT-PCR analyses of gene expression .................................................. 32

Table 2. Sequence and target mRNA transcripts of oligonucleotides used for in situ hybridization ................................................................. 34
LIST OF FIGURES

Figure 1. Striatal neurodegeneration during HD progression is cell-specific. .................5
Figure 2. The CB1 gene, CNR1 .................................................................15
Figure 3. The endocannabinoid system (ECS) and CB1 ...........................................20
Figure 4. mRNA hybridization was quantified in several regions of the mouse brain.....37
Figure 5. Several plasmids were transfected into 7/7, 7/111, and 111/111 cells to study
the CB1 promoter activity .............................................................................43
Figure 6. The cellular distribution of CB1 was analyzed by measuring fluorescence
intensity along a line transecting a cell ........................................................49
Figure 7. CB1 mRNA levels were lower and FAAH mRNA levels were higher in HD
mice compared to age-matched wild-type (WT) littermates .......................58
Figure 8. CB1 mRNA levels were lower in the lateral (A), dorsomedial (B), and
ventromedial (C) striatum and cortical neurons (D) of symptomatic R6/1 mice
compared to pre-symptomatic R6/1 mice and age-matched WT littermates ......59
Figure 9. Cortical FAAH mRNA levels were lower in late-stage symptomatic R6/1 mice
than in pre-symptomatic R6/1 mice, but greater than in age-matched WT mice .60
Figure 10. CB1 mRNA levels were lower in the lateral (A), dorsomedial (B), and
ventromedial (C) striatum and cortical neurons (D) of symptomatic R6/2 mice
compared to pre-symptomatic R6/2 mice and age-matched WT littermates ....61
Figure 11. Cortical FAAH mRNA levels were higher in R6/2 mice compared to age-
matched WT littermates .............................................................................62
Figure 12. Striatal CB2 mRNA levels were higher in late-symptomatic R6/2 mice
Compared to pre-symptomatic R6/2 mice and age-matched WT littermates .....63
Figure 13. CB1 mRNA was expressed at highest levels in the primary motor cortex and
dorsal cerebellum inferior colliculus (DCIC), not the lateral striatum, of P1
R6/2 and WT mice ....................................................................................64
Figure 14. Human CB1 promoter (CNR1) activity was lower in the 7/111 and 111/111
cells than 7/7 cells ....................................................................................66
Figure 15. 7/7, 7/111, and 111/111 cells endogenously expressed CB1 mRNA ...........68
Figure 16. β-actin, not HPRT, was a house-keeping gene in 7/7, 7/111, and 111/111 cells. .69
Figure 17. Endogenous CB$_1$ mRNA levels were lowered in the presence of mHtt in post-mitotic 7/111 and 111/111 cells ................................................................. 70

Figure 18. Endogenous CB$_1$ protein levels were lower in 7/111 and 111/111 cells expressing mHtt ................................................................. 72

Figure 19. CNR1 promoter activity was induced by direct (1 μM ACEA) and indirect (1 μM URB-597) cannabinoid agonism in 7/7 and 7/111 cells ...................... 74

Figure 20. CB$_1$ mRNA levels were induced by direct (1 μM ACEA) and indirect (1 μM URB-597) cannabinoid agonism in 7/7, 7/111, and 111/111 cells ............... 75

Figure 21. Direct (1 μM ACEA) cannabinoid agonism induced CB$_1$ protein levels in 7/7, 7/111, and 111/111 cells ................................................................. 78

Figure 22. mHtt does not impair CB$_1$ protein trafficking to the plasma membrane in 7/7, 7/111 and 111/111 cells ................................................................. 79

Figure 23. CB$_1$ protein distribution and response to cannabinoids were similar in 7/7, 7/111, and 111/111 cells despite lower total CB$_1$ abundance in 7/111 and 111/111 cells ................................................................. 81

Figure 24. CB$_1$ protein distribution was altered following cannabinoid agonism (ACEA) or antagonism (O-2050) in 7/7, 7/111, an 111/111 cells ........................................ 82

Figure 25. Induction of CB$_1$ mRNA expression was unique to CB$_1$ agonism ............... 87

Figure 26. CB$_1$ mRNA levels were lower following type 1 HDAC inhibition (1 μM TSA) in 7/7 and 7/111 cells ................................................................. 88

Figure 27. Direct CB$_1$ receptor agonism induced CB$_1$ mRNA levels in 7/7 cells ............... 89

Figure 28. The maximum effect of direct CB$_1$ receptor agonism on CB$_1$ mRNA level occurred 18 h after drug exposure .................................................. 90

Figure 29. O-2050 competitively antagonized CB$_1$ receptor agonist-mediated CB$_1$ mRNA induction in 7/7 cells ................................................................. 91

Figure 30. CB$_1$ mRNA induction was attenuated in the presence of mHtt .................... 92

Figure 31. ERK2 phosphorylation [pERK2(Y204)] was attenuated in the presence of mHtt but Akt phosphorylation [pAkt(S473)] was not ........................................ 98

Figure 32. CB$_1$ receptor agonism induced CB$_1$ promoter activity via NF-κB-dependent signalling ................................................................. 99
Figure 33. CB₁ receptor agonism induced CB₁ and NF-κB promoter activity in a dose-dependent manner ................................................................. 100

Figure 34. PDE1B, Egr-1 and Dynamin mRNA levels were altered in heterozygous CB₁ knock-out mice (CB₁⁺⁻) ........................................................................................................... 101

Figure 35. A 50% decrease in CB₁ mRNA altered gene expression but did not recapitulate HD transcriptional dysregulation ................................................................. 102

Figure 36. Cell viability was reduced in mHtt-expressing cells and improved following cannabinoid treatment ................................................................. 107

Figure 37. Cell viability was visually lower in the presence of mHtt and higher in cells treated with cannabinoids ........................................................................ 108

Figure 38. ATP concentration was lower in the presence of mHtt and higher following cannabinoid treatment ........................................................................ 109

Figure 39. BDNF-2, PGC1α, and DARPP-32 mRNA levels were lower in mHtt-expressing 7/111 and 111/111 cells .................................................................................. 110

Figure 40. BDNF-2 and PGC1α mRNA levels were increased in an ACEA dose-dependent manner in the presence of mHtt ....................................................... 111

Figure 41. Cannabinoid-mediated induction of CB₁ receptor expression in the presence of mHtt .............................................................................................. 122
ABSTRACT

Type 1 cannabinoid receptor (CB₁) levels decline in the striatum of animal models of Huntington’s disease (HD) and in the brains of human patients suffering from HD prior to other pathogenic changes. CB₁ levels can be elevated by treatment with cannabinoids in non-neuronal cells. We wanted to determine: 1) whether cannabinoid treatment could induce CB₁ expression in a striatal cell line, and 2) determine the molecular mechanisms by which cannabinoids and mutant huntingtin regulate CB₁ expression. Treatment of striatal cell lines with CB₁-specific agonists produced a CB₁ receptor-, Akt-, and NF-κB-dependent increase in CB₁ promoter activity and mRNA expression that was attenuated in the presence of mutant huntingtin. Cannabinoid treatment was associated with increased expression of the trophic factor BDNF-2 and the mitochondrial regulator PGC1α in the cell types tested. In vivo, cannabinoids may initiate a positive feedback loop increasing receptor expression and restoring cannabinoid-dependent inhibition of neurotransmitter release.
# LIST OF ABBREVIATIONS USED

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>111/111</td>
<td>STHdh&lt;sup&gt;Q111/Q111&lt;/sup&gt; striatal cells</td>
</tr>
<tr>
<td>2-AG</td>
<td>2-arachidonyl glycerol</td>
</tr>
<tr>
<td>5′ UTR</td>
<td>5′ untranslated region</td>
</tr>
<tr>
<td>7/111</td>
<td>STHdh&lt;sup&gt;Q7/Q111&lt;/sup&gt; striatal cells</td>
</tr>
<tr>
<td>7/7</td>
<td>STHdh&lt;sup&gt;Q7/Q7&lt;/sup&gt; striatal cells</td>
</tr>
<tr>
<td>ACEA</td>
<td>Arachidonyl-2-chloroethylamide</td>
</tr>
<tr>
<td>AEA</td>
<td>Anandamide</td>
</tr>
<tr>
<td>AM-281</td>
<td>1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide</td>
</tr>
<tr>
<td>AM-630</td>
<td>1-[2-(morpholin-4-yl)ethyl]-2-methyl-3-(4-methoxybenzoyl)-6-iodoindole</td>
</tr>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>AP-1</td>
<td>Activator protein 1</td>
</tr>
<tr>
<td>BDNF</td>
<td>Brain-derived neurotrophic factor</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>CalAM</td>
<td>Calcein AM</td>
</tr>
<tr>
<td>CB&lt;sub&gt;1&lt;/sub&gt;</td>
<td>Type 1 cannabinoid receptor</td>
</tr>
<tr>
<td>CB&lt;sub&gt;2&lt;/sub&gt;</td>
<td>Type 2 cannabinoid receptor</td>
</tr>
<tr>
<td>CMV</td>
<td>Cytomegalovirus</td>
</tr>
<tr>
<td>CNR1</td>
<td>Human type 1 cannabinoid receptor gene</td>
</tr>
<tr>
<td>CRE</td>
<td>cAMP response element</td>
</tr>
<tr>
<td>DARPP-32</td>
<td>Dopamine and cAMP-regulated phosphoprotein 32 kDa</td>
</tr>
<tr>
<td>DCIC</td>
<td>Dorsal colliculus and inferior colliculus of the cerebellum</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>E(_{\text{max}})</td>
<td>The maximum effect</td>
</tr>
<tr>
<td>EC(_{50})</td>
<td>50% effective concentration</td>
</tr>
<tr>
<td>eCBs</td>
<td>Endocannabinoids</td>
</tr>
<tr>
<td>ECS</td>
<td>Endocannabinoid system</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylene diaminetetraacetic acid</td>
</tr>
<tr>
<td>Egr-1</td>
<td>Early growth-response protein 1</td>
</tr>
<tr>
<td>ERE</td>
<td>Estrogen response elements</td>
</tr>
<tr>
<td>ERK</td>
<td>Extracellularly-regulated kinase</td>
</tr>
<tr>
<td>EthD-1</td>
<td>Ethidium homodimer-1</td>
</tr>
<tr>
<td>FAAH</td>
<td>Fatty acid amide hydrolase</td>
</tr>
<tr>
<td>GABA</td>
<td>(\gamma)-amino butyric acid</td>
</tr>
<tr>
<td>GPCR</td>
<td>G-protein coupled receptor</td>
</tr>
<tr>
<td>HD</td>
<td>Huntington’s disease</td>
</tr>
<tr>
<td>HDAC</td>
<td>Histone deacetylase</td>
</tr>
<tr>
<td>HPRT</td>
<td>Hypoxanthine ribosyl transferase</td>
</tr>
<tr>
<td>Htt</td>
<td>huntingtin protein</td>
</tr>
<tr>
<td>HU-308</td>
<td>(((1R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol</td>
</tr>
<tr>
<td>I(\kappa)B(\alpha)</td>
<td>Inhibitor of kappa B</td>
</tr>
<tr>
<td>I(\kappa)(\kappa)</td>
<td>I(\kappa)B kinase</td>
</tr>
<tr>
<td>KO</td>
<td>Knock-out</td>
</tr>
<tr>
<td>LB</td>
<td>Luria broth</td>
</tr>
<tr>
<td>mAEA</td>
<td>meth-anandamide</td>
</tr>
<tr>
<td>MAPK</td>
<td>Mitogen-activated protein kinase</td>
</tr>
<tr>
<td>mHtt</td>
<td>mutant huntingtin protein</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>MSN</td>
<td>Medium spiny projection neuron</td>
</tr>
<tr>
<td>N-mHtt</td>
<td>amino-terminal cleavage product of mutant huntingtin protein</td>
</tr>
<tr>
<td>NaB</td>
<td>Sodium butyrate</td>
</tr>
<tr>
<td>NF-κB</td>
<td>Nuclear factor κ light chain B</td>
</tr>
<tr>
<td>NFAT</td>
<td>Nuclear factor of activated T cells</td>
</tr>
<tr>
<td>O-2050</td>
<td>(6aR,10aR)-3-(1-Methanesulfonylamino-4-hexyn-6-yl)-a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran</td>
</tr>
<tr>
<td>OD</td>
<td>Optical density</td>
</tr>
<tr>
<td>P1</td>
<td>Post-natal day 1</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PDE</td>
<td>Phosphodiesterase</td>
</tr>
<tr>
<td>PFA</td>
<td>Paraformaldehyde</td>
</tr>
<tr>
<td>PGC1α</td>
<td>Peroxisome proliferator activated receptor γ co-activator 1α</td>
</tr>
<tr>
<td>polyQ</td>
<td>polyglutamine</td>
</tr>
<tr>
<td>ppENK</td>
<td>Pre-proenkephalin</td>
</tr>
<tr>
<td>RFLP</td>
<td>Restriction fragment length polymorphism</td>
</tr>
<tr>
<td>RT</td>
<td>Reverse transcriptase</td>
</tr>
<tr>
<td>S.E.M</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>SDS</td>
<td>Sodium dodecyl sulfate</td>
</tr>
<tr>
<td>SSC</td>
<td>Saline sodium citrate buffer</td>
</tr>
<tr>
<td>STAT</td>
<td>Signal transducers and activators of transcription</td>
</tr>
<tr>
<td>Tdt</td>
<td>Terminal deoxynucelotidyl transferase</td>
</tr>
<tr>
<td>THC</td>
<td>Δ^9-tetrahydrocannabinol</td>
</tr>
<tr>
<td>TSA</td>
<td>Trichostatin A</td>
</tr>
<tr>
<td>TY</td>
<td>Tryptone/yeast extract broth</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>URB-597</td>
<td>(3’-(aminocarbonyl)[1,1-bipheynyl]3-yl)-cyclohexylcarbamate</td>
</tr>
<tr>
<td>WT</td>
<td>Wild-type</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENTS

I would like to extend great thanks to my supervisor Dr. Eileen M. Denovan-Wright for her constant support and aid. I would also like to extend my gratitude to Kathleen Murphy, Matthew Hogel, Amina Bagher, Gregory Hosier, and Sarah Hutchings for their constant help and companionship. Thanks to my advisory committee: Drs. Christopher Sinal, Kishore Pasumarthi, and Barbara Karten for their knowledge and assistance. For the provision of certain drugs and animal tissue, thank you Dr. Melanie Kelly. Foremost, I am grateful to God, for in Him are all things possible. I am extremely thankful for the love, help and support of my wife, Kimberly. Without her care and thought this thesis and the work it required would not have been possible. I am appreciative too, for the love and support of my two sons, Ezra and Silas. Finally, I would like to acknowledge the financial support from Dalhousie University, the Canadian Institutes of Health Research (CIHR), the Canadian Consortium for the Investigation of Cannabinoids, the Molly Appeal for Neuroscience Research, and Faith life Financial without which I could not have completed this work.
CHAPTER 1

Introduction

One of the earliest changes that occurs during Huntington’s disease progression is a decline in the level of type 1 cannabinoid receptor (CB₁) expression in the striatum. Activation of CB₁ is considered neuroprotective because Ca²⁺-dependent neurotransmitter release is inhibited and expression of pro-survival genes is increased. Cannabinoid treatment can induce expression of CB₁ in non-neuronal cells. Here, we measured changes in the expression of several components of the endocannabinoid system during Huntington’s disease pathogenesis, determined whether cannabinoid treatment could induce CB₁ expression in striatal cell lines, and if so, whether this treatment was beneficial in cells expressing mutant huntingtin. Overall, we wanted to determine if regulating cannabinoid tone and increasing CB₁ expression would be beneficial means of treating Huntington’s disease.

1.1 Clinical Characteristics and Management of Huntington’s Disease (HD)

Huntington’s disease (HD) is a late onset, progressive, neurodegenerative disorder in which patients suffer from motor, cognitive, and psychiatric impairments (Walker, 2007). The global prevalence of HD is approximately 1 in 10,000, although the disease affects people of western European descent to a greater extent than other ethnicities [7 in 10,000; Huntington’s disease collaborative research group (HDCRG), 1993]. HD was originally named Huntington’s chorea. Chorea is the prominent movement disorder associated with the disease (Newcombe, 1981). Symptoms present as excessive involuntary movement and impaired voluntary movement early in the disease. Excessive involuntary movement describes chorea, whereas impaired voluntary movement causes problems with manual dexterity, swallowing, speech, and balance (Calkins & Van Allen, 1967). During the late phase of HD, excessive movement gives way to bradykinesia, muscular rigidity, and dystonia, similar to impairments observed in patients
suffering from Parkinson’s disease (Calkins & Van Allen, 1967). Cognitive deficits affect ‘executive functions’ such as attention, perception, memory, language, planning and organization (Mestre et al., 2009). Psychiatric impairments in HD are quite variable. The incidence of depression among individuals with HD is 40%, compared to 8% in the general population (Thompson et al., 2012). Patients suffering from HD may also suffer anxiety, paranoia, or obsessive-compulsive disorder (van Duijn et al., 2007). The symptomatic profile for HD differs in presence and degree of severity from individual to individual.

The progression of HD is variable, but can generally be grouped into three stages: early-middle- and late-symptomatic stages based on the effects of motor symptom severity on quality of life (Rosenblatt et al., 2008). Diagnosis of HD, based on chorea, does not usually occur until mid-life, with the median age of onset being between 35 and 55 years, depending on the population studied (Rosenblatt et al., 2008). Choreiform movements are the most recognizable symptom in HD, but cognitive and psychiatric abnormalities may be detected prior to motor symptom onset (Orth et al., 2010; Rosenblatt et al., 2008). After symptom onset, HD symptom severity becomes progressively worse for 15 – 20 years until the patient dies (Rosenblatt et al., 2008). The leading causes of death among patients who had been suffering from HD are pneumonia, nutritional deficiencies, and choking (Conneally, 1984).

HD is classified as a neurodegenerative disease because the most obvious, thoroughly studied, pathophysiological change is neuron-specific degeneration. The Vonsattel grading scale is used to determine the degree of progressive atrophy and neurodegeneration, from grades 0 – 4, in the caudate-putamen, globus pallidus, and nucleus accumbens of HD patients (Vonsattel et al., 1985). Cresyl-violet staining with quantification of cell numbers in the caudate nucleus of HD patients has been used to demonstrate a 50% reduction of neurons in grade 1 patients and a 95%
reduction of neurons in grade 4 patients compared to age-matched controls (Vonsattel et al., 1985). Although the volumes of the caudate and putamen are most severely decreased, the volumes of the internal and external pallidus, cerebellum, and hypothalamus are all decreased in tissue taken from HD patients compared to age-matched controls (Vonsattel et al., 2011). In contrast, the volumes of the medial temporal lobe, thalamus, and white matter were not different in HD patients. Although neuronal atrophy is widespread, degeneration of the caudate and putamen regions of the striatum occurs earlier, and is more severe, than in any other brain region (Vonsattel et al., 2011).

Neurodegeneration within the striatum is cell-type-specific. The striatum is composed of medium spiny projection neurons (MSN) and aspiny interneurons. Aspiny neurons may be cholinergic, γ-aminobutyric acid (GABA)-ergic, and nitric oxide-containing depending on the type of neurotransmitter they synthesize and release (Vonsattel et al., 1985). MSNs are GABA-ergic and subdivided based on the additional type of neurotransmitter they release, the receptors they express, and their projection path (Nestler et al., 2001). The direct movement pathway is innervated by MSNs that project from the striatum to the internal segment of the globus pallidus and substantia nigra pars compacta and substantia nigra pars reticulata, produce substance P, and express dopamine D₁ receptors (Nestler et al., 2001). The indirect movement pathway is innervated by MSNs that project from the striatum to the external globus pallidus, produce enkephalin, and express dopamine D₂ receptors. Initial observations suggested that MSNs were subject to selective degeneration while aspiny neurons were spared (Ferrante et al., 1990). Further investigation has shown that enkephalin-producing neurons of the indirect pathway are more susceptible to degeneration than substance P-producing neurons of the direct pathway (Sapp et al., 1995; Fig. 1).
The most prominent pathological change associated with HD occurs in the striatum, yet peripheral pathologies are also present. The most prominent peripheral pathology is weight loss and an inability to gain weight, both of which occur early in HD progression (Djousse et al., 2002). One study examined body mass index (BMI) in HD individuals within 4 years of initial diagnosis and found BMI to be lower in men and women suffering from HD compared to age-matched controls (Djousse et al., 2002). Weight loss occurs in patients suffering HD despite increased appetite and caloric intake (Trejo et al., 2004).

1.1.1 Genetics of HD

The hereditary nature of HD was originally described by George Huntington in 1872 (HDCRG, 1993). George Huntington was able to infer the dominant hereditary nature of HD when he noted that offspring of an individual affected by HD who did not develop HD themselves did not sire future generations affected by the disease (HDCRG, 1993). More than a century later, restriction fragment length polymorphism (RFLP) and Southern blot analyses of DNA from American and Venezuelan HD families narrowed the location of the gene causing HD to the short arm of chromosome 4 (HDCRG, 1993). Hybridization probes were created and used to screen cDNA libraries for the gene within the short arm of chromosome 4. In 1993, the Huntington’s disease collaborative research group discovered a cDNA transcript with a polymorphic 5’ CAG repeat and high sequence similarity to a region of the short arm of chromosome 4, which they named IT15 (interesting transcript 15; HDCRG, 1993). This gene has since been renamed huntingtin. Huntingtin is 13646 bp in length, containing 67 exons, coding for a 3142 amino acid, 348 kDa protein (Li et al., 2006). Huntingtin mRNA is detectable in the
Figure 1. Striatal neurodegeneration during HD progression is cell-specific. HD pathophysiology is associated with a cell-specific degeneration of MSN of the indirect movement pathway that express D₂ receptors and enkephalin, and to a lesser extent MSN of the direct movement pathway that express D₁ receptors and substance P. Here, a schematic of the direct and indirect pathways is illustrated. The striatum is highlighted red, the MSN of the direct pathway are yellow, and the MSN of the indirect pathway are red. SNC, substantia nigra pars compacta; SNR, substantia nigra pars reticulata; DA, dopaminergic neuron; STN, subthalamic neuron; ACh, acetylcholine; GABA, γ-aminobutyric acid; GLU, glutamate; “+”, excitatory; “-”, inhibitory (modified from Nestler et al., 2001).
hippocampus, cerebellar cortex, neocortex, and corpus striatum, as well as lower levels in the pancreas, liver, colon, and spermatocytes in humans (Strong et al., 1993). The polymorphic 5’ CAG repeat of the huntingtin gene encodes an amino (N)-terminal polyglutamine (polyQ) region in the translated huntingtin (Htt) protein (HDCRG, 1993; Lin et al., 1993; Strong et al., 1993). Several authors examined the CAG repeat length in HD and normal individuals and found that most normal individuals express huntingtin genes with 10 – 29 CAG repeats while the huntingtin alleles of HD patients had greater than 36 CAG repeats (Kremer et al., 1990; HDCRG, 1993; Landwehrmeyer et al., 1995). A small percentage of normal, healthy control subjects carried huntingtin alleles with 36 – 39 CAG repeats. It has since been demonstrated that the HD phenotype has ‘reduced penetrance’ when the CAG repeat length is between 36 – 39 such that these individuals have a 40% chance of being HD symptom free at 65 years of age and a 30% chance of being HD symptom free at 75 years of age (Quarrell et al., 2007). The number of CAG repeats present in an individual’s huntingtin allele determines whether an individual will develop HD as well as the age of onset for the disease. CAG repeat length accounts for approximately 50% of the variation in HD age of onset, with a greater number of CAG repeats corresponding to an earlier age of symptom onset. CAG repeat length does not, however, predicate or indicate symptom severity or disease progression (Rosenblatt et al. 2006; Ravina et al., 2008).

Inheritance of one copy of mutant huntingtin does not change Htt protein expression (Sapp et al., 1995). Because Htt protein levels are not different in HD versus normal individuals, we can assume that altered expression of huntingtin does not contribute to HD pathogenesis. The polyQ expansion of mutant Htt (mHtt), therefore, is the mediator of the pathophysiological changes observed in HD. This could either be the result of a loss-of-function or a toxic gain-of-function for mHtt. If loss-of-function were the case, then we would expect deletion of the
huntingtin gene to produce an HD-like phenotype. However, heterozygous deletion of the huntingtin allele produces no change in phenotype, and homozygous deletion of the huntingtin allele causes embryonic death at day 8.5 in mouse (Dragatsis et al., 1998). If gain-of-function were the case, then we would expect that expression of mHtt, even in the presence of wild-type Htt, would produce an HD phenotype. Indeed, two mouse models of HD that overexpress an N-terminal fragment of mHtt in addition to two copies of wild-type Htt, recapitulate the reduced striatal volume, motor and psychiatric deficits associated with HD pathogenesis (Slow et al., 2005). Thus, inheritance of a single copy of the mutant huntingtin gene containing an expanded CAG repeat, which confers a toxic gain-of-function to the translated mHtt protein, is sufficient to cause HD pathogenesis.

The amino terminus of the Htt protein is a natural substrate for caspase-1, -2, -3, -6, and calpain-mediated cleavage, which releases an N-terminal fragment (N-mHtt; Hermel et al., 2004). PolyQ expansion of the Htt protein is associated with polyQ length-dependent increases in cleavage (Gafni et al., 2002). Inhibition of caspase or calpain-mediated mHtt cleavage to release N-mHtt is associated with a reduction in the severity of HD symptoms in rodent models of the disease (Hermel, 2004; Graham et al., 2006). These data support the hypothesis that N-mHtt is the toxic mediator of HD.

Following cleavage of mHtt, N-mHtt localizes to the nucleus. N-mHtt fragments have been localized to the nuclei of human striatal and cortical cells as well as the nuclei of striatal neurons in transgenic HD mice that overexpress exon 1 of mHtt with 150 CAG repeats (R6/2 HD mice; Gutekunst et al., 1999; Meade et al., 2002; Van Raamsdonk et al., 2005). In contrast, Htt and uncleaved mHtt do not accumulate in the nucleus (Graham et al., 2006). Both cleaved and uncleaved mHtt can form insoluble aggregates in the cytoplasm (Hermel et al., 2004), which
may facilitate a protective role within the cell (Meade et al., 2004). N-mHtt appears to mediate its toxic effects within the nucleus by entering it passively (Graham et al., 2006). Collectively, these data demonstrate that the soluble, nuclear, cleaved, N-terminal, mHtt protein acquires a toxic gain of function that mediates HD pathogenesis.

1.2 Cellular Effects of Mutant Huntingtin Protein

Expression of mHtt is associated with deficits in energy metabolism and mitochondrial function, changes in intercellular signalling and neurotrophic support, and transcriptional dysregulation. With regard to energy metabolism, the concentration of ATP present in cellular lysates derived from HD mouse striatal neurons is lower than the ATP concentration measured in wild-type neurons (Trettel et al., 2000; Cui et al., 2006). Altered intercellular signalling, specifically excitotoxicity, may also contribute to HD pathology. Excitotoxicity is a degeneration of MSNs caused by either an increase in the amount of glutamate released from cortical neurons onto striatal dendrites or an increase in post-synaptic NMDA-mediated sensitivity of those striatal neurons to glutamate. Injection of the NMDA receptor agonist quinolinic acid into mice expressing full-length huntingtin with 72 glutamines led to a greater degree of striatal neuron degeneration than untreated HD or wild-type mice (Zeron et al., 2002). This suggests that HD may be associated with increased susceptibility to excitotoxicity. Treatments that decrease glutamate release may, therefore, have therapeutic potential in HD.

Levels of brain-derived neurotrophic factor (BDNF) are lower in the caudate and putamen of grade 3 HD patients compared to age-matched controls (Zuccato et al., 2008). Cortical BDNF mRNA is less abundant in 6 week old R6/2 (Zuccato et al., 2005), and 3 month old YAC72 HD mice (Hermel et al., 2004). Striatal BDNF protein is less abundant in 5 month old R6/1 mice that overexpress exon 1 of mHtt containing approximately 115 CAG repeats.
compared to controls (Spires et al., 2004). Heterozygous or homozygous knockout of BDNF recapitulates the striatal atrophy observed in HD (Strand et al., 2007). Intracellular protein signaling via extracellularly-regulated kinase (ERK)1/2 is also dysregulated in the presence of mHtt. Gines et al. (2010) observed that TrkB-mediated signalling via Ras, MAPK, and ERK1/2 (mitogen-activated protein kinases) was reduced in a cell culture model of striatal MSNs expressing two copies of the human mHtt transgene knocked into the mouse huntingtin locus (STHdh111/111) compared to wild-type cells, while PI3K/Akt signalling was unaffected. Taken together, these data suggest that decreased neurotrophic support via BDNF and altered intracellular signaling contribute to neuronal cell death in HD.

Expression of mHtt is associated with transcriptional dysregulation of a relatively small subset of genes, with the majority remaining unaffected (Luthi-Carter et al., 2000). Luthi-Carter et al. (2000) found that only 1.7% (6 week old) and 1.2% (12 week old) of the 6000 transcripts analyzed were dysregulated in the presence of mHtt in the striatal tissue of R6/1 HD mice. Microarray analyses of post-mortem brain tissue derived from 44 HD patients (grades 0 – 4) demonstrated that transcriptional dysregulation occurs early in HD progression and is more severe in the caudate nucleus compared to the cerebellum or 2 cortical areas (Hodges et al., 2006). These studies demonstrate that cell-specific transcriptional dysregulation in the striatum is associated with mHtt expression and not cell death. Importantly, the cell autonomous affect of mHtt on transcription can be observed in cell culture models of HD (Luthi-Carter et al., 2000; Cui et al., 2006).

Transcription of type 1 cannabinoid receptor (CB1) mRNA is reduced early in HD symptom progression in HD patients and all animal models of HD tested to date, relative to age-matched, healthy controls (Pazos et al., 2008). In humans, CB1 mRNA and protein abundance, as
well as receptor binding, are lower in the internal and external segments of the globus pallidus, the substantia nigra pars reticulata, and the caudate and putamen of grades 3 and 4 HD patients relative to age-matched healthy controls and other regions of the brain (Denovan-Wright & Robertson, 2000; Allen et al., 2009). The R6/1 and R6/2 HD mouse models exhibit reduced CB₁ mRNA levels in the lateral striatum beginning at 6 and 4 weeks of age, respectively (McCaw et al., 2004). Striatal CB₁ mRNA levels are also reduced in the HD94 tetracycline-inducible and the Hdh mHtt knock-in models of HD (Lastres-Becker et al., 2002; Blazquez et al., 2011). CB₁ mRNA expression is reduced in the presence of mHtt in the STHdh cell line (Blazquez et al., 2011). Thus, CB₁ mRNA levels are lower in cultured neuronal cell models of HD, which lack intercellular signalling, compared to cells that do not express mHtt (Blazquez et al., 2011). McCaw et al. (2004) demonstrated that CB₁ transcription was repressed in R6/2 HD mice, in the presence of N-mHtt, by quantifying the number of primary CB₁ mRNA transcripts. Therefore, tissue-, cell-, and developmental stage-specific factors that normally facilitate high-level CB₁ mRNA transcription in the adult striatum are affected by the cell-autonomous overexpression of N-mHtt.

Transcriptional dysregulation can account for other pathogenic features of HD. The transcriptional co-activator peroxisome proliferator activated receptor γ co-activator 1α (PGC1α) controls the expression of several nuclear genes that regulate mitochondrial function (Lin et al., 2009). PGC1α mRNA levels are lower in pre-symptomatic HD patients, 3 month old R6/2 transgenic mice, and STHdh<sup>111/111</sup> cell models of HD compared to age-matched healthy individuals or wild-type controls (Trettel et al., 2000; Cui et al., 2006). BDNF mRNA expression, specifically BDNF-2, is also lower in the presence of mHtt in 6 week old R6/2 mice and HD patients (grades 1 and 2, Sipione et al., 2002; Valenza et al., 2005). Thus, deficits in
neurotrophic support may be explained by transcriptional dysregulation. mRNA levels of the dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) are lower in striatal neurons derived from 6 week old R6/1 and R6/2 HD mice compared to wild-type mice (Gomez et al., 2006). DARPP-32 is highly expressed within the striatum and lowered DARPP-32 mRNA levels are a unique feature of HD pathogenesis, suggesting that the unique dysregulation of this gene is a direct consequence of mHtt expression. In section 1.3.5, we will discuss how decreased expression of CB1 may contribute to the late-stage transcriptional dysregulation, excitotoxicity, and changes in motor control and behaviour observed in animal models of HD and in HD patients.

Transcriptional dysregulation is dependent upon the presence of soluble N-mHtt fragments within the nucleus. All models of HD tested to date exhibit some degree of transcriptional dysregulation associated with the expression of mHtt. Transcription is regulated at three levels: chromatin folding and structure, basal transcription machinery, and gene-specific co-activators and co-repressors. N-mHtt can interact with proteins involved at any of these levels to mediate transcriptional dysregulation. However, the gene-specific nature of transcriptional dysregulation in HD is indicative of interactions between N-mHtt and specific transcription factors and co-activators. These interactions squelch co-activation of transcription leading to transcriptional dysregulation. The Sp1 transcription factor interacts with N-mHtt and this interaction is associated with decreased promoter activity for the nerve growth factor receptor and D2 receptor genes (Li et al., 2000). Both wild-type and mutant Htt affect the p50 subunit of the nuclear factor κ light chain B (NF-κB) transcriptional activator (Reijonen et al., 2010). Expression of N-mHtt is associated with decreased levels of p50 (Reijonen et al., 2010), while wild-type Htt has been shown to traffic active NF-κB from dendritic spines to the nucleus in
neurons derived from $Hdh^{140/140}$ knock-in mice (Marcora et al., 2010). Thus, N-mHtt expression yields promoter-specific transcriptional dysregulation in a subset of genes.

1.2.1 Treatment of HD

There is no known cure for HD. All pharmacological treatments of HD attempt to control HD symptoms and progression. The majority of research has focused on therapeutic management of chorea. The only approved therapeutic for HD, tetrabenazine, is a monoamine-depleting agent that also antagonizes D$_2$ receptors and effectively reduces chorea (Scott, 2011). Neuroleptics and anti-psychotics that antagonize dopamine receptors have also been investigated for their ability to control chorea in patients suffering from HD. Of these, tiapride, haloperidol, flupenazine, perphenazine, pimozide, clozapine, olanzapine, and thiopropazate are able to improve motor impairments in HD during non-randomized, open-label trials (Killoran & Biglan, 2012). The bradykinesia observed during the late-symptomatic stage of HD can be treated by dopamine-replacement therapy, as in Parkinson’s disease (Reuter et al., 2000; Racette & Perlmutter, 1998). Beyond the treatment of motor impairment, no clinical trials have been undertaken to determine appropriate therapies for improving cognitive or psychiatric impairments in patients with HD. Case reports have described improvements in depression in HD following treatment with imipramine for 3 weeks, mirtazapine for 2 weeks, or venlafaxine for 4 weeks (Whittier et al., 1961; Bonelli, 2003). Although numerous drugs exist that may improve motor or cognitive symptoms for those suffering from HD, no holistic, efficacious pharmacological approach has been found to manage this disease (Killoran & Biglan, 2012). Pre-clinical discoveries of promising therapeutic targets, such as gangliosides (Di Pardo et al., 2012) or kinase inhibitors (Atwal et al., 2011), have not yet been validated clinically. An ideal
therapy for the management of HD symptoms would improve motor coordination, cognition, and weight gain, without inducing unwanted psychoactive effects (Killoran & Biglan, 2012).

1.3 The Type 1 Cannabinoid Receptor

In the past decade, evidence has accumulated indicating that the endocannabinoid system (ECS) plays a critical role in the regulation of numerous biological processes including embryonic development, metabolism, and neurotransmission (Mechoulam & Hanu, 2001; Howlett et al., 2002). The ECS consists of endogenously synthesized endocannabinoids [eCBs, anandamide (AEA) and 2-arachidonoylglycerol (2-AG)], their receptors (the type 1 and type 2 cannabinoid receptors), and their anabolic and catabolic enzymes (Martin et al., 1999; Matsuda et al., 1990; Munro et al., 1993; Di Marzo et al., 1994; Cravatt et al., 1996). In addition to eCBs, phytocannabinoids and synthetic cannabinoids act as cannabinoid receptor ligands. CB₁ mediates cannabinoid-dependent signal transduction in the central nervous system and periphery (Howlett et al., 2002; Basavarajappa et al., 2009), while the type 2 cannabinoid receptor (CB₂) is localized to, and highly inducible in, peripheral haemopoietic cells and glial cells in specific areas of the central nervous system during the inflammatory response (Basavarajappa et al., 2009; Atwood & Mackie, 2012). To date, the majority of CB₁ research has focused on ligand-receptor binding, signal transduction, and protein-protein interactions. In contrast, knowledge of CB₁ gene regulation is limited. CB₁ receptor abundance and the function of the ECS may change in response to altered CB₁ gene expression in different developmental or disease conditions, such as HD, and in response to drug exposure.
1.3.1 Architecture, Splice Variants, and Isoforms of the CNR1 Gene

The human CB₁ gene (*CNR1*) spans 26.1 kb of chromosome 6 (6q14 – q15). *CNR1* contains 4 exons (Fig. 2A) and the protein coding region of CB₁ is contained entirely within exon 4 (Zhang *et al.*, 2004). Outside of the coding region, alternative splicing of CB₁ mRNA produces six 5’ untranslated region (5’ UTR) splice variants. The precise transcription start sites within exon 1 included in 5’ UTR variants 1, 3, 4 and 5 have not been defined, although it appears that multiple transcription start sites may exist within the first 60 bp of exon 1 (Shire *et al.*, 1996). Transcription of variant 6 begins within intron 2 and thus the 5’ most exon of variant 6 has been redefined as exon 3a. Transcription of variant 2 begins at the 5’ end of exon 4.

Transcript variants 1, 3, 4, 5, and 6 encode full-length CB₁ that is 472 amino acids in length encoded without interruption by a single region in exon 4. Exon 4, however, can be differentially spliced to remove 102 nts separating the 5’ end of exon 4 and a new exon identified as exon 4a. This splicing occurs in transcript variant 2 that encodes the truncated, 439 amino acid, and CB₁b protein (Fig. 2D). In CB₁a, different intra-exon 4 splice sites result in the loss of 167 nts. Furthermore, two translation start sites are present at the 5’ end of exon 4. Translation from the first produces CB₁ and CB₁b. Translation from the second is thought to produce the amino-terminal variant CB₁ₐ, also known as CB₁_short (*Ryberg et al.*, 2005). The macaque monkey (*Macaca mulatta*) CB₁ gene is located on chromosome 4. Although the number of exons is not known, the protein coding region of the gene is contained entirely within one contiguous coding region [Fig. 2B; National Institutes of Biotechnology (NCBI), 2011]. The mouse and rat CB₁ genes are located on chromosomes 4 and 5, respectively; both genes contain 2 exons with the protein coding regions existing entirely within the second exon in both species (Fig. 2C; Miller and Devi, 2011).
Figure 2. A) The human CB₁ gene, CNR1, spans 26.1 kb on chromosome 6. Six splice variants of the 5’ UTR have been identified by sequencing cDNA ESTs. Splice variants are illustrated in blue and numbered on the left. Exons are numbered within the blue boxes. Each splice variant is aligned with respect to its nucleotide sequence in the CNR1 gene (green, at top). The scale bar represents 5 kb of nucleotides. B) The non-human primate (Macaca mulatta) CB₁ gene is poorly characterized yet it is known that the entire protein coding region is contained within 1 exon (NCBI, 2012). The protein isoforms CB₁a and CB₁b have been described in non-human primates (Gustaffson et al., 2008). C) The rat and mouse CB₁ genes span approximately 20 kb on chromosome 4 and contain 2 exons. The second exon contains the entire protein coding region. D) CNR1 CB₁ coding-region variants. Three coding regions for protein isoforms of CB₁ have been described in humans and non-human primates: the 472 amino acid, intron-less CB₁, the 439 amino acid CB₁b, and the 411 amino acid CB₁a. In this figure, position 1 is 300 bp downstream of the 5’ end of exon 4 in CNR1. Translation of CB₁ and CB₁b begins at the same ATG codon located 309 bp downstream of the first nucleotide in exon 4. Translation of CB₁a begins 326 bp downstream of the first nucleotide in exon 4. Fifty-nine bp downstream of the CB₁b translation start site, CB₁b contains a 102 bp intron that is spliced from the pre-mRNA at an atypical intron-exon splice junction (CT/cc and ag/GG). Eighty-eight bp downstream of the CB₁a translation start site, CB₁a contains a 167 bp intron that is spliced from the pre-mRNA at a typical 5’ intron-exon boundary (AG/gt) and an atypical ag/GA 3’ splice junction. Downstream of the CB₁a intron-exon junction the coding sequences of the three CB₁ isoforms are identical. ATG start codons are bold, Intron sequences are designated by ‘-‘.
To date, CB$_{1a}$ and CB$_{1b}$ isoforms have only been identified in humans and higher primates (Ryberg et al., 2005; Gustafsson et al., 2008; Palermo et al., 2009), and some evidence suggests CB$_{1a}$ may be expressed in the rat (Shire et al., 1996). Several authors have demonstrated that CB$_1$, CB$_{1a}$, and CB$_{1b}$ receptors signal via G$_{i/o}$-type G-proteins and that the amino-terminal variants CB$_{1a}$ and CB$_{1b}$ have reduced affinity for cannabinoid agonists and antagonists (Rinaldi-Carmona et al., 1996; Ryberg et al. 2005). However, Xiao and colleagues (2008) did not observe differences in the ligand affinity or localization of the three CB$_1$ protein isoforms. Moreover, the signalling properties of CB$_1$ receptor variants may be altered depending on the model system they are being studied in (Straiker et al., 2012), which complicates our ability to understand receptor differences. In the majority of reports, steady-state CB$_1$ mRNA levels were measured *via* amplification of the common, 3’ end, of the CB$_1$ coding region outside of the 5’ region in exon 4 involved in differential splicing. The cell-specific relative abundance of CB$_1$ *versus* CB$_{1a}$ or CB$_{1b}$ is, therefore, poorly characterized (Gustaffson et al., 2008). Early research suggested that CB$_{1a}$ mRNA accounted for approximately 20% of the CB$_1$ transcript population (Shire et al., 1996), yet more recent evidence suggests that less than 5% of the total population of CB$_1$ transcripts obtained from human fetal and adult brain tissue are CB$_{1a}$ or CB$_{1b}$ (Xiao et al., 2008). Studies to define the relative abundance and distribution of the 5’ UTR variants, 1 – 6 have measured the levels of expressed sequence tags. The 5’ UTR transcript variants 1 (5732 bp), 3 (5863 bp), 4 (5901 bp), and 5 (5776 bp) are most abundant in the brain, lymphocytes, testes, and liver, relative to other tissues (NCBI, 2011); transcript variant 2 (5387 bp mRNA) is expressed at highest levels in the brain and testes (NCBI, 2011); transcript variant 6 (8974 bp mRNA) has only been isolated from brain tissue (NCBI, 2011). Regulation of the transcription of 5’ UTR variants and how 5’ UTR differences relate to CB$_1$ mRNA stability and
translation to different CB₁ isoforms has not been characterized. The abundance and activity of the different amino-terminal CB₁ isoforms may be regulated by different physiological conditions, isoform-specific ligand-receptor affinity, and the CB₁ isoform complement expressed in a given cell type (Ryberg et al., 2005).

### 1.3.2 CB₁-mediated Signal Transduction

CB₁ is a G-protein coupled receptor (GPCR) composed of 7 transmembrane α-helices (Stadel et al. 2011). The receptor is classically considered to exist on pre-synaptic nerve terminals of GABA-ergic neurons in the central nervous system, but is also present at the pre-synaptic nerve terminals of glutamatergic neurons in the central nervous system (Stadel et al., 2011). CB₁ protein is most abundant in pre-synaptic boutons, while the remainder of CB₁ receptors are present at the endoplasmic reticulum or the lysosome (Puente et al., 2010; Rozenfeld, 2011). In this setting, CB₁-mediated signal transduction is documented as occurring, most often, via coupling with Gᵢₒ-type G-proteins (reviewed by de Lago & Fernandez-Ruiz, 2007). Following the release of neurotransmitter, the post-synaptic neuron synthesizes and releases the endogenous cannabinoid receptor agonists AEA or 2-AG. The synthesis and release of eCBs occurs on demand by the phospholipase A2 and C enzymes, which are phosphorylated and activated following membrane depolarization in the post-synaptic nerve terminal. The agonists cross the synaptic cleft to activate CB₁ receptors on the pre-synaptic neuron and induce Gᵢₒ-type signal transduction. CB₁-dependent activation of Gᵢₒ-proteins causes L-, N-, and P/Q-type Ca²⁺ channel inhibition, protein kinase A inhibition, rectifying K⁺ channel activation, ERK activation, and activation of the PI3K/Akt pathway (Fig. 3). Inhibition of Ca²⁺ currents and activation of rectifying K⁺ currents causes a decrease in Ca²⁺-dependent neurotransmitter release. CB₁ activation modulates neurotransmitter release from the pre-synaptic neuron. For this reason, CB₁ activation is considered protective against excitotoxicity due to excessive glutamate release.
(de Lago & Fernandez-Ruiz, 2007). Inhibition of protein kinase A yields a downstream decrease in transcription of cAMP response element (CRE)-dependent genes in the pre-synaptic neuron. Active MAPK induces immediate early gene transcription factors, such as Jun and c-Fos, in the pre-synaptic neuron (reviewed by Howlett et al., 2002). Activation of the PI3K/Akt pathway leads to activation of pro-survival signal cascades, phosphorylation of Iκκ, and subsequent activation of NF-κB (Ghose et al., 2011; Reijonen et al., 2010; Fig. 3). Aside from the predominant Gi/o-coupled signalling, CB1 can couple to Gα-proteins to cause an increase in cAMP, Gq-proteins to cause an increase in intracellular Ca2+ release, or the non-G-protein factor associated with neutral sphingomyelinase to cause a transient increase in MAPK activity (Bosier et al., 2010). Finally, cannabinoid agonists are taken into the cell through the AEA membrane transporter and degraded by the enzymes fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase, which degrade AEA and 2-AG, respectively.

Many GPCRs exist as hetero- or homo-dimers, or as multimers. GPCR oligomerization influences receptor ligand affinity, endocytosis, and G-protein coupling (reviewed by Hudson et al., 2010). CB1 has been shown, in cell culture via bioluminescence resonance energy transfer, to form CB1 homodimers, CB1a and CB1b heterodimers (unpublished data), and D2 dopamine receptor, β2-adrenoceptor, and μ- and δ-opiod receptor heterodimers, all of which co-exist and co-localize with CB1 receptors in vivo (Fig. 3; Bortolato et al., 2010; Uriguen et al., 2009; Pacheco et al., 2009; Navarro et al., 2008; Rozenfeld et al., 2012).

CB1 receptors can also bind synthetic agonists, antagonists, and inverse agonists. Approximately 85 phytocannabinoids have been isolated from the Cannabis plant, the most abundant being Δ9-tetrahydrocannabinol (THC) and cannabidiol (Huffman, 2000). THC is a full agonist of CB1 and CB2. Cannabidiol has been shown to paradoxically inhibit and activate AEA
Figure 3. The endocannabinoid system (ECS) and CB₁. The GPCR CB₁ is activated by endocannabinoid ligands such as AEA, which cross the synaptic cleft toward the pre-synaptic neuron in a retrograde direction, and exogenous ligands such as THC. In the central nervous system, activation of CB₁, which is typically coupled to Gᵢₒ-proteins, inhibits adenylyl cyclase, activates the MAPK and PI3K/Akt pathways, and causes changes in gene expression. Activation of CB₁ also causes inhibition of L-, N-, and P/Q-type Ca²⁺ channels and inhibits focal adhesion kinase (FAK). CB₁ can couple to several other GPCRs, which influences receptor trafficking and ligand affinity. The major catabolic enzyme of cannabinoids is fatty acid amide hydrolase (FAAH).
reuptake in mice by independent research groups, it antagonizes the putative cannabinoid receptor GPR55, and acts as a serotonin 5-HT$_{1A}$ receptor agonist (Russo et al., 2005; Mechoulam et al., 2007). Despite the confusion surrounding cannabidiol’s mechanism of action, it is currently being investigated for its anticonvulsant, anti-inflammatory, and anxiolytic properties (Mechoulam et al., 2007). Synthetic cannabinoids are grouped into 5 classes: classical cannabinoids (structurally related to THC), aminoalkylindoles, diarylpyrazoles, quinolines, and cannabinoid-like eicosanoids (Lambert & Fowler, 2005). Notable synthetic cannabinoid agonists include: arachidonyl-2-chloroethylamide (ACEA), meth-anandamide (mAEA), and WIN 55,212-2, all of which have longer half-lives, and greater affinities for CB$_1$, than THC or AEA. These cannabinoids are far more potent than their naturally occurring analogs and their medicinal use is typically associated with profound psychoses (Lambert & Fowler, 2005). CB$_1$ can also be activated indirectly via inhibitors of FAAH, the major catabolic enzyme of cannabinoids, such as URB-597 (Hudson et al., 2010) or positive allosteric modulation of the receptor (Ahn et al., 2012). Two important cannabinoid antagonists are the diarylpyrazoles rimonabant (SR141716) and O-2050. Rimonabant was used clinically as an anti-obesity drug as well as an aid to smoking cessation. However, use of rimonabant is associated with severe depression and suicidal tendencies and the drug is no longer available for clinical use (Fong & Heymsfield, 2009). The synthetic inverse agonist AM-281 preferentially binds to CB$_1$ in its inactive conformation and has been used to study signalling cascades downstream of CB$_1$.

1.3.3 The When and Where of CB$_1$ Expression

In mammals, steady-state levels of CB$_1$ mRNA vary in different tissues and during different developmental periods. In humans, CB$_1$ is detected in neocortical progenitor cells and in the subventricular zone during the early cortical plate stages of development (9 to 17 weeks
gestation; Zurolo et al., 2010). CB₁ mRNA is also abundant at 19 weeks gestation in humans in white matter, which is nearly devoid of CB₁ expression in adulthood (Zurolo et al., 2010). In the human visual cortex, CB₁ mRNA levels rise during early development and plateau approximately 1 year after birth (Pinto et al., 2010); from the steady-state CB₁ mRNA plateau achieved 1 year after birth, CB₁ mRNA levels increase further in the visual cortex to reach a new steady-state level during adolescence, after which, CB₁ mRNA abundance declines throughout adulthood (Pinto et al. 2010). In the non-human primate, Macaca mulatta, high levels of CB₁ mRNA have been observed in the prefrontal cortex during neonatal development (Eggan et al., 2010); CB₁ mRNA abundance increases in the prefrontal cortex until reaching a steady-state at P5 (Eggan et al., 2010). In the same manner as is observed in the human visual cortex, a higher steady-state level of CB₁ mRNA is observed in the Macaca mulatta prefrontal cortex during adolescence, and steady-state CB₁ mRNA levels decline in the prefrontal cortex following adolescence (Eggan et al., 2010). In mice, CB₁ mRNA is detectable during embryonic development at the four-cell and eight-cell/morula stages (Paria et al., 1995), and can still be detected at E12 in glutamatergic neurons of the cerebral cortex and hippocampus (Vitalis et al., 2008). CB₁ mRNA is abundant in the adult mouse thalamus, amygdala, dorso-lateral prefrontal cortex, hypothalamus, and pituitary (NCBI, 2011). Further, CB₁ expression is enriched in the striatum, relative to other brain regions, within the adult mouse central nervous system (Fernandez-Ruiz et al., 2004; McCaw et al., 2004). It is within the striatum that high steady-state levels of CB₁ expression are dysregulated in Parkinson’s disease and HD (Zeng et al., 1999; Denovan-Wright & Robertson, 2000). The temporal and anatomical distribution of CB₁ expression during early development is similar in mice and rats (NCBI, 2011). Six to 8 week-old rats, which are sexually mature, have lower levels of CB₁ mRNA in the limbic/associative brain
areas compared to adolescents (Heng et al., 2011). Following periods of peak neurodevelopment associated with high CB₁ levels, CB₁ mRNA abundance declines in these brain regions (Heng et al., 2011). Taken together these data demonstrate that, in mammals, CB₁ mRNA levels peak during adolescence within the prefrontal cortex, limbic/associative areas, and visual cortex and subsequently decrease with age. Early development and adolescence represent critical developmental windows where the regulation of CB₁ expression changes in order for higher levels of expression to be achieved. It is likely that developmental stage-specific transcription factors or modifiers regulate the different steady-states of CB₁ expression.

High levels of CB₁ expression are related to the establishment of neuronal circuitry; during critical development periods, areas associated with neurogenesis and synapse formation, such as the subventricular zone, are enriched for CB₁ yet these areas are depleted of CB₁ expression in adulthood. The activity or abundance of the factors that enabled high steady-state CB₁ levels during development and adolescence may decrease in concentration or activity as part of the aging process (Eggan et al., 2010; Heng et al., 2011). Greater expression and subsequent activation of CB₁ receptors facilitates higher expression of several genes required for brain development, including tyrosine hydroxylase (TH), preproenkephalin (ppENK), the neural adhesion molecule L1, and Bcl-2/Bax genes involved in apoptotic regulation of development (reviewed in Fernandez-Ruiz et al., 2004). Mice lacking CB₁ exhibit altered dendritic morphology and lower synapse density in the prefrontal cortex (Fitzgerald et al., 2012), impaired locomotor activity (Zimmer et al., 1999), and increased anxiety (Hill et al., 2011) compared to wild-type littermates. Thus, the developmental stage-specific expression of CB₁ facilitates the proper establishment of neuronal circuitry and the consequent normalization of behaviour (Fernandez-Ruiz et al., 2004). In adulthood, expression of CB₁ is cell-specific within the central
nervous system. Striatal MSNs and interneurons are enriched for CB₁ mRNA expression, relative to other cell populations, within the basal ganglia (Fernandez-Ruiz et al., 2004). Consistent with central nervous system anatomical distribution, CB₁ appears to be involved with aspects of motor coordination, mechanisms of reward and motivation, emotion, and central endocrine regulation during adulthood (Fernandez-Ruiz et al., 2004).

1.3.4 CB₁ mRNA Expression is Induced by Inflammation

Although CB₂ receptors are considered the major eCB receptor in the periphery, particularly as regulators of inflammation (Rajesh et al., 2007; reviewed in Atwood & Mackie, 2010), CB₁ receptors also contribute to regulation of the inflammatory response. Pro-inflammatory molecules induce CB₁ and CB₂ mRNA expression in cells that mediate the inflammatory responses (Gutierrez et al., 2006; Borner et al., 2008). The involvement of CB₁ in the inflammatory response was first examined in rat dorsal root ganglia (DRG), where complete Freund’s adjuvant increased CB₁ mRNA abundance in glial cells of the DRG 4 hours post-treatment, relative to untreated controls (Amaya et al., 2006). Freund’s adjuvant produces an inflammatory response and activates such transcription factors as nuclear factor of activated T cells (NFAT) and NF-κB in glial cells (Amaya et al., 2006; Borner et al., 2007a). Activation of NFAT and NF-κB is dependent on the endogenous pro-inflammatory cytokines CD3/28 and interleukin-4 (Borner et al., 2007a). CD3/28 and interleukin-4 induce CB₁ mRNA expression in human peripheral T cells and immortalized Jurkat cells (Borner et al., 2007a, 2008). Borner and colleagues (2007a) examined CD3/28- or interleukin-4-mediated induction of CB₁ via a promoter-reporter plasmid in which chloramphenicol acetyl transferase activity was driven by a 3 kb fragment of the CNR1 promoter. Short, double-stranded, decoy oligonucleotides containing the consensus sequences normally bound by NFAT or NF-κB were used to titrate NFAT or NF-
κB enhancers of transcription away from their endogenous promoters (Borner et al., 2007a). NFAT and NF-κB facilitate a CD3/28- or interleukin-4-dependent increase in CB₁ expression (Borner et al., 2007a). Using the same techniques, it was found that activator protein 1 (AP-1) and the signal transducers and activators of transcription 5 and 6 (STAT5 and STAT6) are also recruited to the CNR1 promoter to mediate increased mRNA expression in Jurkat cells (Borner et al., 2007b and 2008). Together, these data demonstrate that pro-inflammatory cues mediate an increase in CB₁ mRNA level from an initial steady-state to a second, higher state through common mechanisms.

1.3.5 CB₁ Expression is Reduced in the Presence of mHtt

As mentioned earlier (Section 1.2), CB₁ mRNA and protein levels decline early in the pathogenesis of HD. In human grades 3 and 4 HD patients, CB₁ protein abundance is lower in the caudate and putamen compared to other brain regions and age-matched controls (Denovan-Wright & Robertson, 2000). The synthetic cannabinoid positron emission tomography tracer \[^{18}\text{F}]\text{MK-9470}\) was used to demonstrate that CB₁ receptor binding was reduced in the striatum of early-symptomatic HD rats and rats lesioned with quinolinic acid (Casteel et al., 2010). More recently, it has been shown that CB₁ receptor levels are decreased in GABA-ergic striatal neurons to a greater extent than glutamatergic striatal neurons in 4 week-old R6/1 mice (Chiodi et al., 2012).

 Decreased CB₁ receptor function may contribute to progressive decline in HD. Separate research groups bred two different mouse models of HD with homozygous CB₁ knock-out mice (CB₁⁻/⁻; Mievis et al., 2011; Blazquez et al., 2011). Both research groups found that mice over-expressing N-mHtt and having reduced CB₁ levels (Htt⁺/⁺/mHtt x CB₁⁺/⁻) exhibited an earlier HD symptom onset, a more rapid disease progression, and a greater degree of MSN degeneration.
than wild-type mice or mice over-expressing N-mHtt with a full complement of CB1 (Mievis et al., 2011; Blazquez et al., 2011). Their findings suggest CB1 normally performs a neuroprotective role in the striatum and loss of this receptor contributes to HD pathogenesis.

Some additional evidence exists that suggests the ECS as a whole is dysregulated during HD pathogenesis. FAAH mRNA and protein abundance are higher in striatal neurons derived from late-symptomatic R6/1 and R6/2 mice compared to age-matched wild-type controls (Blazquez et al., 2011). More importantly, FAAH protein levels are higher in grade 3 HD patients compared to age-matched controls (Blazquez et al., 2011). Additionally, eCB levels are dysregulated in HD patients and mouse models. 2-AG levels are higher in the cortex of 12 week-old R6/1 mice, while AEA levels are reduced in the striatum and hippocampus of these mice (Dowie et al., 2009). AEA, not 2-AG, is considered the predominant endogenous ligand of striatal CB1 receptors (Dowie et al., 2009). Further, evidence suggests that binding of 2-AG to the CB1 receptor is associated with receptor desensitization and AEA binding is associated with G\textsubscript{i/o}-type signal transduction (Dowie et al., 2009). Therefore, several components of the ECS may be dysregulated during HD pathogenesis, all of which may exacerbate the disease.

If CB1 receptor levels are decreased, but not lost, then cannabinoid-based therapeutics may relieve some symptoms of HD (Dowie et al., 2009). In cell culture it has been shown that treatment with THC or the synthetic cannabinoid agonist HU-210 reduces cell death in PC12 cells over-expressing exon 1 of mutant huntingtin and STHdh\textsuperscript{111/111} cells (Scotter et al., 2010; Blazquez et al., 2011). In the PC12 model of HD, the protective benefit was conferred via G\textsubscript{i/o}-coupling because co-administration of Pertussis toxin eliminated the protective benefit (Scotter et al., 2010). Treatment of quinolinic acid or 3-NP lesion models of HD with cannabidiol or the synthetic CB1 agonist WIN 55,212-2 reduces striatal neurodegeneration (Pinto et al., 2006;
Sagredo et al., 2007). Moreover, treatment of 3-NP-lesioned mice with AM-404, a cannabinoid reuptake inhibitor, reduces hyperkinesias relative to untreated controls (Lastres-Becker et al., 2002). Environmental enrichment increases CB₁ receptor levels in the striatum of R6/1 mice and is associated with delayed symptom onset and slower HD progression (Glass et al., 2004). Dowie et al. (2010) observed that chronic THC or synthetic cannabinoid HU-210 treatment (8 weeks) of R6/1 mice beginning at 6 weeks of age had no affect on CB₁ receptor binding, CB₁ mRNA level, motor control, or striatal atrophy compared to untreated controls. However, treatment with the FAAH inhibitor URB-597 was associated with higher striatal CB₁ receptor binding in R6/1 mice compared to age-matched, wild-type controls (Dowie et al., 2010). From this, the authors concluded that extremely potent CB₁ agonists may not be suitable for treatment of HD symptoms, but manipulation of eCB levels for the treatment of HD remains an intriguing option. A more recent study, performed on symptomatic R6/2 mice, demonstrated that chronic treatment with THC (3 weeks) improved motor coordination, as measured by rotarod performance, and reduced striatal atrophy, compared to untreated controls (Blazquez et al., 2011). Thus, preclinical evidence suggests that CB₁ remains a promising target for HD treatment, although the potency and exposure to a given cannabinoid molecule will have a great affect on the outcome of the treatment.

1.3.6 CB₁ mRNA Level is Modulated by Cannabinoids

Cannabinoids modulate steady-state CB₁ mRNA abundance. Chronic treatment with THC has been shown to decrease CB₁ mRNA levels in the central nervous system of rodents. Repeated exposure to THC, once daily for 14 days by intra-peritoneal injection, decreases CB₁ mRNA levels in the caudate and putamen of adult male rats (Corchero et al., 1999). The extent of CB₁ mRNA decrease correlates to the number of repeated exposures. Cannabinoids have also
been shown to increase CB1 mRNA levels in primary and immortalized cell culture systems (Borner et al., 2007a; Mukhopadhyay et al., 2010; Proto et al., 2011). Treatment of primary mouse hepatic stellate cells with 2-AG induces CB1 mRNA, up to 30-fold relative to basal expression in untreated cells (Mukhopadhyay et al., 2010). 2-AG-mediated CB1 induction is retinoic acid receptor (RAR)γ- and CB1 receptor-dependent in this model system (Mukhopadhyay et al., 2010). AEA has been reported to increase CB1 mRNA levels in DLD-1 and SW620 cells (Proto et al., 2011). This effect was estrogen receptor- and RARα-dependent. Finally, THC, mAEA, and the CB2-selective agonist JWH-015 induce CB1 mRNA expression in Jurkat cells in a CB2-dependent manner (Borner et al., 2008). Borner and colleagues (2008) observed that CB2 activation leads to phosphorylation of STAT5/6 – thereby inducing CB1 promoter activity (Borner et al., 2008). Thus, in some systems, cannabinoid-dependent activation of CB1 and CB2 receptors stimulates the activity of specific transcription factors, such as the estrogen receptor, RARα, and STAT6 and augments steady-state CB1 mRNA level above basal levels. In other systems, cannabinoid exposure down-regulates CB1 mRNA levels (Corchero et al., 1999). Cannabinoid treatment therefore, as in various pathological conditions, is associated with, malleable, context-specific regulation of CB1 expression.

In vivo, repeated exposure to cannabinoid agonists is associated with receptor tachyphylaxis (Corchero et al., 1999); whereas in cell culture, single acute doses of cannabinoid agonists induce CB1 mRNA expression (Mukhopadhyay et al., 2010; Borner et al., 2008). From these observations, it is clear that the response of CB1 mRNA level to cannabinoid treatment depends on the nature of treatment, chronic versus acute, as well as the potency and efficacy of the ligand. For example, CB1 mRNA expression may be inducible in in vivo studies examining
acute doses of cannabinoids, indirect cannabinoid agonism via FAAH inhibitors (Kim & Alger, 2010), or allosteric modulation of CB₁ receptor activity (Ahn et al., 2012; Navarro et al., 2009).

CB₁ protein levels are also increased following acute cannabinoid-dependent induction of CB₁ mRNA levels (Mukhopadhyay et al., 2010; Proto et al., 2011). This increase is modest (4 – 5-fold) compared to the increased mRNA expression (29 – 30-fold) observed (Mukhopadhyay et al., 2010; Proto et al., 2011), yet represents an increase in the pool of CB₁ receptors. In these studies, CB₁ protein abundance was quantified via western blot. Therefore, it is not known whether cannabinoid-mediated CB₁ induction affects the localization or functionality of CB₁ receptors.

1.4 Objectives of this Study

From the existing literature, it appears that CB₁ expression is decreased in HD, and this decrease may be implicated in the pathogenesis of HD (Mievis et al., 2011). There is no cure for HD and existing treatment strategies have limited efficacy. CB₁ receptor activation enhances pro-survival signalling pathways and modulates neurotransmitter release. These effects improve neuronal health, and modulate appetite, motor coordination, cognition, and mood. Preclinical evidence suggests that cannabinoid-based therapeutics may be a useful means of treating HD patients (Blazquez et al., 2011). However, no study has yet determined how manipulation of the ECS as a whole may affect HD pathogenesis nor determined whether cannabinoids can increase expression of their cognate receptors in neuronal cell populations.

The objectives of my research were 1) to determine whether expression of mHtt was associated with changes in the ECS, such as cortical FAAH mRNA levels, striatal CB₂ mRNA levels, and cortical and region-specific striatal CB₁ mRNA levels, 2) to establish whether cannabinoid treatment can or cannot induce CB₁ mRNA and protein expression, and if
cannabinoid treatment was associated with increased CB₁ levels, to determine the molecular mechanism by which this occurred, 3) to examine the affect of decreased expression of CB₁, in the absence of mHtt, on transcriptional regulation, and 4) to determine if cannabinoid treatment, and subsequent CB₁ receptor induction, were associated with improved cellular viability and ameliorated transcriptional dysregulation in the presence of mHtt.

We analyzed the mRNA expression of components of the ECS in R6/1 and R6/2 HD mice and age-matched wild-type littermates via in situ hybridization and quantitative reverse transcriptase PCR (qRT-PCR). In situ hybridization allowed us to monitor tissue-specific and time-dependent changes in the abundance and distribution of mRNAs over the course of the animal’s lifespan in two well-characterized mouse models of HD. We chose to analyze the regulation of CB₁ levels, the mechanism of cannabinoid-mediated CB₁ induction, and changes in cell viability in the STHdh cell culture model of HD.

Given that modulation of the CB₁ levels and the ECS may represent a viable means of treating HD symptoms, the primary aim of this research is to better understand changes in the ECS during HD progression. Specifically, I sought to characterize the regulation and malleability of CB₁ in the presence of mHtt.
CHAPTER 2

Materials and Methods

2.1 Animal Care, Tissue Collection, and Preparation

Animal care and handling protocols were in accordance with the guidelines provided by the Canadian Council on Animal Care, and were approved by the Carleton Animal Care Committee at Dalhousie University. Mice were terminally anaesthetized by injection of sodium pentobarbital and their pedal reflexes were monitored. Adults were decapitated and brains were removed, and post-natal day 1 (P1) mice were killed by an overdose of sodium pentobarbital. Tissue was stored at -80°C. Fourteen micrometer coronal brain tissue sections (adult mice), or 14 μm whole-body sagittal sections (P1 mice), were made from previously frozen tissue using a 2800 Frigocut Reichard-Jung cryostat. Sections were thaw mounted onto Superfrost slides (Fisher Scientific, Ottawa, ON). Mounted tissue sections were archived at -80°C for future use.

 Archived tissue from R6/1, R6/2, or CB1+/− and wild-type littermate mice was collected. R6/1 and R6/2 mice were previously genotyped via PCR amplification of the human huntingtin transgene, using DNA extracted from an ear punch (Hebb et al., 2004). CB1+/− mice were genotyped via PCR amplification of the Cnr1 coding region, using primers flanking this coding region (Table 1), according to the instructions provided in the Extract-N-Amp blood PCR kit (Sigma-Aldrich, Oakville, ON). Tissue was obtained from four animals in each of the four disease stages identified for R6/1 mice [pre- (4 week), early- (8 week), mid- (14 week), and late- (26 week) symptomatic], and each of the three disease stages identified for R6/2 mice [pre- (3 week), early- (6 week), and late- (11 week) symptomatic], 4 P1 R6/2 mice, and 3 10 week-old heterozygous CB1 (CB1+/−) knock-out mice. Tissue derived from wild-type, age-matched, littermates were used as controls.
Table 1. Sequence, annealing temperatures, and target PCR products of primers used in RT-PCR and qRT-PCR analyses of gene expression

<table>
<thead>
<tr>
<th>Target</th>
<th>Oligonucleotide Sequence (5’-3’)</th>
<th>Annealing Temperature (°C)</th>
<th>MgCl₂ (mM)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CB₁ genotype</td>
<td>GTACCCATCACCACAAGACCTCC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CB₂ genotype</td>
<td>GTACCCATCACCACAAGACCTCC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CB₁</td>
<td>GGATCCAGAATCATGAAGC (WT)</td>
<td>58</td>
<td>1</td>
<td>Self-designed</td>
</tr>
<tr>
<td></td>
<td>AAGAAGGATCAGCGCCCTC (KO)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CB₂</td>
<td>GGATGCCGGGAGACAGAAGTGA</td>
<td>57</td>
<td>2</td>
<td>Self-designed</td>
</tr>
<tr>
<td></td>
<td>CCCATGAGCAGGGAGTAAGAAAT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CB₁</td>
<td>GGGCAATTTTCCTGTAGCA</td>
<td>58</td>
<td>1</td>
<td>Blazquez et al., 2011</td>
</tr>
<tr>
<td></td>
<td>GGCTAACGTGACTGAGAAA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDNF-2</td>
<td>AAGGATGGTATCATACTTTCTCTCA</td>
<td>58</td>
<td>1</td>
<td>Blazquez et al., 2011</td>
</tr>
<tr>
<td></td>
<td>AGTCTCCAGGACAAGGATGAAC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AAGGATGGTATCATACTTTCTCTCA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGC1α</td>
<td>TTGCTAGCGGTTCCTCACAGA</td>
<td>60</td>
<td>2</td>
<td>Cui et al., 2006</td>
</tr>
<tr>
<td></td>
<td>GGCTTTCTGCCTCTGCA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DARPP-32</td>
<td>AGGAGGCCTCTCCACATCAG</td>
<td>58</td>
<td>2</td>
<td>Yamamoto et al., 2009</td>
</tr>
<tr>
<td></td>
<td>CCCTATGGGCAGATTGAGTA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td>AAGGCAACGTGAAAAAGAT</td>
<td>59</td>
<td>2</td>
<td>Blazquez et al., 2011</td>
</tr>
<tr>
<td></td>
<td>GTGGTACGACCAGGCAATC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPRT</td>
<td>GCTGTGCAAAGAAGACCTCT</td>
<td>59</td>
<td>3</td>
<td>McCaw et al., 2004</td>
</tr>
<tr>
<td></td>
<td>CACAGGACTGAACACACCTGC</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CB₁, type 1 cannabinoid receptor; CB₂, type 2 cannabinoid receptor; BDNF, brain-derived neurotrophic factor; PGC1α, peroxisome proliferator activated receptor γ co-activator 1α; DARPP-32, dopamine and cAMP-regulated phospho-protein of 32 kDa; HPRT, hypoxanthine ribosyl transferase. WT, wild-type CB₁ genotype reverse primer; KO, knock-out CB₁ genotype reverse primer.
2.2 **In situ Hybridization**

*In situ* hybridization was performed on coronal sections of mouse brains (spanning Bregma 1.7 to -2.2 mm; Paxinos and Franklin, 2004) or whole-body mounts of P1 mice using radiolabelled oligonucleotide probes specific to several mRNAs (Table 2). Synthetic oligonucleotide probes (Sigma-Aldrich) were 3’-end labelled with [$\alpha$-P$^{33}$]dATP (3000 Ci/mmol; Perkin Elmer, Waltham, MA) as follows: oligonucleotide probe (0.4 μM), 20% terminal deoxynucleotidyl transferase (Tdt) buffer, Tdt enzyme (30 U, Promega, Madison, WI), and [$\alpha$-P$^{33}$]dATP (600 Ci/mmol) were added together in RNase- and DNase-free dH$_2$O to a final volume of 25 μL. The end-labelling reaction was carried out at 37°C for 90 min. Ethylene diaminetetraacetic acid (EDTA, 0.05 M, Sigma-Aldrich) was added to stop the reaction and RNase- and DNase-free dH$_2$O was added to a final volume of 50 μL. Unincorporated radionucleotides were removed from the labelled oligonucleotide probes via gel exclusion chromatography with Microspin G-25 spin columns (Amersham Biosciences, Piscataway, NJ) which were used according to the manufacturer’s instructions and were discarded. Eluted radiolabelled oligonucleotides were used for hybridization.

Selected slides were removed from storage at -80°C and allowed to reach room temperature. All reagents used to make solutions were RNase-free and obtained from Sigma-Aldrich, unless otherwise noted. Tissue was fixed in 4% paraformaldehyde (PFA) for 5 min. Slides were rinsed twice for 5 min each in 1X phosphate-buffered saline (PBS; 0.137 M NaCl, 0.027 M KCl, 0.014 M KH$_2$PO$_4$, 0.043 M Na$_2$HPO$_4$•7 H$_2$O) and once for 20 min in 2X saline sodium citrate buffer (SSC; 0.3 M NaCl, 30 mM tri-sodium citrate, pH 7.0) at room temperature.
<table>
<thead>
<tr>
<th>Target</th>
<th>Oligonucleotide Sequence (5'- 3')</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CB₁</td>
<td>ATGTCTCTTTTGAATATCTTCGTACTGAATGTCATTTG</td>
<td>McCaw et al., 2004</td>
</tr>
<tr>
<td>CB₂</td>
<td>GGCGTAATACGACTCACTATAGGGCCTTTATTAGGGAGGCTGA</td>
<td>Munro et al., 2004</td>
</tr>
<tr>
<td>FAAH</td>
<td>GTCAGCCAGATAGGAGGTGTCACACAGTTGGTCCCTTTGGTCACTTT</td>
<td>Self-designed</td>
</tr>
<tr>
<td>DARPP-32</td>
<td>TCCACTTTGGTCCTCAGAGTTCCATCTCTC</td>
<td>Gomez et al., 2006</td>
</tr>
<tr>
<td>PDE10A</td>
<td>GACCAATGTCAAGTGGGATAGCTCGATGTCCCGGC</td>
<td>Hebb et al., 2004</td>
</tr>
<tr>
<td>PDE1B</td>
<td>CATGTAAGCGCAGCAGAGGCTAGCTTAATCCACA</td>
<td>Hebb et al., 2004</td>
</tr>
<tr>
<td>Egr-1</td>
<td>CCGTTGCTCAGCAGCATCCTCCTCCTCCAGTTGGGTAGTTGTCC</td>
<td>Rodriguez-Lebron et al., 2005</td>
</tr>
<tr>
<td>ppENK</td>
<td>TCCACTTTGGTCCTCAGAGTTCCATCTCTC</td>
<td>Rodriguez-Lebron et al., 2005</td>
</tr>
<tr>
<td>D₂</td>
<td>GGCAGGGTTGGCAATGATACTACCTATTGGTCTGTATT</td>
<td>Rodriguez-Lebron et al., 2005</td>
</tr>
<tr>
<td>PGC1α</td>
<td>AATAGGCCATCCATGGCTAGTC</td>
<td>McKee et al., 2005</td>
</tr>
<tr>
<td>Dynamin</td>
<td>CACTGGCTTTCTTTGTCCCAAGAGGCTC</td>
<td>Rodriguez-Lebron et al., 2005</td>
</tr>
<tr>
<td>β-actin</td>
<td>TCCACTTTGGTCTCAGAGTTCCATCTCTC</td>
<td>Rodriguez-Lebron et al., 2005</td>
</tr>
</tbody>
</table>

CB₂, type 2 cannabinoid receptor; FAAH, fatty acid amide hydrolase; DARPP-32, dopamine and cAMP-regulated phosho-protein 32 kDa; PDE10A, phosphodiesterase 10A; PDE1B, phosphodiesterase 1B; Egr-1, early growth-response protein 1; ppENK, pre-proenkephalin; D₂, type 2 dopamine receptor; PGC1α, peroxisome proliferator activated receptor γ co-activator 1α.
Slides were allowed to dry for 60 min. Hybridization buffer, consisting of 5X SSC (0.75 M NaCl, 75 mM tri-sodium citrate, pH 7.0), 2% Denhardt’s solution, 0.02 M Na$_3$PO$_4$ (pH 6.8), 0.2% sodium dodecyl sulfate (SDS), 5 mM M EDTA, 10 μg/mL polyA oligonucleotides, 50 μg/mL salmon sperm DNA, 50 μg/mL Yeast tRNA, and 10% (w/v) dextran sulphate was made up to a final volume of 100 mL in dH$_2$O. The hybridization buffer was boiled for 10 min and rapidly chilled. The entire 50 μL radiolabelled oligonucleotide probe was added to the chilled hybridization buffer. The solution was mixed on a rocking platform for 10 min. Once the slides had dried for 60 min, 200 μL of hybridization buffer containing approximately 1x10$^6$ cpm of labelled probe were added to each slide. Individual slides were placed in 10 cm petri dishes and covered in parafilm. Petri dishes were placed in Tupperware containers with a piece of wet filter paper. Containers were sealed and incubated overnight at 42°C. Following hybridization, slides were subjected to twelve, 30 min, 55°C, consecutive washes: four in 1X SSC (0.15 M NaCl, 15 mM tri-sodium citrate, pH 7.0), four in 0.5X SSC (0.075 M NaCl, 7.5 mM tri-sodium citrate, pH 7.0), and four in 0.25X SSC (0.0375 M NaCl, 3.75 mM tri-sodium citrate, pH 7.0). Slides were dipped once in dH$_2$O and allowed to dry overnight at room temperature.

All slides were exposed to Kodak Biomax MR film (Simga-Aldrich), in a light-tight case for 4 weeks at room temperature. Following X-ray autoradiography, the tissue on the slides was counter-stained with cresyl violet to visualize anatomical structures. Autoradiographic films were scanned using a flat bed scanner and stored as digital images. mRNA distribution and densitometry were analyzed using Kodak 3D imaging software (version 3.6.1). Optical density (OD) of the mRNA hybridization signals was measured in various regions of the mouse brain or post-natal mouse body. Local film background was subtracted from each of the mRNA hybridization measurements to account for variability between sections and background signal.
mRNA hybridization was measured in each of the wild-type, R6/1, R6/2, and CB1+/- mice in the lateral striatum. CB1 mRNA expression was also measured in the cortex, dorsomedial and ventromedial striatum. FAAH, early growth-response protein 1 (Egr-1), and dynamin expression were measured in the cortex (Fig. 4). mRNA hybridization measurements were averaged at each disease stage to attain a measurement of mRNA level in the mouse brains.

2.3  **STHdh Cell Culture**

The STHdh cell lines are derived from striatal precursor cells obtained from embryonic day 14 wild-type mice [STHdhQ7/Q7 (7/7)] or knock-in mice expressing one copy [STHdhQ7/Q111 (7/111)] or two copies [STHdhQ111/Q111 (111/111)] of exon 1 of the human huntingtin allele in the mouse huntingtin locus that have been transduced with a defective SV40 retrovirus containing the temperature-sensitive A58/U19 large T antigen and geneticin-resistance genes, which confers conditional immortalization (Coriell Institute, Camden, NJ; Trettel et al., 2000; Paoletti et al., 2008). Cells were maintained at the permissive temperature of 33°C, at 5% CO2, 95% O2, in Dulbecco’s modified eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1x10^4 U/mL penicillin/streptomycin, and 400 μg/mL geneticin in cell-culture treated flasks or 0.01% poly-D-lysine-coated wells (Invitrogen, Burlington, ON; Paoletti et al., 2008). Cells were not maintained past the fifth passage. Multi-well plates were coated with 0.01% poly-D-lysine to provide an adherent substrate for growing cells. Wells were rinsed once with dH2O, incubated with 0.01% poly-D-lysine for 2 h at 37°C, rinsed twice with 1X PBS, and allowed to air-dry overnight at room temperature before being stored at 4°C.

2.3.1  **Serum Deprivation and Drug Treatments**

STHdh cells normally exist in a permissive, dividing state. Temperature shift to 39°C inactivates the temperature-sensitive large T antigen and causes STHdh cells to exit the cell cycle.
Figure 4. mRNA hybridization was quantified in several regions of the mouse brain. Representative coronal sections derived from R6/2 mice illustrate the specific brain regions used to quantify mRNA hybridization. The OD of hybridization signal specific to several mRNAs was measured in the areas outlined in each panel. A) mRNA hybridization measurements were taken from the lateral, dorsomedial, and ventromedial striatum (Bregma 1.7 to -2.2 mm) for CB1, and the lateral striatum for all other mRNAs, B) with the exceptions of Egr-1, FAAH, and dynamin, which were measured in the cortex. C) CB1 mRNA expression was measured in the cortex by counting CB1-positive neurons because cortical hybridization was punctate.
and differentiate into cells whose phenotype resembles glia (Trettel et al., 2000). Serum deprivation also causes STHdh cells to exit the cell cycle. However, serum deprivation is associated with increased neurite outgrowth, flattening of cells, and expression of DARPP-32 and D2 receptors (Trettel et al., 2000; Paoletti et al., 2008). Therefore, the phenotype of serum-deprived STHdh cells resembles that of ‘adult’ striatal MSNs (Paoletti et al., 2008; Blazquez et al., 2011). Here, serum-deprived STHdh cells were used as models of MSNs. STHdh cells were normally maintained in serum-containing media. Media was aspirated from cells and the cells were rinsed once with 1X PBS. Media lacking serum, but otherwise equivalent to STHdh media described above, was then added and cells were allowed to grow for an additional 24 h. These cells are considered ‘post-mitotic’ and referred to in the remainder of this text as ‘untreated’. Also, cells are referred to according to their specific genotype for the remainder of the text, that is, 7/7, 7/111, or 111/111.

All drugs were obtained from Tocris Bioscience (Ellisville, MI). The CB1 agonists ACEA, mAEA, and AEA, and the FAAH inhibitor (3’-(aminocarbonyl)[1,1-bipheynl]3-yl)-cyclohexylcarbamate (URB-597) were dissolved in ethanol and added directly to cell media to achieve the correct dose. The pan-HDAC inhibitor sodium butyrate (NaB), the type 1 HDAC inhibitor trichostatin A (TSA), D2 receptor agonist quinpirole, the D1/2 receptor agonist apomorphine, the CB2 agonist [(1R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol (HU-308), the CB2 antagonist 1-[2-(morpholin-4-yl)ethyl]-2-methyl-3-(4-methoxybenzoyl)-6-iodoindole (AM-630), and the CB1 antagonists 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide (AM-281) and (6aR,10aR)-3-(1-Methanesulfonylamino-4-hexyn-6-yl)-a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran (O-2050) were dissolved in dimethyl sulfoxide (DMSO).
and added directly to cell media to achieve the correct dose. STHdh cells appear morphologically distinct within 4 – 6 h of serum deprivation (Trettel et al., 2000). Therefore, cells were treated with drug 6 h post serum-deprivation.

2.4 Plasmid Manipulation and Cloning

In order to study transcriptional regulation of CB1 in the presence of mutant huntingtin a promoter-reporter construct containing 904 bp of the human CNR1 promoter driving expression of the Renilla luciferase gene was used. In this way, promoter activity could be quantified using the dual luciferase assay (Promega). In addition, promoter-reporter constructs containing 5 tandem repeat estrogen response elements (ERE) or NF-κB response elements driving firefly luciferase activity were used to study CB1 promoter activity and cannabinoid-mediated signal transduction. Plasmids were propagated in electrocompetent cells, which were prepared as follows. Escherichia coli [E. coli strain IVNaF’ DH1 (K-12); Invitrogen] were grown overnight at 37°C on luria broth (LB) plates. A single colony was chosen and inoculated in 25 mL Tryptone/Yeast extract (TY) broth, and was incubated overnight at 37°C, 250 rpm. Five millilitres of this culture were added to 500 mL fresh TY broth. Cell growth was monitored by absorption spectrophotometry at 600 nm until an A600 of 0.4 was achieved. The 500 mL culture was incubated on ice 30 min, centrifuged at 1000 x g for 15 min, and the supernatant was discarded. The pellet was resuspended in 250 mL sterile dH2O, centrifuged at 1000 x g for 20 min, and the supernatant was discarded. The pellet was resuspended in 125 mL sterile dH2O, centrifuged at 1000 x g for 20 min, and the supernatant was discarded. The pellet was resuspended in another 125 mL sterile dH2O, centrifuged at 1000 x g for 20 min, and the supernatant was discarded. The pellet was resuspended in 20 mL 10% glycerol, centrifuged at 1000 x g for 20 min, and the supernatant was discarded. The pellet was resuspended in 1.5 mL
10% glycerol, distributed in 40 μL aliquots, and the cells were stored at -80°C. For electroporation, 10 ng of plasmid were added to 40 μL of electrocompetent *E. coli*. This solution was placed in an electroporation cuvette and an electric pulse was applied, followed by immediate addition of 410 μL LB. The solution was transferred to a sterile tube and incubated for 1 h at 37°C, 250 rpm. Cells were cultured on LB media containing carbenicillin (50 μg/mL, Invitrogen) overnight at 37°C. Carbenicillin-resistant colonies were selected and plasmids were purified using the GenElute Plasmid MidiPrep system according to the manufacturer’s instructions (Sigma-Aldrich).

2.4.1 **pLight_Switch CNR1 Promoter-Renilla Luciferase Construct**

The pLight_Switch CNR1 promoter-Renilla luciferase construct (pCNR1) was purchased from SwitchGear Genomics (Menlo Park, CA). This plasmid is a 3656 bp variant of the pGL3-basic (Promega) line of promoters. The plasmid contains the following features, which are illustrated in figure 5A: the 904 bp CNR1 promoter sequence inserted into the multiple cloning site between the *Mlu*I and *Bgl*II restriction sequences, the *Renilla* luciferase gene and SV40 late poly-adenylation signal, an origin of replication site, and an ampicillin resistance gene. An empty vector, pLS_Empty (pELS), was made from pCNR1 to serve as a negative control. The CNR1 promoter was restriction enzyme digested from 500 ng pCNR1 in 1 U FastDigest® *Hind*III, 1 U FastDigest® *Sac*I, and 20% FastDigest® Green Buffer in dH₂O to a final volume of 20 μL at 37°C for 15 min (Fermentas Canada, Burlington, ON). The reaction was heat inactivated at 80°C for 5 min. The 2656 bp product was resolved on a 0.7% agarose gel, the DNA was purified using the GenElute Gel Extraction Kit (Sigma). Five and 3’ overhangs were removed from the entire volume of gel-purified DNA via mung bean nuclease (4 U) in 5% mung bean nuclease buffer in dH₂O to a final volume 50 μL at 30°C for 30 min (New England Biolabs, Pickering, ON). Mung
bean nuclease was inactivated by the addition of 0.01% SDS and the DNA was purified by phenol/chloroform extraction. Two hundred nanograms of plasmid were circularized using T4 DNA ligase (400 U; New England Biolabs) in 10% T4 DNA ligase buffer in dH2O to a final volume of 20 μL at 16°C over-night. The resulting pELS plasmid was chilled on ice and used to transform electrocompetent *E. coli* as described above. An aliquot of pELS was sequenced by GeneWiz Inc. (South Plainfield, NJ) to confirm the removal of the *CNR1* promoter.

### 2.4.2 Firefly Luciferase Constructs

The pGL3-basic cytomegalovirus (CMV) promoter-firefly luciferase construct (pCMV) was used as a control for the dual luciferase assay because activity of this promoter had been characterized in 7/7, 7/111, and 111/111 cells (Hogel, 2011; Promega). This plasmid is a 6600 bp variant of the pGL3-basic (Promega) line of promoters. The plasmid contains the following features, which are illustrated in figure 5B: an 825 bp CMV immediate early enhancer/promoter sequence inserted into the multiple cloning site, followed immediately by the firefly luciferase gene and SV40 late poly-adenylation signal, an SV40 early enhancer/promoter driving expression of the hygromycin resistance gene, an origin of replication site, and an ampicillin resistance gene.

The pTL-basic (pTL) promoter-firefly luciferase construct was purchased from Panomics (Santa Clara, CA). This plasmid is a 4800 bp variant of the pGL3-basic (Promega) line of promoters. The plasmid contains the following features, which are illustrated in figure 5C: a multiple cloning site, followed immediately by the firefly luciferase gene and SV40 late poly-adenylation signal, an origin of replication site, an ampicillin resistance gene, and an f1 origin of replication. Two tandem repeat promoter-reporter constructs were derived from the pTL promoter (Panomics). These were the NF-κB construct (pNF) and the ERE construct (pERE),
which contain 5 tandem repeat response elements for their respective transcription factors inserted between the \textit{Bgl}II and \textit{Hind}III restriction sites of the pTL plasmid (Panomics).

2.4.3 \textbf{pEGFP Construct}

The pEGFP construct was purchased from Promega. This plasmid is a 4700 bp variant of the pGL3-basic (Promega) line of promoters. The plasmid contains the following features, which are illustrated in figure 5D: an 825 bp CMV immediate early enhancer/promoter sequence inserted into the multiple cloning site, followed immediately by the enhanced green fluorescent protein (\textit{Aequorea victoria}) gene and SV40 late poly-adenylation signal, an SV40 early enhancer/promoter driving expression of the kanamycin/neomycin resistance gene, an origin of replication site, and an ampicillin resistance gene.

2.5 \textbf{Transfection of Vectors into Cells and the Dual Luciferase Assay}

The pCNR1 or pELS plasmids were transfected alone or co-transfected with pERE, pNF or pTL plasmids into 7/7, 7/111, and 111/111 cells. Promoter activity was then quantified by measuring firefly and \textit{Renilla} luciferase activity in cell lysates \textit{via} the dual luciferase assay. The pCMV plasmid was transfected into 7/7, 7/111, and 111/111 cells as a control because the activity of this promoter in the presence of mHtt in 7/111 and 111/111 cells had been previously characterized (data not shown; Hogel, 2011). The pEGFP plasmid was transfected into all cells in order to visually estimate transfection efficiency by fluorescence microscopy.

Transfections were performed using Lipfectamine 2000\textsuperscript{®} reagent according to the manufacturer’s instructions (Invitrogen). Transfections were performed on cells grown in 24-well plates. Briefly, 1 \textmu L Lipofectamine 2000\textsuperscript{®} reagent was mixed with 50 \textmu L opti-MEM media (Invitrogen), per transfection, and incubated at room temperature for 20 min. In a separate tube, promoter-reporter plasmids were mixed with 50 \textmu L opti-MEM media, per transfection, and
Figure 5. Several plasmids were transfected into 7/7, 7/111, and 111/111 cells to study the CB₁ promoter activity. A) The pCNR1 plasmid (SwitchGear Genomics) contains 904 bp of the CB₁ promoter driving expression of the Renilla luciferase gene. B) The pCMV plasmid contains the CMV promoter driving expression of the firefly luciferase gene. D) pTL is a minimal promoter plasmid from which the tandem repeat ERE and NF-κB response element promoters (pERE and pNF) are built. C) The pEGFP plasmid (Promega) was used to visually assess transfection efficiency and contains the CMV promoter driving EGFP gene expression. Amp<sup>R</sup>, ampicillin resistance; ori, origin of replication; Hyg<sup>R</sup>, hygromycin resistance; Neo<sup>R</sup>, neomycin resistance; Kan<sup>R</sup>, kanamycin resistance; MCS, multiple cloning site.
incubated at room temperature for 5 min. Plasmid concentrations were: 400 ng pCNR1 or pELS, 200 ng pERE, pNF, or pTL, or 50 ng pCMV, and 50 ng pEGFP. The plasmid and Lipofectamine 2000® solutions were combined and allowed to incubate for 30 min at room temperature. Media was aspirated from cells, cells were washed twice with 1X M PBS, and were then given 500 μL antibiotic-free media. The combined Lipofectamine 2000®/plasmid solution was added to each well (100 μL/well) and cells were incubated at 33°C for 24 h.

The dual luciferase assay protocol was adapted from the manufacturer’s instructions (Promega). The protocol is described here for 1 well in a 24-well plate. Media was aspirated from cells and they were washed once with 1X M PBS. One hundred microlitres of 20% passive lysis buffer (PLB) were added and this solution was allowed to incubate for 30 min at room temperature with shaking. The cell lysate was scraped and collected into a 0.5 mL eppendorf tube. The luciferase assay substrate was resuspended in luciferase assay buffer II to make luciferase assay reagent. Ten microlitres of cell lysate solution were added to 50 μL luciferase assay reagent and firefly luciferase activity measured on a GloMax-20/20® single tube luminometer (Promega). The Stop&Glo® substrate was diluted 1 in 50 in Stop&Glo® buffer to make Stop&Glo® reagent. Fifty microlitres of Stop&Glo® reagent were added to the cell lysate/luciferase assay solution, this was rapidly mixed, and Renilla luciferase activity measured on the luminometer.

Luciferase activity data were normalized to total protein content in cell lysates. This was done because nearly all promoters tested to date are affected to some degree by expression of mHtt (Hogel et al., 2011), protein concentration accounts for differences in cell growth and number, and normalizing to total protein is a verified method of analyzing luciferase data (Krainc et al., 2007; Schagat et al., 2007). Four microlitres of cell lysate solution were added to
796 μL dH₂O and 200 μL Bradford dye reagent (Bio-Rad, Mississauga, ON). This solution was mixed for 5 min at room temperature. Protein concentrations were then determined by measuring absorption at 595 nm and comparing absorption values to those generated by a series of bovine serum albumin (BSA) solutions with known concentrations between 0.05 and 10 μg/μL protein.

2.6 Quantitative Reverse Transcriptase (qRT)-Polymerase Chain Reaction (PCR)

qRT-PCR was employed in order to measure the endogenous levels of several genes in the 7/7, 7/111, and 111/111 cells.

2.6.1 Trizol Harvest of RNA from Cell Culture

RNA was harvested from 7/7, 7/111, and 111/111 cells grown to approximately 80% confluency in 24-well plates using the Trizol® (Invitrogen) extraction method. Media was aspirated from cells and cells were washed once in 1X PBS. Cells were lysed with 200 μL Trizol®, and lysates were incubated on ice for 3 min. Forty microlitres of chloroform were added and samples were centrifuged at 12,000 x g for 20 min at 4°C. The aqueous upper layer was drawn off and mixed with 100 μL isopropanol. This solution was incubated on ice for 10 min and centrifuged at 12,000 x g for 10 min at 4°C. The supernatant was discarded and the pellet resuspended in 200 μL ice-cold, 75% ethanol. This solution was incubated on ice for 10 min and centrifuged at 7,500 x g for 5 min at 4°C. The supernatant was discarded, the pellet was incubated on ice for 10 min, to evaporate any remaining ethanol, and resuspended in 10 μL dH₂O. RNA samples were stored at -80°C.

2.6.2 Reverse Transcriptase Reaction

Reverse transcription reactions were used to synthesize cDNA from an mRNA template. Reactions were carried out with SuperScript III® reverse transcriptase (+RT, Invitrogen), or without (-RT) as a negative control for use in subsequent PCR experiments. The concentration of
RNA was determined by absorption spectrophotometry at 260 nm. Based on the concentration of RNA determined by spectrophotometry, 2 μg of RNA were added to the reverse transcriptase reaction containing 0.5 μM dNTPs and 7.5 μM oligo-d(T)12-18 (Invitrogen) in dH2O to a final volume of 13 μL for +RT reactions, or 14 μL for –RT reactions. This solution was incubated at 65°C for 5 min then chilled on ice for 1 min. Twenty percent SuperScript buffer, 5% RNase OUT (RNase inhibitor cocktail), 5 mM dithiothreitol, and 200 U SuperScript III® reverse transcriptase (Invitrogen) were added to the reaction, which was incubated for 1 h at 50°C, followed by 15 min at 70°C to end the reaction. The reaction was diluted 1 in 2 in dH2O and stored at -20°C.

2.6.3 RT-PCR

One microlitre of cDNA produced via RT reaction was added to 10% PCR buffer, 0.3 mM dNTPs, 0.5 μM forward and 0.5 μM reverse primers, and 0.75 U Pfu DNA polymerase in dH2O to a final volume of 20 μL (Fisher Scientific, Ottawa, ON). The PCR program was: 95°C for 3 min, 35 cycles of 95°C 30 s, a primer-specific annealing temperature (Table 1) for 30 s, and 72°C for 30 s, and 72°C for 4 min. PCR products were mixed with 0.2% xylene cyanol and bromophenol blue (1:1, v/v) and resolved by electrophoresis on 2% (w/v) agarose gels at 80 V for 120 min.

2.6.4 LightCycler® SYBR Green qRT-PCR

mRNA expression of several genes was quantified via real-time PCR using cDNA synthesized from RT reactions. qRT-PCR was conducted using the LightCycler® system and software (version 3.0; Roche, Laval, QC). cDNA abundance was measured using SYBR Green (Roche), contained in the PCR buffer, which intercalates with double-stranded DNA and fluoresces green. Fluorescence is then quantified by the LightCycler® on a per-sample basis.
during each round of PCR amplification of cDNA. qRT-PCR reactions were composed of a primer-specific concentration of MgCl₂, 0.5 μM each of forward and reverse primers, 2 μL of LightCycler® FastStart Reaction Mix SYBR Green I [0.3 mM dNTP, 10% SYBR Green I dye, 1.2 U FastStart Taq DNA polymerase], and 1 μL cDNA to a final volume of 20 μL with dH₂O (Roche). The PCR program was: 95°C for 10 min, 50 cycles of 95°C 10 s, a primer-specific annealing temperature (Table 1) for 5 s, and 72°C for 10 s. Melting curve analysis was performed immediately after the PCR program to determine the purity of the PCR product produced. The melting curve program was 95°C for 10 s, 60°C for 30 s, a ramp to 99°C at 0.20°C/s, and 40°C for 30 s. qRT-PCR experiments always included sample-matched –RT controls, a no-sample dH₂O control, and a standard control containing 1 μL of product-specific cDNA of a known concentration in copies/μL. Expression data were quantified by comparing the crossing points (i.e. the cycle number during PCR amplification at which the amount of product measured began to increase at a logarithmic rate) of each sample to a product-specific standard curve generated by plotting the crossing points of known standards against their respective concentrations in copies/μL.

2.7 Immunocytochemistry

7/7, 7/111, and 111/111 cells were grown to approximately 50% confluency on 0.01% poly-D-lysine coated cover-slips in 24-well plates. Media was aspirated from wells and cells were washed twice in 1X PBS. Cells were fixed for 10 min at room temperature with 4% PFA and washed three times with 1X M PBS, 5 min each, with shaking. Cells were incubated with blocking solution [1X PBS, 5% normal goat serum, 0.3% TritonX-100 (Sigma-Aldrich) in dH₂O] for 1 h at room temperature, with shaking. Following blocking, cells were washed with primary antibody solutions of anti-N-CB₁ (polyclonal rabbit anti-amino-terminal CB₁ IgG,
Cayman Chemical, Ann Arbor, MI) diluted 1:500 in antibody dilution buffer [1X PBS, 1% (w/v) BSA, 0.3% TritonX-100 (Sigma-Aldrich) in dH2O] overnight at 4°C, with shaking. Cells were washed three times with 1X PBS, 5 min each, with shaking. Cells were incubated in Cy2 (cyanine-conjugated polyclonal goat anti-rabbit IgG, Jackson ImmunoResearch, West Grove, PA) diluted 1:500 in antibody dilution buffer for 1 h at room temperature, protected from light, with shaking. Cells were washed three times with 1X M PBS, 5 min each, with shaking. Cover-slips were removed from wells and placed on SuperFrost slides with 2 μL Hoescht nuclear stain (Sigma-Aldrich) and 2.5 μL Fluorsave® reagent (Calbiochem via Cedarlane, Burlington, ON). Immunofluorescence was visualized with a Zeiss Axioplan II MOT fluorescent microscope, images were captured using Axionvision Rel. Version 4.8.2 and an Axiocam HRC Colour Camera (Carl Zeiss Canada, Toronto, ON). Immunofluorescence was also visualized with a Zeiss 510 Upright Laser Scanning Microscope, images were captured using Zen Image Capture 2009 edition (Carl Zeiss Canada). The following excitation/emission filters were used to visualize fluorescence: for Cy2 492 nm/510 nm, and for Hoescht nuclear staining 350 nm/461 nm. For confocal analysis, 24 images were captured using Zen Image Capture with a section thickness of 0.35 μm. Individual cells were analyzed as follows. A line 50 μm long, passing through the nucleus, was drawn across the cell. The Zen program quantified fluorescence along that line per μm. Data were then binned into 5 μm segments, and the value of each bin calculated as the mean fluorescence within each 5 μm segment (i.e. 5 μm/bin; Fig. 6). For each treatment group fifty cells were analyzed and the mean of each 5 μm segment was calculated.
Figure 6. The cellular distribution of CB₁ was analyzed by measuring fluorescence intensity along a line transecting a cell. Confocal images acquired using the Zen Image Capture software were analyzed as illustrated here. Cells were grown on cover-slips for the immunocytochemical detection of CB₁. A 50 μm line transecting the nucleus was drawn over 50 cells per treatment group. Fluorescence intensity along this line was quantified per cell per μm and the mean of each 5 μm segment was calculated. Here, a 7/111 cell incubated with anti-N-CB₁ and Cy² secondary antibody (green) is depicted and the corresponding data for the first 15 μm is provided to the right.
2.8 On- and In-cell Western Analyses Using the Odyssey Imaging System

7/7, 7/111, and 111/111 cells were grown to approximately 90% confluency in 0.01% poly-D-lysine coated 96-well plates. Media was aspirated from wells and cells were washed twice in 1X PBS. Cells were fixed for 10 min at room temperature with 4% PFA and washed three times with 1X M PBS, 5 min each, with shaking. For on-cell assays, cells were incubated with blocking solution (as described in 2.7, without TritonX-100) for 1 h at room temperature, with shaking. Following blocking, cells were washed with primary antibody solutions directed against N-CB1 diluted 1:500, pERK2(Tyr204) diluted 1:200 [polyclonal mouse anti-pERK(Tyr204) IgG, Santa Cruz Biotechnology, Santa Cruz, CA], ERK2 diluted 1:200 (polyclonal rabbit anti-ERK2 IgG, Santa Cruz Biotechnology), pAkt(Ser473) diluted 1:200 [polyclonal mouse anti-pAkt(Ser473) IgG, Cell Signalling Technology, Danvers, MA), panAkt diluted 1:250 [polyclonal rabbit anti-Akt IgG, Cell Signalling Technology], or β-actin diluted 1:2000 (monoclonal mouse anti-β-actin IgG, Millipore) in antibody dilution buffer (as described in 2.7, for on-cell assays) overnight at 4°C, with shaking. Cells were washed three times with 1X PBS, 5 min each, with shaking. Cells were incubated in IR\textsuperscript{CW700} dye [infrared dye-conjugated polyclonal goat anti-mouse IgG (red)] and/or IR\textsuperscript{CW800} dye [infrared dye-conjugated polyclonal anti-rabbit IgG (green), Rockland Immunochemicals, Gilbertsville, PA] diluted 1:500 in antibody dilution buffer (without TritonX-100) for 1 h at room temperature, protected from light, with shaking. Cells were washed three times with 1X PBS, 5 min each, with shaking. Cells were allowed to air-dry overnight, protected from light. On-cell western analyses were then conducted using the Odyssey Imaging system and software (version 3.0; Li-Cor, Lincoln, NE). Image acquisition and quantification were completed using the default settings for the Microplate2 and Multi-96well programs, respectively.
In-cell assays followed the completion of on-cell assays. The process described above was repeated, but TritonX-100 was added to all blocking and dilution solutions to permeabilize cells.

2.9 Cell Viability Assay

The Live/Dead® cell viability assay (Invitrogen) employs the dyes calcein AM (CalAM) and ethidium homodimer-1 (EthD-1). CalAM is cleaved to produce the green fluorophore calcein by enzymatic activity of esterases in metabolically active cells. Cells staining positive for EthD-1 have become permeable to the dye, which cannot passively enter cells, and the dye fluoresces red upon intercalation with nucleic acids. Cells can exist along a continuum of CalAM and EthD-1 staining from positive for CalAM and negative for EthD-1 to *vice versa*, but not negative or positive for both stains. The intensity of green and red fluorescence are therefore directly and indirectly correlated measures of general cell viability, respectively. Cells were grown to approximately 90% confluency on 0.01% poly-D-lysine-coated cover-slips in 24-well plates or in 0.01% poly-D-lysine-coated 96-well plates. Media was aspirated from wells and cells were washed twice in 1X PBS. Cells were incubated with 2 μM EthD-1 and 4 μM CalAM (diluted in 1X PBS) for 45 min, at room temperature, with shaking. Following incubation, cells were washed once with 1X PBS. 7/7 cells grown in serum-containing media were used as a positive control for CalAM staining and a negative control for EthD-1 staining. 7/7 cells incubated for 45 min with 70% methanol prior to dye incubation were used as a positive control for EthD-1 staining and a negative control for CalAM staining. Cover-slips were removed from wells, placed on SuperFrost slides, and fluorescence was visualized with a Zeiss Axioplan II MOT fluorescent microscope, images were captured using Axionvision Rel. Version 4.8.2 and an Axiocam HRC Colour Camera (Carl Zeiss Canada). For cells grown in 96-well plates,
fluorescence was quantified using a SynergyHT fluorescent/luminescent plate reader (Promega) set to read from the bottom of the plate with a sensitivity setting of 50. Fluorescence readings were acquired twice for each sample. The following excitation/emission filters were used to visualize fluorescence: for EthD-1 528 nm/617 nm, and for CalAM 494 nm/517 nm.

2.10 CellTiter-Glo® ATP Quantification

The CellTiter-Glo® cell viability assay (Promega) measures ATP concentration in a cell culture solution. Firefly luciferase enzymes require ATP to catalyze a light-yielding reaction. In this assay, the firefly luciferase protein and its substrate, luciferin, are mixed with cells grown in culture, and the ATP endogenously produced by the cells is the limiting reagent in the luciferase reaction. Thus, the amount of light produced is directly proportional to the concentration of ATP present. Cells were grown to approximately 90% confluency in 0.01% poly-D-lysine-coated 96-well plates. Fifty microlitres of media were aspirated from wells. Fifty microlitres of CellTiter-Glo® reagent (resuspended in CellTiter-Glo® buffer according to the manufacturer’s instructions) were added to the wells. Cells were incubated with CellTiter-Glo® reagent for 2 min, at room temperature, with shaking, followed by 10 min incubation at room temperature without shaking. Luminescence was quantified using a SynergyHT fluorescent/luminescent plate reader (Promega) set to read from the bottom of the plate with a sensitivity setting of 200. Luminescence readings were acquired twice for each sample. The excitation and emission filters used were Lum/E and 645 nm, respectively. Background luminescence was collected using a cell-free well containing 50 μL of media and 50 μL CellTiter-Glo® reagent and subtracted from each sample reading. For each experiment, an ATP standard curve was created with ATP concentrations from 1 nM to 100 μM in a final volume of 50 μL cell culture media and 50 μL
CellTiter-Glo® reagent. This standard curve was used to calculate ATP concentration in each sample.

2.11 Statistical Analyses

The *in situ* hybridization OD values for mRNA expression in wild-type, R6/1, R6/2 and mice were analyzed by two-way analysis of variance (ANOVA). The factors considered were genotype and disease stage. Fold-change values derived from *in situ* hybridization OD values for mRNA expression in CB$_1^{+/−}$ mice were analyzed by two-tailed Student’s *t*-test. Data produced from viability assays, dual luciferase assays, qRT-PCR, and on- and in-cell western assays, were analyzed by one- or two-way ANOVA, as indicated. *Post-hoc* analyses were performed using the Tukey’s Honest Significance Test. Homogeneity of variance was confirmed using Bartlett’s Test. The level of significance was set to $P < 0.001$, $< 0.01$, or $< 0.05$, as indicated, and all results are reported as the mean ± standard error of the mean (S.E.M). Analyses were performed, and graphs were constructed, using Microsoft Excel (2011) and GraphPad (version 5.04, Prism, La Jolla, CA).
CHAPTER 3

Results

3.1 CB₁, Fatty Acid Amide Hydrolase (FAAH), and CB₂ mRNA Levels were Dysregulated in R6/1 and R6/2 HD Transgenic Mice.

To determine whether the observation that CB₁ mRNA abundance is reduced in the striatum of adult transgenic HD mice reflected a uniform or region-specific decrease in CB₁ mRNA level (Denovan-Wright & Robertson, 2000), we used in situ hybridization to examine CB₁ mRNA levels in the lateral, ventromedial and dorsomedial striatum, and cortex of HD mice relative to age-matched, wild-type controls. We chose to examine both the R6/1 and R6/2 transgenic HD mouse lines. R6/1 mice express exon 1 of the mHtt transgene containing approximately 115 CAG repeats and develop HD motor symptoms at approximately 8 weeks of age when their performance in the rotarod task is poorer than similarly aged wild-type littermates (Li et al., 2005). Motor control progressively deteriorates in R6/1 mice until death at approximately 30 weeks of age (Mangiarini et al., 1996). R6/2 mice express exon 1 of the mHtt transgene containing approximately 150 CAG repeats (Li et al., 2005). HD progression is more rapid in R6/2 mice than R6/1 mice and rotarod performance declines in R6/2 mice at approximately 4 weeks of age (Li et al., 2005). R6/2 mice die at approximately 12 weeks of age (Bjorkqvist et al., 2005). Thus, the two models experience the same order of development of HD symptoms over different time periods and can be compared to examine how disease pathogenesis correlates with molecular phenomena such as transcriptional dysregulation (Zuccato et al., 1998). We also examined cortical FAAH mRNA levels via in situ hybridization in R6/1 and R6/2 HD mice, relative to age-matched wild-type controls. Following autoradiography, the optical density (OD) corresponding to mRNA hybridization with the radiolabeled probe was measured at ages corresponding to four stages of disease progression [pre- (4 week), early- (8
week), mid- (14 week), and late- (26 week) symptomatic] in R6/1 and three stages of disease progression [pre- (3 week), mid- (6 week), and late- (11 week) symptomatic] in R6/2 mice. These measurements were compared to age-matched wild-type littermates. Representative sections illustrating CB₁ and FAAH hybridization are presented in figure 7. CB₁ mRNA levels were lower in the lateral striatum, but unchanged in the dorsomedial and ventromedial striatum, of 26 week-old wild-type mice compared to 4 week-old wild-type mice \((n = 4; P < 0.05; \text{Fig. 8A,B,C})\). The number of CB₁-labelled cortical neurons was greater in 26 week old wild-type mice compared to 4 week-old wild-type mice \((n = 4; P < 0.05; \text{Fig. 8D})\). In wild-type mice, there was a decrease in the lateral striatum, and an increase in the cortex, in CB₁ mRNA abundance with age. There was no difference in CB₁ mRNA abundance in the lateral, ventromedial, and dorsomedial striatum, and the number of cortical neurons in pre-symptomatic R6/1 mice compared to wild-type littermates at the ‘pre’ stage. A lower level of CB₁ mRNA was observed at early-, mid-, and late-symptomatic disease stages in the lateral, ventromedial, and dorsomedial striatum of R6/1 mice, relative to age-matched wild-type littermates and pre-symptomatic R6/1 mice \((n = 4; P < 0.05; \text{Fig. 8A,B,C})\). The number of CB₁-labelled cortical neurons was lower in R6/1 mice at early-, mid-, and late-symptomatic disease stages, relative to age-matched wild-type littermates and pre-symptomatic R6/1 mice \((n = 4; P < 0.05; \text{Fig. 8D})\). Cortical FAAH mRNA levels were lower in 26 week-old wild-type mice compared to 4 week-old wild-type mice \((n = 4; P < 0.05; \text{Fig. 9})\). In R6/1 mice, cortical FAAH mRNA levels were lower in mid- and late-symptomatic stages compared to the pre-symptomatic period \((n = 4; P < 0.05; \text{Fig. 9})\). FAAH mRNA levels were higher in late-stage symptomatic R6/1 mice than in age-matched wild-type littermates \((n = 4; P < 0.05; \text{Fig. 9})\).
Similar to the wild-type littermates of R6/1 mice, CB₁ mRNA levels were lower in the lateral striatum, but unchanged in the ventromedial and dorsomedial striatum, of 11 week-old wild-type littermates of R6/2 mice compared to 3 week-old wild-type mice (n = 4; P < 0.05; Fig. 10A,B,C). Further, the number of CB₁-labelled cortical neurons was greater in 11 week-old wild-type mice compared to 3 week-old littermates (n = 4; P < 0.05; Fig. 10D). In R6/2 mice, CB₁ mRNA abundance was reduced at mid- and late-symptomatic stages in the lateral, dorsomedial, and ventromedial striatum of R6/2 mice compared to age-matched wild-type littermates and 3 week-old R6/2 mice (n = 4; P < 0.05; Fig. 10A,B,C). The number of CB₁-labelled cortical neurons was lower in R6/2 mouse cortical neurons at mid-, and late-symptomatic disease stages compared to age-matched wild-type littermates and 3 week-old R6/2 mice (n = 4; P < 0.05; Fig. 10D). Cortical FAAH mRNA levels were lower in 11 week-old wild-type and 6 and 11 week-old R6/2 mice compared to 3 week-old littermates (n = 4; P < 0.05; Fig. 11). FAAH mRNA abundance was greater in pre-, mid-, and late-symptomatic disease stages of R6/2 mice compared with age-matched wild-type littermates (n = 4; P < 0.05; Fig. 11). CB₁ mRNA abundance was decreased in the lateral striatum and increased in cortical neurons as part of the aging process in wild-type littermates of R6/1 and R6/2 mice. CB₁ mRNA levels declined early in HD symptom onset in 3 regions of the striatum, and in cortical neurons. Cortical FAAH mRNA levels were lower in aged wild-type, R6/1, and R6/2 mice compared to young mice of the same genotype. Cortical FAAH expression was higher in aged HD mice than age-matched wild-type littermates. If FAAH levels are higher in HD mice than in wild-type mice, then eCB tone (AEA abundance) may be lower in older HD mice compared to similarly aged wild-type mice because FAAH is the major catabolic enzyme of AEA (Navarro et al., 2009).
We also wanted to determine whether expression of CB$_2$ was altered during HD disease progression in R6/2 mice. We were unable to specifically detect CB$_2$ mRNA using in situ hybridization (data not shown). Instead, CB$_2$ was quantified via qRT-PCR. CB$_2$ mRNA abundance was greater in late-symptomatic stage R6/2 mice compared to pre-symptomatic R6/2 mice and age-matched wild-type littermates ($n = 4$; $P < 0.05$; Fig. 12). Expression of CB$_2$ mRNA is inducible in the presence of pro-inflammatory cytokines such as interleukin-1$\beta$, and TNF$\alpha$ (Borner et al., 2007a). Therefore, inflammation occurring at the late stages of HD progression may be responsible for induction of CB$_2$ levels.

CB$_1$ mRNA levels decline during adulthood in the presence of mHtt (Denovan-Wright & Robertson, 2000). To determine whether CB$_1$ mRNA levels were different in the central nervous system of HD mice relative to wild-type mice early in development, we probed sections from P1 wild-type and HD R6/2 mice for CB$_1$ using in situ hybridization. No differences were observed in CB$_1$ mRNA abundance or distribution between genotypes in the central nervous system and specifically in the primary and secondary motor cortices, lateral striatum, or dorsal colliculus and inferior colliculus (DCIC; Fig. 13). Importantly, the anatomical distribution of CB$_1$ mRNA at P1 was distinct from that of adulthood. In adulthood, CB$_1$ mRNA levels were highest in the striatum, relative to other tissues (Fig. 7; Denovan-Wright & Robertson, 2000). Therefore, the factors that facilitate high steady-state CB$_1$ mRNA levels in the striatum during adulthood are not present in the striatum at P1. In HD, during adulthood, the factors that facilitate high steady-state CB$_1$ mRNA levels are dysregulated in the presence of mHtt.
Figure 7. CB₁ mRNA levels were lower and FAAH mRNA levels were higher in HD mice compared to age-matched wild-type (WT) littermates. *In situ* hybridization was used to determine the distribution and relative abundance of CB₁ and FAAH mRNAs in WT, R6/1, and R6/2 mice. This figure presents representative sections of each disease stage for WT and HD mice. Disease stage is indicated above each section. Mouse line and probe used are indicated to the left.
Figure 8. CB₁ mRNA levels were lower in the lateral (A), dorsomedial (B), and ventromedial (C) striatum and cortical neurons (D) of symptomatic R6/1 mice compared to pre-symptomatic R6/1 mice and age-matched WT littermates. OD measurements were collected using Kodak 3D imaging software. Local background was subtracted from each measurement to correct for background variability. CB₁-labelled cortical neurons were counted because cortical mRNA hybridization was punctate rather than homogeneous over a wide area, as in the striatum (Fig. 4). Significance was determined via two-way ANOVA for genotype and age followed by post-hoc Tukey’s test. ** P < 0.05 between genotypes within disease stage, * P < 0.05 within genotype compared to pre-symptomatic, n = 4.
Figure 9. Cortical FAAH mRNA levels were lower in late-stage symptomatic R6/1 mice than in pre-symptomatic R6/1 mice, but greater than in age-matched WT mice. OD measurements were collected using Kodak 3D imaging software. Local background was subtracted from each measurement to correct for background variability. Significance was determined via two-way ANOVA for genotype and age followed by post-hoc Tukey's test. ** $P < 0.05$ between genotypes within disease stage, * $P < 0.05$ within genotype compared to pre-symptomatic, $n = 4$. 
Figure 10. CB₁ mRNA levels were lower in the lateral (A), dorsomedial (B), and ventromedial (C) striatum and cortical neurons (D) of symptomatic R6/2 mice compared to pre-symptomatic R6/2 mice and age-matched WT littermates. OD measurements were collected using Kodak 3D imaging software. Local background was subtracted from each measurement to correct for background variability. CB₁-labelled cortical neurons were counted because cortical mRNA hybridization was punctate rather than homogeneous over a wide area, as in the striatum (Fig. 4). Significance was determined via two-way ANOVA for genotype and age followed by post-hoc Tukey’s test. ** P < 0.05 between genotypes within disease stage, * P < 0.05 within genotype compared to pre-symptomatic, n = 4.
Figure 11. Cortical FAAH mRNA levels were higher in R6/2 mice compared to age-matched WT littermates. OD measurements were collected using Kodak 3D imaging software. Local background was subtracted from each measurement to correct for background variability. Significance was determined via two-way ANOVA for genotype and age followed by post-hoc Tukey’s test. ** $P < 0.05$ between genotypes within disease stage, * $P < 0.05$ within genotype compared to pre-symptomatic, $n = 4$. 
Figure 12. Striatal CB$_2$ mRNA levels were higher in late-symptomatic R6/2 mice compared to pre-symptomatic R6/2 mice and age-matched WT littermates. Archived striatal mRNA was converted to cDNA. CB$_2$ mRNA abundance was quantified and normalized to β-actin mRNA levels. Significance was determined via two-way ANOVA for genotype and age followed by post-hoc Tukey’s test. ** $P < 0.05$ between genotypes within disease stage, * $P < 0.05$ within genotype compared to pre-symptomatic, $n = 4$. 
Figure 13. CB₁ mRNA was expressed at highest levels in the primary motor cortex and dorsal cerebellum inferior colliculus (DCIC), not the lateral striatum, of P1 R6/2 and WT mice. *In situ* hybridization for CB₁ in sagittal sections derived from P1 WT and R6/2 mice. Sections were counter-stained with cresyl violet for the identification of specific anatomical features. 1. Layer II & III Primary motor cortex. 2. Lateral striatum. 3. DCIC.
3.2  \textit{CNR1} Promoter Activity was Lower in 7/111 and 111/111 Cells Expressing mHtt.

The number of primary CB$_1$ mRNA transcripts is reduced in 6 week-old R6/1 and 4 week-old R6/2 transgenic mice, which indicates that, in adult mice, mHtt affects the rate of CB$_1$ transcription in adult HD mice (McCaw \textit{et al.}, 2004). To determine whether mHtt directly decreased activity of the CB$_1$ gene promoter (\textit{CNR1}), we transfected serum-deprived 7/7, 7/111, and 111/111 cells with a promoter-reporter vector containing a 904 bp fragment of the human CB$_1$ promoter driving expression of the \textit{Renilla} luciferase enzyme (pCNR1). 7/7, 7/111, and 111/111 cells express 2 copies of wild-type mouse \textit{huntingtin} containing 7 CAG repeats (7/7), 1 copy of wild-type \textit{huntingtin} and 1 copy of mouse \textit{huntingtin} where exon 1 is replaced with exon 1 of the human \textit{huntingtin} gene containing 111 CAG repeats (HD; 7/111), or 2 copies of mouse \textit{huntingtin} containing the human mutant \textit{huntingtin} exon 1 allele (111/111). The mouse and human/mouse \textit{huntingtin} genes are under the control of the mouse \textit{huntingtin} promoter. Twenty-four hours of serum deprivation causes STHdh cells to exit the cell cycle, increase neurite outgrowth, and express D$_2$ and DARPP-32 (Paoletti \textit{et al.}, 2008). Consequently, serum deprivation produces a ‘MSN’ phenotype (Trettel \textit{et al.}, 2000; Paoletti \textit{et al.}, 2008). \textit{Renilla} luciferase activity was quantified and normalized to the total protein in each cell lysate. The pELS promoter-less plasmid was used as a negative control. \textit{CNR1} promoter activity was lower in 7/111 and 111/111 cells compared to 7/7 cells ($n = 12$, $P < 0.05$, Fig. 14). That is, \textit{CNR1} promoter activity was negatively correlated to the relative levels of mHtt in cells modeling ‘MSNs’.
Figure 14. Human CB₁ promoter (CNR₁) activity was lower in the 7/111 and 111/111 cells than 7/7 cells. A 904 bp CNR₁ promoter-Renilla luciferase construct (pCNR1) was transfected into serum-deprived 7/7, 7/111, and 111/111 cells. Eighteen hours post-transfection promoter activity was quantified via luciferase assay and relative light units (RLU) were normalized to total protein on a per sample basis. The promoter-less control pELS-Renilla luciferase plasmid served as a negative control. Significance was determined via one-way ANOVA followed by post-hoc Tukey’s test. * P < 0.01 relative to 7/7, ~ P < 0.01 relative to 7/111, n = 12.
3.3 CB₁ mRNA Levels were Lower in 7/111 and 111/111 Cells Expressing mHtt.

CNR1 promoter activity was lower in the presence of mHtt than in wild-type cells in a reporter assay and CB₁ mRNA levels were lower in transgenic HD mice than in wild-type mice. We wanted to determine whether endogenous CB₁ mRNA levels were lower in mHtt-expressing 7/111 and 111/111 cells compared to 7/7 cells. We used RT-PCR and agarose gel electrophoresis to show that CB₁ mRNA was expressed in 7/7, 7/111, and 111/111 cells and that primers were sufficiently specific to generate a single product of the expected size and sequence for CB₁ (Fig. 15). qRT-PCR was used to determine CB₁ mRNA levels in 7/7, 7/111, and 111/111 cells. Hypoxanthine ribosyltransferase (HPRT) has been used to normalize gene expression in animal and cell models of HD (McCaw et al. 2004; Gomez et al., 2006). However, HPRT levels varied between 7/7, 7/111, and 111/111 cells (n = 12; P < 0.01, Fig. 16). An alternative house-keeping gene for these cells is β-actin (Blazquez et al., 2011). We were able to confirm that β-actin levels were constant relative to total RNA in 7/7, 7/111, and 111/111 cells (n = 12; P < 0.01, Fig. 16). We then quantified relative CB₁ mRNA levels in dividing and post-mitotic 7/7, 7/111, and 111/111 cells. Levels of CB₁ mRNA were not different in dividing 7/7, 7/111, and 111/111 cells (Fig. 17A). In post-mitotic cells, CB₁ mRNA levels were reduced in a mHtt gene dose-dependent manner (n = 12; P < 0.01, Fig. 17A). CB₁ mRNA levels were elevated in post-mitotic 7/7 cells relative to dividing 7/7 cells (n = 12; P < 0.01, Fig. 17B). However, the relative increase in CB₁ mRNA abundance in post-mitotic cells compared to dividing cells was attenuated in cells expressing mHtt. Striatal CB₁ levels appeared lower at P1 compared to adulthood (Figs. 7 and 13). Therefore, the transition from low- to high-level CB₁ expression when 7/7 cells enter a post-mitotic state from a dividing state may model the transition from an ‘embryonic’ to an ‘adult’ neuronal phenotype. From these data two important points were drawn. First, mHtt affected CB₁
Figure 15. 7/7, 7/111, and 111/111 cells endogenously expressed CB₁ mRNA. RNA was harvested, converted to cDNA, and amplified by PCR before being resolved on a 2% agarose gel. Genomic DNA (gDNA) was used as a positive control, and –RT reactions were used as negative controls. An 89 bp band, the expected product size for CB₁, is shown here.
Figure 16. β-actin, not HPRT, was a house-keeping gene in 7/7, 7/111, and 111/111 cells. RNA was harvested from cells grown with (mitotic) or without (post-mitotic) serum-containing media, converted to cDNA, amplified and quantified by qRT-PCR. Significance was determined via two-way ANOVA for genotype and treatment followed by post-hoc Tukey’s test. ** $P < 0.01$ between treatments within genotype, * $P < 0.01$ relative to 7/7 within treatment, ~ $P < 0.01$ relative to 7/111 within treatment, $n = 12$. 
Figure 17. Endogenous CB₁ mRNA levels were lowered in the presence of mHtt in post-mitotic 7/111 and 111/111 cells. A) RNA was harvested and converted to cDNA, which was quantified by qRT-PCR. Expression data were normalized to β-actin mRNA levels. B) The fold-increase in CB₁ mRNA levels following serum-deprivation (i.e. post-mitotic/mitotic) were calculated for 7/7, 7/111, and 111/111 cells. Significance was determined via two-way ANOVA for genotype and treatment (A), or one-way ANOVA (B), followed by post-hoc Tukey’s test. ** P < 0.05 between treatments within genotype, * P < 0.05 relative to 7/7 within treatment, ~ P < 0.05 relative to 7/111 within treatment, n = 12.
expression at the level of transcription because both promoter activity and endogenous mRNA expression were reduced in the presence of mHtt, and second, mHtt reduced CB₁ expression in post-mitotic 7/111 and 111/111 cells. In all subsequent experiments, we chose to focus our attention on serum-deprived, post-mitotic, 7/7, 7/111, and 111/111 cells because they model adult striatal neurons, which are the sub-population of neurons most severely degenerated over the course of HD pathogenesis (Trettel et al., 2000; Kim et al., 2011).

3.4  CB₁ Protein Levels were Lower in 7/111 and 111/111 Cells Expressing mHtt.

To determine whether CB₁ protein levels were also lower in cells expressing mHtt we used an on- and in-cell western approach, rather than a traditional western blot methodology, because on- and in-cell westerns can be used to gather information about the cellular localization of GPCRs (Hudson et al., 2010; Wright et al., 2011) Moreover, anti-CB₁ antibodies were not amenable to traditional western blot approaches. The on- and in-cell western technique utilized primary antibodies directed against the N-terminal of CB₁ (Howlett et al., 1998), and fluorescent secondary antibodies directed against the anti-CB₁ antibodies to detect and quantify CB₁ protein abundance at the plasma membrane and, following permeabilization, total CB₁ levels in cells (Hudson et al., 2010). We found that total CB₁ protein levels were lower in 7/111 and 111/111 cells relative to 7/7 cells \( n = 24; P < 0.05, \text{Fig. 18A,C} \). There was no difference in CB₁ protein levels in 7/111 and 111/111 cells. The relative percentage of CB₁ protein present at the plasma membrane was greater in 7/111 cells, and greater still in 111/111 cells, compared to 7/7 cells \( n = 24; P < 0.05, \text{Fig. 18B,C} \). That is, although the total amount of CB₁ protein was lower in the presence of mHtt in 7/111 and 111/111 cells, the relative abundance of protein at the plasma membrane was higher. Therefore, although the mHtt-mediated decrease in CB₁ mRNA translated
Endogenous CB₁ protein levels were lower in 7/111 and 111/111 cells expressing mHtt. The percentage of CB₁ receptors at the plasma membrane was greater in 7/111 and 111/111 cells. A) Total CB₁ protein abundance was determined via in-cell western normalized to β-actin levels. B) The percent of CB₁ protein at the plasma membrane was determined via on-cell fluorescence for CB₁ over total CB₁ fluorescence in the same replicate. Significance was determined via one-way ANOVA followed by post-hoc Tukey’s test. * \( P < 0.05 \) relative to 7/7, ~ \( P < 0.05 \) relative to 7/111, \( n = 24 \). C) Representative immunocytochemical staining for CB₁ demonstrating a decrease in the overall abundance of CB₁ in 7/111 and 111/111 cells.
to a lower CB₁ protein level, the fraction of receptors at the plasma membrane was higher in mHtt-expressing cells.

3.5 Cannabinoid Agonists Increased CB₁ Promoter Activity, mRNA and Protein Levels in 7/7, 7/111, and 111/111 Cells

Given the known functional effects of cannabinoid agonism, including neuroprotection and increased expression of pro-survival genes (Fernandez-Ruiz et al., 2004), we wanted to determine whether cannabinoid treatment could alter CB₁ levels in 7/7, 7/111, and 111/111 cells. 7/7, 7/111, and 111/111 cells were transfected with pCNRI and treated with 1 μM ACEA (direct agonist), 1 μM URB-597 (FAAH inhibitor, indirect agonist), or ethanol (vehicle) for 18 h. Eighteen hours is the approximate half-life of ACEA in cell culture (Hillard et al., 1999). Renilla luciferase activity was quantified and normalized to total protein. Vehicle treatment reduced CNRI promoter activity relative to untreated cells (n = 12; P < 0.05, Fig. 19A). For this reason, we compared all drug treatments to vehicle treatment. CNRI promoter activity was greater in all cells treated with 1 μM ACEA, and 7/111 cells treated with 1 μM URB-597, relative to the vehicle control (n = 12; P < 0.05, Fig. 19B,C).

CB₁ mRNA levels were quantified and normalized to β-actin levels in cells treated with 1 μM ACEA, 1 μM URB-597, or vehicle for 18 h. Ethanol (vehicle) treatment reduced CB₁ mRNA levels in 7/7 and 7/111 cells, but these were not reduced in 111/111 cells, which were already low compared to 7/7 and 7/111 cells (n = 16; P < 0.05, Fig. 20A). CB₁ mRNA levels were greater in all cell lines treated with 1 μM ACEA and 1 μM URB-597 relative to vehicle (n = 16; P < 0.05, Fig. 20B,C). In 111/111 cells treated with ACEA or URB-597, CB₁ mRNA levels were reduced relative to 7/7 cells treated with ACEA or URB-597, respectively. ACEA- or URB-597-mediated fold induction of CB₁ was not different across cell lines (Fig. 20D).
Figure 19. CNRI promoter activity was induced by direct (1 μM ACEA) and indirect (1 μM URB-597) cannabinoid agonism in 7/7 and 7/111 cells. Activity of the pCNR1 promoter was quantified in cells treated with ACEA, URB-597 or vehicle control and normalized to total protein. A) Vehicle (ethanol) treatment was associated with lower CNRI activity in all cell types. B) 1 μM ACEA induced CNRI promoter activity in all cells types. C) 1 μM URB-597 induced CNRI promoter activity in 7/111 cells. Significance was determined via two-way ANOVA for genotype and treatment group followed by post-hoc Tukey’s test. ** $P < 0.05$ within genotype between treatments, * $P < 0.05$ relative to 7/7 within treatment group, ~ $P < 0.05$ relative to 7/111 within treatment group, $n = 12$. 
Figure 20. CB₁ mRNA levels were induced by direct (1 μM ACEA) and indirect (1 μM URB-597) cannabinoid agonism in 7/7, 7/111, and 111/111 cells. CB₁ mRNA levels were quantified via qRT-PCR. A) Vehicle (ethanol) treatment was associated with lower CB₁ mRNA levels in all cell types. B) 1 μM ACEA treatment induced CB₁ mRNA levels, and C) 1 μM URB-597 treatment also induced CB₁ mRNA levels. D) ACEA- and URB-597-mediated fold induction of CB₁ was not different when cell lines were compared. Significance was determined via two-way ANOVA for genotype and treatment group followed by post-hoc Tukey’s test. ** P < 0.05 within genotype between treatments, * P < 0.05 relative to 7/7 within treatment group, ~ P < 0.05 relative to 7/111 within treatment group, n = 16.
Cannabinoid agonism was associated with greater endogenous CB₁ mRNA levels in 7/7, 7/111, and 111/111 cells in the presence of mHtt. However, even when induced by cannabinoid agonism, both promoter activity and mRNA abundance were lower in cells expressing mHtt. That is, the higher steady-state level of CB₁ expression following cannabinoid agonism was reduced by mHtt and the fold induction was not different across cell lines. Therefore, cannabinoid agonism induced CB₁ promoter activity mRNA abundance above a basal level. In the presence of mHtt, the basal level of CB₁ was lower and consequently the induced level was also lower than in 7/7 cells.

Next, we asked whether cannabinoid agonism was associated with elevated CB₁ protein levels in 7/7, 7/111, and 111/111 cells. The half-life of CB₁ receptors is approximately 30 h (ExPASy, 2012) and protein abundance is a less transient measure of cannabinoid-mediated CB₁ induction than mRNA (Howlett et al., 1998). Further, an increase in CB₁ protein may represent an increase in functional receptor abundance. Vehicle treatment did not change total CB₁ protein levels in cells (n = 24; Fig. 21A). We found that treatment with 1 μM ACEA was associated with higher CB₁ protein levels, by approximately 2-fold, in all cell lines, relative to the vehicle control (n = 24; P < 0.05, Fig. 21B). The absolute level of ACEA-mediated CB₁ protein induction was reduced in the presence of mHtt (7/111 and 111/111 cells), relative to 7/7 cells. Additionally, CB₁ protein levels were not altered when cells were treated with 1 μM ACEA and 2 μM O-2050, a specific antagonist of CB₁ receptors (n = 24; P < 0.05, Fig. 21B). From these observations we concluded that cannabinoid-mediated induction of CB₁ mRNA translated to an increase in CB₁ receptors, and cannabinoid-mediated induction of CB₁ was reduced in the presence of mHtt, as is the basal expression of CB₁ in the presence of mHtt. The cannabinoid antagonist O-2050 blocked
the effect of ACEA on increasing CB₁ protein levels, which suggested that cannabinoids mediated their effect on CB₁ mRNA and protein levels via functional CB₁ receptors.

The initial reason for employing O-2050 in these experiments was to understand how CB₁ protein trafficking might differ between 7/7, 7/111, and 111/111 cells. First, we found that the percent of CB₁ at the plasma membrane was reduced in vehicle-treated 7/111 and 111/111 cells, relative to untreated controls \((n = 24; P < 0.05, \text{Fig. } 22A)\). However, the percentage of CB₁ protein present at the plasma membrane remained greater in 7/111 and 111/111 cells compared to 7/7 cells. Treatment of cells with 1 μM ACEA resulted in receptor internalization \([i.e.\, a\, \text{reduction in the percentage of CB₁ protein at the membrane; } (P < 0.05, \text{Fig. } 22B)]\). Treatment of cells with 1 μM ACEA and 2 μM O-2050 was associated with a greater (approximately 1.5-fold) percentage of CB₁ protein at the plasma membrane, relative to vehicle-treated cells (Fig. 22B). The percentage of CB₁ protein at the membrane was higher in 7/111 and 111/111 cells treated with 1 μM ACEA and 2 μM O-2050 than in 7/7 cells. Since the percentage of CB₁ protein at the membrane was greater in vehicle-treated 7/111 and 111/111 cells, this trend was anticipated. Therefore, the percentage of total CB₁ receptors present at the plasma membrane was greater in 7/111 and 111/111 cells expressing mHtt than 7/7 cells, yet the processes of CB₁ internalization and recruitment to the plasma membrane were still observed in all the cell types tested.

3.6 CB₁ Receptor Localization and Trafficking were Altered in 7/111 and 111/111 Cells Expressing mHtt

To gain a better understanding of CB₁ receptor trafficking, localization, and abundance, we employed immunocytochemistry and confocal imaging to detect CB₁ in untreated, vehicle-treated, 1 μM ACEA-treated, or 2 μM O-2050-treated 7/7, 7/111, and 111/111 cells. The
Figure 21. Direct (1 μM ACEA) cannabinoid agonism induced CB₁ protein levels in 7/7, 7/111, and 111/111 cells. CB₁ protein levels were quantified in cells treated with 1 μM ACEA or 1 μM ACEA and 2 μM O-2050 or vehicle control via in-cell western. A) Vehicle (ethanol) treatment did not change CB₁ protein levels. B) 1 μM ACEA treatment was associated with higher CB₁ protein levels, and this effect was blocked by 2 μM O-2050. Significance was determined via two-way ANOVA for genotype and treatment group followed by post-hoc Tukey’s test. ** P < 0.05 within genotype between treatments, * P < 0.05 relative to 7/7 within treatment group, ~ P < 0.05 relative to 7/111 within treatment group, n = 24.
Figure 22. mHtt does not impair CB₁ protein trafficking to the plasma membrane in 7/7, 7/111 and 111/111 cells. Plasma membrane CB₁ protein expression was quantified for cells treated with 1 μM ACEA or 1 μM ACEA and 2 μM O-2050 or vehicle control via on- and in-cell western. A) Vehicle-treatment was associated with lower plasma membrane CB₁ protein expression in 7/111 and 111/111 cells. B) 2 μM O-2050 treatment was associated with greater plasma membrane CB₁ expression in all cell types. Significance was determined via two-way ANOVA for genotype and treatment group followed by post-hoc Tukey’s test. ** P < 0.05 within genotype between treatments, * P < 0.05 relative to 7/7 within treatment group, ~ P < 0.05 relative to 7/111 within treatment group, n = 24.
intensity of fluorescence corresponding to CB₁ detection was reduced in untreated and vehicle-treated 7/111 and 111/111 cells, relative to 7/7 cells (Fig. 23). Fluorescence was visibly greater in all cells treated with 1 μM ACEA relative to vehicle-treated and untreated cells (Fig. 23). CB₁ fluorescence was not changed in cells treated with 2 μM O-2050 compared to vehicle-treated and untreated cells (Fig. 23). In untreated or vehicle-treated cells, CB₁ appeared evenly distributed throughout the cytoplasm, with slightly more fluorescence present at the plasma membrane. In cells treated with 1 μM ACEA, CB₁ was localized away from the plasma membrane, often in distinct foci, which may represent endoplasmic reticulum or endosomes. Finally, in cells treated with 2 μM O-2050 CB₁ was abundant at the plasma membrane and away from the interior of the cell (Fig. 23).

Fluorescence intensity was measured along a 50 μm line across the cell soma, spanning the nucleus, in 50 cells per treatment group. Fluorescence intensity data gathered per μm were averaged in 5 μm segments (Fig. 6). We observed that CB₁ fluorescence intensity was greater, overall, in untreated 7/7 cells, relative to 7/111 and 111/111 cells (n = 50; Fig. 24). In untreated 7/7 cells, CB₁ was evenly distributed throughout the cell, including the nucleus (~15 – 20 μm), although CB₁ fluorescence was greater at the plasma membrane (5 μm and 50 μm; n = 50; P < 0.01). CB₁ was distributed throughout the cytoplasm of untreated 7/111 and 111/111 cells but excluded from the nucleus. Following treatment with 1 μM ACEA, CB₁ levels were lowest at the plasma membrane and greatest at the peri-nuclear region corresponding with the location of the endoplasmic reticulum in all cell types (n = 50; P < 0.01; Fig. 24). Finally, in each of the cell lines treated with 2 μM O-2050, the abundance of CB₁ at the plasma membrane was higher and the cytoplasmic fraction was lower (n = 50; P < 0.01; Fig. 24). By studying intracellular CB₁ distribution in 7/7, 7/111, and 111/111 cells, we were able to verify a
Figure 23. CB₁ protein distribution and response to cannabinoids were similar in 7/7, 7/111, and 111/111 cells despite lower total CB₁ abundance in 7/111 and 111/111 cells. Representative confocal micrographs of CB₁ protein expression in cells treated with 1 μM ACEA or 2 μM O-2050 or vehicle control. Cell types are described to the left of each row and treatments above each column.
Figure 24. CB₁ protein distribution was altered following cannabinoid agonism (ACEA) or antagonism (O-2050) in 7/7, 7/111, and 111/111 cells. CB₁ protein expression was quantified as mean fluorescence intensity (MFI) along a 50 μm axis in cells treated with 1 μM ACEA or 2 μM O-2050. CB₁ protein expression was uniform in vehicle-treated 7/7 cells, but excluded from the nucleus (~15 – 20 μm) in 7/111 and 111/111 cells (top row). 1 μM ACEA treatment was associated with lower plasma membrane CB₁ and higher peri-nuclear CB₁ in all cell types (middle row). 2 μM O-2050 treatment was associated with higher plasma membrane CB₁ in all cell types (bottom row). Significance was determined via one-way ANOVA followed by post-hoc Tukey’s test. * P < 0.01 across axis relative to the 5 μm point, n = 50.
mHtt-dependent decrease in CB\textsubscript{1} protein levels, illustrate the uniform distribution of CB\textsubscript{1} in untreated cells, verify an ACEA-dependent induction of CB\textsubscript{1} expression, demonstrate an agonist-dependent internalization of CB\textsubscript{1} receptors, and an antagonist-dependent localization of CB\textsubscript{1} receptors to the plasma membrane. We also observed the presence of CB\textsubscript{1} in the nucleus of untreated 7/7 cells and not untreated 7/111 or 111/111 cells. The functional significance of this observation is not clear. Treatment with 1 μM ACEA was associated with increased nuclear CB\textsubscript{1} fluorescence in 7/111, but not 111/111, cells. ACEA treatment may, therefore, localize CB\textsubscript{1} receptors to the nucleus. mHtt appears to impair nuclear localization of CB\textsubscript{1} in 111/111, but not 7/111, cells.

3.7 Cannabinoid Agonists Induced CB\textsubscript{1} Levels Via Functional CB\textsubscript{1} Receptors

Next, we wanted to determine if cannabinoid-mediated induction of CB\textsubscript{1} mRNA and protein occurred by activation of CB\textsubscript{1} receptors. To do this, we first explored the possibility that other GPCRs could mediate the same induction of CB\textsubscript{1}. 7/7, 7/111, and 111/111 cells express dopamine D\textsubscript{2} receptors and CB\textsubscript{2} (Fig. 25A). These receptors are known to be co-expressed with CB\textsubscript{1} in vivo (Uriguen et al., 2009). CB\textsubscript{2} and CB\textsubscript{1} receptors share 95% sequence similarity. Therefore, even highly selective cannabinoid receptor ligands may interact with both CB\textsubscript{1} and CB\textsubscript{2} receptors (Hillard et al., 1999). We used several highly selective CB\textsubscript{1} and CB\textsubscript{2} ligands to determine the cannabinoid receptor that mediated CB\textsubscript{1} mRNA induction. We treated 7/7 cells with the CB\textsubscript{1} agonist ACEA (1 μM, CB\textsubscript{1} K\textsubscript{d} = 1.4 nM, CB\textsubscript{2} K\textsubscript{d} = 1.9 μM), the CB\textsubscript{1} neutral antagonist O-2050 (1 μM, CB\textsubscript{1} K\textsubscript{d} = 2.5 nM, CB\textsubscript{2} K\textsubscript{d} = 2.5 μM), the CB\textsubscript{2} agonist HU-308 (1 μM, CB\textsubscript{1} K\textsubscript{d} > 10 μM, CB\textsubscript{2} K\textsubscript{d} = 22.7 nM), the CB\textsubscript{2} antagonist AM-630 (2 μM, CB\textsubscript{1} K\textsubscript{d} = 5.1 μM, CB\textsubscript{2} K\textsubscript{d} = 31.2 nM), the D\textsubscript{2} receptor agonist quinpirole (1 μM), the D\textsubscript{1}/D\textsubscript{2} receptor agonist apo-morphine (1 μM), and vehicle controls and quantified the resulting CB\textsubscript{1} mRNA abundance.
The CB₁-selective agonist ACEA induced CB₁ mRNA expression in 7/7 cells while all other compounds employed did not alter CB₁ levels, relative to vehicle (ethanol and DMSO) controls \((n = 12; P < 0.05, \text{Fig. 25B})\). Therefore, CB₁-specific agonism, and not D₂R or CB₂ agonism, induced CB₁ expression in 7/7 cells.

Next, we sought to determine if a general inducer of transcription like a histone deacetylase (HDAC) inhibitor, could also increase CB₁ mRNA levels in cells. Cells were treated with the pan-HDAC inhibitor NaB (100 nM), the type 1 HDAC inhibitor TSA (1 μM), or vehicle (DMSO) for 18 h and CB₁ mRNA abundance was quantified. CB₁ levels were not altered by vehicle or NaB treatment (Fig. 26A,B). TSA treatment was associated with reduced CB₁ mRNA abundance in 7/7 and 7/111 cells, relative to vehicle treatment \((n = 12, P < 0.05; \text{Fig. 26C})\). Therefore, HDAC inhibition, which is popularly considered an inducer of general transcription (Cui et al., 2006), did not induce CB₁ mRNA levels in cells, whether they expressed mHtt or not.

If cannabinoid-mediated induction of CB₁ transcription was CB₁ receptor-dependent, then the induction should be cannabinoid dose-dependent. To test this hypothesis, 7/7 cells were treated with ACEA, mAEA, or AEA at 0.01, 0.10, 0.25, 0.50, 0.75, 1.00, and 5.00 μM for 18 h. Additionally, 7/7 cells were treated with 0.25, 0.50, or 0.75 μM ACEA or mAEA in conjunction with 1.0, 1.5, or 2.0 μM O-2050 (CB₁ neutral antagonist) or AM-281 (CB₁ antagonist/inverse agonist). CB₁ mRNA levels were induced, in a dose-dependent manner by ACEA, mAEA, and AEA (Fig. 27A). When plotted on a logarithmic scale for cannabinoid dose, the data assume a sigmoidal form indicative of a dose-response relationship for a non-linear regression assuming a variable slope (Hill coefficient). The \(EC_{50}\) values for ACEA, mAEA, and AEA were 0.36 μM, 0.53 μM, and 0.42 μM, respectively. The \(E_{max}\) values for ACEA, mAEA, and AEA were 0.32, 0.26, and 0.29 (CB₁/β-actin), respectively. Therefore, ACEA was the most potent inducer of CB₁
expression tested. This result was expected because ACEA has a greater affinity for CB₁ than mAEA or AEA (K<sub>d</sub> = 1.4 for ACEA vs. 20 nM for mAEA or AEA) and a longer half-life in cell culture (18 h for ACEA vs. 12 h for mAEA or AEA; Corchero et al., 1999; Pertwee et al., 1999).

We wanted to determine how quickly cannabinoid treatment could increase CB₁ mRNA levels. Previously, our experiments had utilized an 18 h treatment period. 7/7 cells were treated with 1 μM ACEA or vehicle control for 0.5, 1, 3, 6, 12, 18, 24, and 30 h and CB₁ mRNA abundance was quantified and normalized to β-actin mRNA levels. CB₁ mRNA levels were increased within 0.5 h of treatment and further increased within 18 h of treatment compared to vehicle control (n = 12; P < 0.05; Fig. 28). At 30 h post-ACEA exposure CB₁ mRNA levels were decreased relative to 18 h post-ACEA exposure. Thus, the maximum effect of ACEA treatment was observed at 18 h, which is a single half-life for this drug. After 18 h, CB₁ mRNA levels began to decline. From these data two hypotheses were formed. First, the down-stream transcription factors that mediated CB₁ induction were likely pre-existing and resident at the promoter and subject to post-translational modification or recruited quickly to the promoter in order to have facilitated the rapid (0.5 h) increase in CB₁ mRNA levels. Second, the gradual increase in CB₁ mRNA level during the first 18 h of treatment provided evidence that newly synthesized receptors were activated by the remaining cannabinoids in the media to further induce CB₁ expression.

Next, we wanted to establish whether ACEA and mAEA facilitated a dose-dependent induction of CB₁ mRNA via CB₁ receptors. To do this, 7/7 cells were treated with 0.25, 0.50, or 0.75 μM cannabinoid agonist and 1.0, 1.5, or 2.0 μM O-2050 or AM-281. Treatment with O-2050 resulted in an antagonist dose-dependent shift of the cannabinoid agonist-CB₁ mRNA level dose-response curve to the right (n = 16; P < 0.05, Fig. 27B,C). A similar result was observed
when AM-281 was employed; however, the magnitude of shift of the curve to the right was not antagonist dose-dependent \((n = 16; P < 0.05; \text{Fig.27D})\). AM-281 is known to act as an inverse agonist and this may explain the different results observed (Pertwee et al., 1999). To conclusively demonstrate CB\(_1\) induction was dependent upon the activation of CB\(_1\) receptors, a Schild plot was constructed as the logarithm of the dose-ratio minus 1 against the negative logarithm of the antagonist dose. In the Schild plot, competitive antagonism of a response appears as a linear relationship between the two variables with a slope approaching -1. The x-intercept of a line with a slope approaching -1 represents the dose of antagonist at which a two-fold increase in agonist concentration would be required to evoke the same response in the absence of antagonist \((\text{i.e. the pA}_2\))

Consequently, O-2050 produced a linear Schild plot with a slope of -1.03 and a pA\(_2\) value of 1.3 μM (Fig. 29). Thus, O-2050 inhibited CB\(_1\) receptor activation, and a consequent increase in CB\(_1\) mRNA levels, in a dose-dependent manner. AM-281 also inhibited CB\(_1\) receptor activation, but AM-281 did not perform as a pure competitive antagonist because the slope of this line was significantly different from 1 \(\left( P < 0.05 \right)\). From these data, we had shown that ACEA, mAEA, and AEA induce CB\(_1\) expression in a CB\(_1\) receptor-dependent manner, which can be competitively inhibited by CB\(_1\) antagonism.

Next, we wanted to determine what effect mHtt had on the observed cannabinoid dose-CB\(_1\) induction response relationship. We measured CB\(_1\) mRNA abundance in 7/7, 7/111, and 111/111 cells treated with 0.01, 0.10, 0.25, 0.50, 0.75, 1.00, and 5.00 μM ACEA. Cannabinoid-mediated CB\(_1\) induction was attenuated in 7/111 and 111/111 cells \((n = 16; P < 0.05, \text{Fig. 30})\). That is, the E\(_{\text{max}}\) was reduced in 7/111 and 111/111 cells relative to 7/7 cells while the E\(_{50}\) was
Figure 25. Induction of CB₁ mRNA expression was unique to CB₁ agonism. A) 7/7, 7/111, and 111/111 cells express CB₂ and D₂ receptors (RT-PCR). B) 1 μM ACEA treatment elevated CB₁ mRNA levels in 7/7 cells while 1 μM apo-morphine (D₁/D₂ antagonist), quinpirole (D₂ agonist), HU-308 (CB₂ agonist), O-2050 (CB₁ antagonist), and AM-630 (CB₂ antagonist) did not change CB₁ mRNA abundance. Significance was determined via one-way ANOVA followed by post-hoc Tukey’s test. * P < 0.05, n = 12.
CB₁ mRNA levels were lower following type 1 HDAC inhibition (1 μM TSA) in 7/7 and 7/111 cells. CB₁ mRNA abundance was quantified in cells treated with 100 nM NaB or 1 μM TSA or vehicle control. A) Vehicle (DMSO) treatment did not change CB₁ mRNA level. B) 100 nM NaB did not change CB₁ mRNA level. C) 1 μM TSA treatment was associated with lower CB₁ mRNA levels in 7/7 and 7/111 cells compared to vehicle treatment. Significance was determined via two-way ANOVA for genotype and treatment followed by post-hoc Tukey’s test. ** P < 0.05 within genotype between treatments, * P < 0.05 relative to 7/7 within treatment group, ~ P < 0.05 relative to 7/111 within treatment group, n = 12.
Figure 27. Direct CB₁ receptor agonism induced CB₁ mRNA levels in 7/7 cells. CB₁ mRNA abundance was quantified in 7/7 cells treated with 0.01 – 5.00 μM ACEA, mAEA, or AEA with or without 1 or 2 μM AM-281 or O-2050. A) ACEA, mAEA, and AEA treatment induced CB₁ mRNA levels in a dose-dependent manner in 7/7 cells. O-2050 antagonized the effect of ACEA (B) and mAEA (C) in an antagonist dose-dependent manner. D) AM-281 antagonized the effect of ACEA, but not in an antagonist dose-dependent manner. Significance was determined via one-way ANOVA followed by post-hoc Tukey’s test. *P < 0.05 relative to 2 μM antagonist dose, ~P < 0.05 relative to 1 μM antagonist dose, n = 16.
Figure 28. The maximum effect of direct CB₁ receptor agonism on CB₁ mRNA level occurred 18 h after drug exposure. CB₁ mRNA abundance was quantified in 7/7 cells treated with 1.00 μM ACEA for 0.5, 1, 3, 6, 12, 18, 24, and 30 h. ACEA treatment was associated with higher-than-basal CB₁ mRNA levels by 0.5 h, with a maximum at 18 h, drug treatment. Significance was determined via one-way ANOVA for exposure time followed by post-hoc Tukey’s test. * P < 0.05 relative to 0 h vehicle treatment, ~ P < 0.05 relative to 0.5 h ACEA treatment, n = 12.
Figure 29. O-2050 competitively antagonized CB₁ receptor agonist-mediated CB₁ mRNA induction in 7/7 cells. A Schild regression was used to demonstrate O-2050, and not AM-281, acts as a competitive inhibitor of ACEA. On the Schild plot a slope approaching -1 represents competitive antagonism. The pA₂ value for a competitive antagonist is the x-intercept of the line whose slope approaches -1. Here, the pA₂ for O-2050 is 1.3 μM. n = 12.
Figure 30. CB₁ mRNA induction was attenuated in the presence of mHtt. CB₁ mRNA abundance was quantified in cells treated with 0.01 – 5.00 μM ACEA. ACEA treatment induced CB₁ mRNA levels in a dose-dependent manner in all cells but Eₘₐₓ was lower in 7/111 and 111/111 cells. Significance was determined via one-way ANOVA followed by post-hoc Tukey’s test. * P < 0.05, n = 16.
not different in each of the three cell lines. Taken together, these two observations demonstrate that mHtt acted as a non-competitive inhibitor of cannabinoid-mediated CB₁ induction. In all cell lines, CB₁ receptors were activated by cannabinoids to induce CB₁ mRNA transcription. In the presence of mHtt, the basal expression of CB₁ was lower and the absolute level of CB₁ receptor-dependent CB₁ mRNA induction, was lower compared to 7/7 cells.

3.8 Activated CB₁ Receptors Signal Through Akt and NF-κB to Induce CB₁ mRNA Transcription.

Our next task was to determine the pathways mediating CB₁ receptor signalling in 7/7, 7/111, and 111/111 cells. CB₁ is classically considered to couple with Gᵢₒ-proteins (reviewed by Hudson et al., 2009; Scotter et al., 2010). Downstream of Gᵢₒ-coupling, ERK2 and PI3K are activated and PKA is inhibited. We chose to measure ERK2 phosphorylation at Tyrosine 204 [pERK2(Y204)], relative to total ERK2, in cells treated with 0.01, 0.10, 0.25, 0.50, 0.75, 1.00, and 5.00 μM ACEA for 18 h. We found that pERK2(Y204) levels increased in an ACEA dose-dependent manner in 7/7 cells (Fig. 31A). The EC₅₀ for this dose-response curve was 0.38 μM, which approaches the EC₅₀ observed for ACEA-dependent CB₁ mRNA induction (0.36 μM). The dose-response relationships between pERK2(Y204) and ACEA concentration were attenuated in 7/111 and 111/111 cells, in a mHtt-dependent manner (n = 16; P < 0.05, Fig. 31A). What was unclear, however, was whether reduced pERK2(Y204) was due solely to reduced CB₁ protein levels or if Htt also directly affected pERK2-mediated signal transduction. Treatment with ACEA induced CB₁ mRNA levels in all cell types (Fig. 30). This induction was approximately 50% lower in the presence of mHtt, but not different in 7/111 cells compared to 111/111 cells (Fig. 30). In contrast, pERK2(Y204) levels were induced in an ACEA dose-dependent manner, yet ERK2 phosphorylation was attenuated by approximately 50% in 7/111 cells and approximately 80% in 111/111 cells (n = 16; P < 0.05; Fig. 31A). If ERK2 mediated
CB₁ induction, then we would not expect to observe an 80% attenuation in CB₁ mRNA induction in 111/111 cells, but this was not the case. Therefore, it did not seem likely that pERK2(Y204) mediated CB₁ mRNA induction downstream of CB₁ receptor activation.

The PI3K/Akt pathway is also downstream of Gᵢₒ-coupled signalling (Scotter et al., 2010). Moreover, evidence suggests that Akt phosphorylation is unchanged, while ERK2 phosphorylation is lower, in the presence of mHtt (Scotter et al., 2010; Gines et al., 2010). We quantified Akt phosphorylation at Serine 473 [pAkt(S473)], relative to total Akt (panAkt), in cells treated with 0.01, 0.10, 0.25, 0.50, 0.75, 1.00, and 5.00 μM ACEA for 18 h. We found that pAkt(S473) levels increased in an ACEA dose-dependent manner in 7/7, 7/111, and 111/111 cells (Fig. 31B). The common EC₅₀ for these dose-response curves was 0.40 μM, which approaches the EC₅₀ observed for ACEA-dependent CB₁ mRNA induction (0.36 μM). The E₉₅ was not different in 7/7, 7/111 and 111/111 cells. From this result, we concluded that 1) mHtt did not alter Akt phosphorylation and 2) downstream effectors of Akt could facilitate CB₁ induction.

One downstream target of pAkt(S473) is IκB kinase (Iκκ). Activated Iκκ phosphorylates and inactivates the inhibitor of kappa B (IκBα), which normally inhibits the translocation of NF-κB to the nucleus. Once Iκκ is activated, inhibition of NF-κB is relieved and NF-κB translocates to the nucleus to affect gene expression (Reijonen et al., 2011). Activated Iκκ phosphorylates IκB, thereby unmasking the nuclear localization signals of the p50/p52 and p65/RelA subunits of NF-κB (Reijonen et al., 2010). We wanted to determine whether cannabinoid treatment led to greater NF-κB-mediated transcription of CB₁ mRNA. Expression of mHtt is associated with decreased p65/RelA-dependent transcription (Reijonen et al., 2010). We also wanted to determine whether mHtt inhibited NF-κB-dependent transcriptional activation in 7/111 and
111/111 cells. To do this, we co-transfected 7/7, 7/111, and 111/111 cells with pCNR1 and an NF-κB reporter plasmid containing 5 tandem repeats of the NF-κB response element driving expression of firefly luciferase (pNF). In addition, 7/7, 7/111, and 111/111 cells were co-transfected with pCNR1 and an estrogen reporter plasmid containing 5 tandem repeat estrogen response element sites (pERE) because cannabinoids have also been shown to signal via ERE-dependent mechanisms (Proto et al., 2011). Transfected cells were untreated, vehicle-treated, 0.01 – 5.00 μM ACEA-treated, 1 μM 17β-estradiol-treated, and 5 ng/mL IL-4-treated for 18 h. 17β-estradiol served as a positive control for ERE induction (Proto et al., 2011) and IL-4 served as a positive control for NF-κB induction (Borner et al., 2007a). CB₁ promoter activity was lower in the presence of mHtt compared to levels observed in 7/7 cells that were untreated, vehicle-treated, and 17β-estradiol-treated (n = 8; P < 0.05; Fig. 32A). Treatment of cells with 1 μM ACEA or 5 ng/mL IL-4 was associated with an approximately 10-fold induction in CB₁ promoter activity and this induction was attenuated in 7/111 and 111/111 cells (n = 8; P < 0.05; Fig. 32A). NF-κB promoter activity was lower in the presence of mHtt than in 7/7 cells that were untreated and vehicle-treated (n = 8; P < 0.05; Fig. 32B). Treatment of cells with 1 μM ACEA or 5 ng/mL IL-4 was associated with an approximately 2- or 5-fold induction, respectively, in NF-κB promoter activity and this induction was attenuated in the presence of mHtt (n = 8; P < 0.05; Fig. 32B). ERE promoter activity was not different among untreated or vehicle-treated 7/7, 7/111, and 111/111 cells (n = 8; P < 0.05; Fig. 32C). Treatment of cells with 1 μM 17β-estradiol was associated with greater ERE promoter activity and this induction was attenuated in the presence of mHtt (n = 8; P < 0.05; Fig. 32C).

ERE promoter activity was induced following treatment with 17β-estradiol, but not ACEA. We had previously shown that CB₁ mRNA levels responded to ACEA in a dose-
dependent manner. We wanted to determine whether CB₁ and NF-κB promoter activity responded to ACEA in a dose-dependent manner. CB₁ promoter activity increased in an ACEA dose-dependent manner and the Eₘₐₓ of the dose-response was attenuated by approximately 50% in 7/111 and 111/111 cells expressing mHtt relative to 7/7 cells (n = 8; P < 0.05; Fig. 33A). The EC₅₀ was approximately 0.64 μM ACEA and not different between 7/7, 7/111 and 111/111 cells. Similarly, NF-κB promoter activity increased in an ACEA dose-dependent manner and the Eₘₐₓ was also attenuated by approximately 50% in 7/111 and 111/111 cells compared to 7/7 cells (n = 8; P < 0.05; Fig. 33B). The EC₅₀ was approximately 0.82 μM ACEA and not different between cell types. Therefore, the response of the transcription factor NF-κB was ACEA dose-dependent and the dose-response relationship resembled that observed for CB₁ promoter activity and mRNA levels in 7/7, 7/111, and 111/111 cells (Figs. 30, 33A,B). Based on this, we believe NF-κB participated in CB₁ receptor-dependent induction of CB₁ promoter activity and NF-κB promoter activity was inhibited in the presence of mHtt.

3.9 Transcriptional Dysregulation in Heterozygous CB₁ Knock-out Mice (CB₁⁺⁻) did not Recapitulate HD Transcriptional Dysregulation.

CB₁ receptor activation is known to effect gene expression via up-regulation of ERK- and Akt-mediated signalling and inhibition of cAMP-dependent signalling (Scotter et al., 2010; Reijonen et al., 2010). Therefore, we sought to determine if decreased CB₁ expression alone affected expression of genes dysregulated in HD. We measured the expression of 12 genes, via in situ hybridization, in 10 week-old heterozygous CB₁ knock-out mice (CB₁⁺⁻; i.e. mice expressing 50% the wild-type level of CB₁). Coronal sections were used for in situ hybridization and the radiographic signals corresponding to mRNA hybridization were measured as OD relative to background (Fig. 34). Of these genes, CB₁ (P < 0.001), PDE1B (P < 0.01), and PGC1α (P < 0.01) mRNA levels were lower in the lateral striatum of CB₁⁺⁻ mice relative to
wild-type ($n = 3$; Fig. 35). Dynamin ($P < 0.001$) and Egr-1 ($P < 0.001$) mRNA levels were greater in the cortex of CB$_1^{-/-}$ mice than the cortex of wild-type mice ($n = 3$; Fig. 35). mRNA levels of the remaining genes, DARPP-32, PDE10A, ppENK, CB$_2$, FAAH, dopamine D$_2$ receptor, and β-actin, were not changed (Fig. 35). Therefore, a 50% decrease in CB$_1$ mRNA level did affect the expression of some, but not all, genes whose expression is altered in HD (Luthi-Carter et al., 2000).
Figure 31. ERK2 phosphorylation [pERK2(Y204)] was attenuated in the presence of mHtt but Akt phosphorylation [pAkt(S473)] was not. pERK2(Y204) relative to total ERK2 and pAkt(S473) relative to total Akt were quantified in 7/7, 7/111, and 111/111 cells treated with 0.01 – 5.00 μM ACEA. A) pERK2(Y204) levels were induced in an ACEA dose-dependent manner but the E_max was attenuated in the presence of mHtt. B) pAkt(S473) levels were also induced in an ACEA dose-dependent manner and the E_max was not different between cell types. Significance was determined via one-way ANOVA within agonist dose followed by post-hoc Tukey’s test. * P < 0.05 relative to 7/7, ~ P < 0.05 relative to 7/111, n = 16.
Figure 32. CB₁ receptor agonism induced CB₁ promoter activity via NF-κB-dependent signalling. 7/7, 7/111 and 111/111 cells were co-transfected with pCNR1, driving Renilla luciferase expression, and pNF or pERE, driving firefly luciferase expression, or empty vector control. A) pCNR1 promoter activity was lower in the presence of mHtt and induced by 1 μM ACEA or 5 ng/mL IL-4, but not 1 μM 17β-estradiol. The induced level of pCNR1 activity was attenuated in the presence of mHtt. B) pNF promoter activity was lower in the presence of mHtt and induced by 1 μM ACEA or 5 ng/mL IL-4, but not 1 μM 17β-estradiol. The induced level of pNF activity was attenuated in the presence of mHtt. C) pERE promoter activity was not different in 7/7, 7/111, or 111/111 cells that were untreated, vehicle-treated, or 1 μM ACEA-treated. pERE promoter activity was induced following 1 μM 17β-estradiol treatment and this higher pERE activity was attenuated in the presence of mHtt. Significance was determined via two-way ANOVA for cell type and treatment followed by *post-hoc* Tukey’s test. **$P < 0.05$ between treatment groups within genotype, *$P < 0.05$ within treatment relative to 7/7, ~$P < 0.05$ within treatment relative to 7/111, $n = 8$. 
Figure 33. CB₁ receptor agonism induced CB₁ and NF-κB promoter activity in a dose-dependent manner. 7/7, 7/111 and 111/111 cells were co-transfected with pCNRI, driving Renilla luciferase expression, and pNF, driving firefly luciferase expression. A) pCNRI promoter activity was induced by ACEA in a dose-dependent manner that was attenuated by mHtt. B) pNF promoter activity was induced by ACEA in a dose-dependent manner that was attenuated by mHtt. Significance was determined via one-way ANOVA within dose followed by post-hoc Tukey’s test. * P < 0.01 within treatment relative to 7/111 and 111/111, n = 8.
Figure 34. PDE1B, Egr-1 and Dynamin mRNA levels were altered in heterozygous CB₁ knock-out mice (CB₁⁺⁻). CB₁⁺⁻ mice expressed 50% less CB₁ mRNA than WT litter-mates. Altered CB₁ levels changed the mRNA abundance of some, but not all, genes dysregulated in HD. These are representative coronal sections derived from WT and CB₁⁺⁻ mice used for *in situ* hybridization. The probes used are indicated to the left.
Figure 35. A 50% decrease in CB₁ mRNA altered gene expression but did not recapitulate HD transcriptional dysregulation. OD measurements were collected using Kodak 3D imaging software. Local background was subtracted from each measurement to correct for background variability. This graph presents the fold-change for mRNA hybridization in CB₁⁺/- relative to WT (CB₁⁺/-/WT). Significance was determined via two-tailed Student’s t-test. * P < 0.01, ** P < 0.001, n =3.
3.10 Cannabinoid Agonism Improved Cell Functionality and Viability

We wanted to determine if 7/111 and 111/111 cells expressing mHtt were phenotypically distinct from 7/7 cells in terms of their general viability, and whether deficits in cellular viability could be reversed following ACEA treatment. We analyzed the proportion of viable 7/7, 7/111, and 111/111 cells using the Cell Viability kit® (Invitrogen) to quantify and visualize esterase activity and membrane permeability in cells that were untreated, vehicle-treated, or treated with 1 μM ACEA. The cell-permeable dye CalAM is taken up by viable cells and hydrolyzed by esterases to produce green fluorescence. EthD-1 is taken up by cells with compromised membranes. When EthD-1 enters cells, it intercalates with DNA and fluoresces red. The proportion of fluorescent cells and the relative intensity of fluorescence were quantified via a plate reader and visualized by fluorescent microscopy, respectively. We found that esterase activity was reduced in 111/111 cells (n = 32; P < 0.05, Fig. 36A). The percentage of cells exhibiting EthD-1 intercalation was greater in the presence of mHtt. EthD-1 intercalation was exacerbated by vehicle treatment (n = 32; P < 0.05, Fig. 36C). Esterase activity was elevated, although not to levels observed in 7/7 cells, by 1 μM ACEA in 111/111 cells, relative to vehicle treatment (n = 32; P < 0.05, Fig. 36B). One micromolar ACEA lowered EthD-1 intercalation, relative to vehicle treatment, to levels similar to untreated cells. However, EthD-1 intercalation was higher in ACEA-treated 7/111 and 111/111 cells than in 7/7 cells (n = 32; P < 0.05, Fig. 36D). These quantified data were visually confirmed by fluorescence microscopy (Fig. 37). ACEA treatment visually elevated CalAM staining and reduced EthD-1 intercalation in 7/7, 7/111, and 111/111 cells, relative to vehicle treatment. From these data we concluded that cannabinoid treatment had a beneficial effect on cell viability in 7/111 and 111/111 cells.
HD progression is associated with cellular energy deficit, as demonstrated in MSNs in mouse models of HD and in 7/111 and 111/111 cells (Trettel et al., 2000; Cui et al., 2006). Specifically, there are deficits in mitochondrial biogenesis, and a reduced ATP/ADP ratio (Gines et al., 2003). We wanted to determine whether cannabinoid treatment could improve cellular ATP levels. We quantified ATP concentration in 7/7, 7/111, and 111/111 cells using the CellTiter-Glo® assay (Promega). This assay is based on the conversion of luciferin to oxyluciferin catalyzed by firefly luciferase and dependent on cellular ATP, which is the limiting reagent necessary for the reaction. We found that ATP concentration was reduced in 7/111 and 111/111 cells relative to 7/7 cells in both untreated and vehicle-treated cells (n = 32; P < 0.05, Fig. 38A). Following 3 or 24 h of treatment with 1 μM ACEA, ATP concentration was higher in all cell types relative to vehicle control (n = 32; P < 0.05, Fig. 38B; 3 h data not shown). ACEA-dependent increases in ATP were attenuated in the presence of mHtt, yet ATP concentration was still greater in cannabinoid-treated 7/111 and 111/111 cells, which suggested improved cellular function following cannabinoid treatment.

Levels of BDNF-2, PGC1α, and DARPP-32 mRNA are, like CB₁, dysregulated early in HD progression (Zuccato et al., 2005; Cui et al., 2006; Gomez et al., 2006). Decreased expression of these genes is thought to contribute to HD pathogenesis via neuronal degeneration and mitochondrial dysfunction (Zuccato et al., 2005; Cui et al., 2006; Gomez et al., 2006). In CB₁⁺/⁻ mice, PGC1α mRNA levels were lower, while DARPP-32 mRNA levels remained unchanged, which suggested that PGC1α levels may have been influenced by CB₁ levels but that DARPP-32 levels were not. Decreased BDNF-2 expression has previously been observed with decreased CB₁ expression (De Chiara et al., 2010). We quantified the levels of these transcripts in cells that were untreated, vehicle-treated or treated with 0.01, 0.10, 0.25, 0.50, 0.75, 1.00, and
5.00 μM ACEA for 18 h. We found that BDNF-2 mRNA levels were reduced by mHtt in untreated and vehicle treated cells \((n = 12; \ P < 0.05, \ Fig. \ 39A)\). ACEA treatment was associated with elevated BDNF-2 mRNA levels in 7/7 cells \((n = 12; \ P < 0.05, \ Fig. \ 40A)\). The \(EC_{50}\) for this dose-response relationship was 0.42 μM. ACEA induced BDNF-2 expression in 111/111 cells as well, but the maximal response was less than observed in 7/7 cells \((n = 12; \ P < 0.05, \ Fig. \ 40A)\). The \(EC_{50}\) for the dose-response relationship in 111/111 cells was 0.38 μM. Only a modest dose-response relationship was observed in 7/111 cells treated with ACEA. Despite this unexpected result, ACEA treatment was associated with a modest induction of BDNF-2 in cells expressing mHtt. It is important to note that the maximal induction, even in 7/111 cells, exceeded BDNF-2 levels measured in untreated 7/7 cells. Therefore, a relative increase of BDNF-2 mRNA abundance to levels observed in 7/7 cells was achieved in 7/111 and 111/111 cells expressing mHtt treated with ACEA.

Next, we measured PGC1α mRNA levels in 7/7, 7/111, and 111/111 cells. PGC1α mRNA levels were reduced in untreated and vehicle-treated 7/111 and 111/111 cells relative to 7/7 cells \((n = 12; \ P < 0.05, \ Fig. \ 39B)\). Additionally, vehicle treatment reduced PGC1α levels in 7/7 cells relative to untreated cells \((n = 12; \ P < 0.05)\). PGC1α mRNA abundance was elevated, in an ACEA dose-dependent manner, in all cell types \(Fig. \ 40B)\). The \(EC_{50}\) values for these dose-response relationships were 0.32, 0.56, and 0.79 μM for 7/7, 7/111, and 111/111 cells, respectively. The \(E_{\text{max}}\) values were 0.39, 0.33, and 0.24 \((\text{PGC1α/β-actin})\) for 7/7, 7/111, and 111/111 cells respectively \(Fig. \ 40B)\). The shallow dose-response relationship between ACEA dose and PGC1α level, as well as the change in \(EC_{50}\) and \(E_{\text{max}}\) for these dose-response relationships in the presence of mHtt, suggested that PGC1α levels may not be induced by the same mechanism as \(CB_1\), or may be downstream of \(CB_1\) induction. In terms of biological
significance, ACEA treatment was associated with an increase in PGC1α mRNA abundance in the presence of mHtt equal to, or greater than, was observed in untreated 7/7 cells.

Finally, we measured DARPP-32 mRNA levels in 7/7, 7/111, and 111/111 cells. DARPP-32 mRNA expression was reduced in untreated and vehicle-treated 7/111 and 111/111 cells relative to 7/7 cells (n = 12; P < 0.05, Fig. 39C). Unlike BDNF-2 and PGC1α, DARPP-32 mRNA levels were not altered by ACEA treatment (n = 12, data not shown). DARPP-32 mRNA levels were unchanged in the striatum of CB$_1^{+/-}$ mice compared to wild-type mice (Fig. 35). The unresponsiveness of DARPP-32 mRNA levels to ACEA and the observation that DARPP-32 mRNA levels were unchanged in CB$_1^{+/-}$ mice suggested that DARPP-32 was not regulated by CB$_1$ receptors. In the context of HD this implies that cannabinoid treatment was capable of restoring the expression of some, but not all, of the subset of genes repressed in the presence of mHtt.
Figure 36. Cell viability was reduced in mHtt-expressing cells and improved following cannabinoid treatment. Cell viability was measured by two methods: esterase activity via CalAM fluorescence and membrane permeability via EthD-1 fluorescence. A) Esterase activity was lower in the presence of mHtt. B) 1 μM ACEA treatment was associated with higher esterase activity in 111/111 cells compared to vehicle control. C) EthD-1 intercalation was higher in the presence of mHtt and augmented by vehicle treatment. D) 1 μM ACEA reduced EthD-1 intercalation relative to vehicle control in all cell types. Significance was determined via two-way ANOVA for cell genotype and treatment followed by post-hoc Tukey’s test. ** $P < 0.05$ between treatments within genotype, * $P < 0.05$ relative to 7/7 within treatment, ~ $P < 0.05$ relative to 7/111 within treatment, $n = 32$. 
Cell viability was visually lower in the presence of mHtt and higher in cells treated with cannabinoids. Cell viability was measured by two methods: esterase activity via CalAM fluorescence and EthD-1 permeability and fluorescence. These representative images depict the effect described and quantified in figure 36.
Figure 38. ATP concentration was lower in the presence of mHtt and higher following cannabinoid treatment. ATP concentration was measured using the CellTiter-Glo® assay. A) ATP concentration was lower in 7/111 and 111/111 cells compared to 7/7 cells. B) 1 μM ACEA treatment was associated with higher ATP concentration in 7/7 and 7/111 cells compared to vehicle control. Significance was determined via two-way ANOVA for cell genotype and treatment followed by post-hoc Tukey’s test. ** P < 0.05 between treatments within genotype, * P < 0.05 relative to 7/7 within treatment, ~ P < 0.05 relative to 7/111 within treatment, n = 32.
Figure 39. BDNF-2, PGC1α, and DARPP-32 mRNA levels were lower in mHtt-expressing 7/111 and 111/111 cells. BDNF-2, PGC1α, and DARPP-32 mRNA abundance was quantified by qRT-PCR and normalized to β-actin mRNA levels. A) BDNF-2 mRNA levels were lower in the presence of mHtt. B) PGC1α mRNA levels were lower in the presence of mHtt and further reduced by vehicle treatment. C) DARPP-32 mRNA levels were lower in the presence of mHtt. Significance was determined via two-way ANOVA for cell genotype and treatment followed by post-hoc Tukey’s test. ** P < 0.05 between treatments within genotype, * P < 0.05 relative to 7/7 within treatment, ~ P < 0.05 relative to 7/111 within treatment, n = 12.
Figure 40. BDNF-2 and PGC1α mRNA levels were increased in an ACEA dose-dependent manner in the presence of mHtt. BDNF-2, and PGC1α mRNA abundance was quantified by qRT-PCR and normalized to β-actin mRNA levels. A) BDNF-2 mRNA levels were increased in an ACEA dose-dependent manner and this effect was attenuated in the presence of mHtt. B) PGC1α mRNA levels were increased in an ACEA dose-dependent manner and this effect was attenuated in the presence of mHtt. Significance was determined via one-way ANOVA for ACEA dose followed by post-hoc Tukey’s test. * $P < 0.05$ relative to 7/7 within treatment, ~ $P < 0.05$ relative to 7/111 within treatment, $n = 12$. 
4.1 Hypotheses of this Research

We hypothesized that the ECS was dysregulated during HD progression, that treatment of striatal neurons with cannabinoids would induce expression of CB₁, and that, in cells expressing mHtt, increased CB₁ levels would be associated with improved cellular function.

4.2 The Endocannabinoid System was Dysregulated During HD Progression

Prior research concerning repression of CB₁ expression during HD pathogenesis has focused on mRNA and protein abundance in the whole brain (Luthi-Carter et al., 2000), GABA-ergic MSNs of the lateral striatum (Denovan-Wright & Robertson, 2000; Blazquez et al., 2011; Chiodi et al., 2012), and in cell culture models of HD (Scotter et al., 2010; Blazquez et al., 2011). Expression of mHtt is associated with an approximately 50% decrease in CB₁ mRNA expression prior to, or early in, HD symptom onset in all human samples, animal and cell culture models tested to date (reviewed in Pazos et al., 2008). Here, we found that CB₁ mRNA levels declined, as part of the normal aging process, in all regions of the striatum of wild-type mice. CB₁ mRNA levels were repressed early in HD progression in HD mice relative to age-matched wild-type mice in all regions of the striatum and in the cortex. Therefore, striatal CB₁ levels declined with age and this decline was exacerbated in the presence of mHtt. Steady-state CB₁ mRNA levels have been shown to decline in the dorso-lateral prefrontal cortex of humans and non-human primates (Eggan et al., 2010), the visual cortex of humans (Vitalis et al., 2008), and the hippocampus and lateral striatum of mice (NCBI, 2011) as part of the aging process. Neurodegeneration during HD is most pronounced in striatal MSNs, but cortical atrophy also occurs at late stages of HD progression (Vonsattel et al., 1985). The mHtt-dependent repression
of CB₁ below wild-type levels in three regions of the striatum and cortical neurons observed here demonstrated that mHtt dysregulated CB₁ expression in two regions of the brain particularly sensitive to mHtt. Because CB₁ levels were decreased early in HD progression in both R6/1 and R6/2 HD mouse models this change was likely a direct consequence of mHtt expression and not a compensatory response to other cellular changes. The early decrease in CB₁ abundance may contribute to other pathogenic changes observed to HD pathogenesis. Mievis et al. (2011) found that HD94 tetracycline-inducible HD mice that lacked a full complement of CB₁ (Htt⁺/⁺/mHtt x CB₁⁺/-) exhibited reduced motor coordination and greater striatal atrophy than HD/CB₁⁺/+ mice. We concluded that CB₁ mRNA expression was repressed in the presence of mHtt in a tissue-specific manner in two regions of the brain – the cortex and striatum.

FAAH is the major catabolic enzyme of the ECS. Blazquez et al. (2011) found that FAAH mRNA and protein levels are higher in the lateral striatum of late-stage R6/1 HD mice compared to age-matched wild-type controls. Further, FAAH protein levels are higher in the lateral striatum of grade 3 and 4 HD patients compared to age-matched, healthy controls (Blazquez et al., 2011). Thus, FAAH expression may change late in the striatum during HD, yet FAAH is more abundant in the cortex than striatum (NCBI, 2011) and cortical neurons expressing FAAH regulate cannabinoid tone within the striatum (Fig. 1). We found that FAAH mRNA levels were higher in late-stage R6/1 mice and at all stages of development in R6/2 mice compared to age-matched wild-type controls. This observation provides evidence for altered endocannabinoid tone during HD progression. Indeed, levels of AEA are lower in the cortex, hippocampus, and striatum of 12 week-old (early symptomatic) R6/1 mice compared to wild-type littermates (Dowie et al., 2009). If cannabinoid levels regulate CB₁ expression, these changes may also alter CB₁ levels in the presence of mHtt.
CB2 mRNA levels are elevated in multiple sclerosis, ischemic stroke, Parkinson’s disease, and Alzheimer’s disease (Pini et al., 2012). We hypothesized that CB2 mRNA levels would be higher in late-stage HD mice than age-matched wild-type littermates because striatal inflammation would induce CB2 expression and that was what we observed in R6/2 mice. Induction of CB2 during late-stage HD pathogenesis may be due to inflammation and altered endocannabinoid tone. Altered CB2 expression was probably not a direct consequence of mHtt because we observed this change late in HD progression in R6/2 mice. It remains unclear whether CB2 induction was specific to glia or neurons.

4.3 CB1 mRNA Abundance and Distribution were Developmental Stage-specific

We had shown that the ECS was dysregulated during HD pathogenesis, but did mHtt alter CB1 expression early in development? We found that CB1 mRNA abundance and distribution were similar in wild-type and R6/2 mice at P1. At P1, CB1 mRNA levels were highest in the cortex and inferior cerebellum. In dividing STHdh cells, which exist in an embryonic, striatal precursor state, CB1 mRNA levels were low and expression was not altered by mHtt. In contrast, wild-type, ‘adult’ striatal neurons expressed CB1 at higher levels than other regions of the brain and CB1 expression was higher in post-mitotic STHdh cells that model adult MSNs compared to dividing STHdh cells. The observations we made in P1 and adult mice, and dividing and post-mitotic STHdh cells, prompted us to conclude that CB1 levels are increased in the striatum as MSNs mature. It is in mature, adult MSNs that specific factors facilitate a relatively high steady-state level of CB1 expression. Further, it is this high level of CB1 expression that is repressed by mHtt. CB1 mRNA abundance has been shown to fluctuate in the human visual cortex such that levels increase and reach a plateau at 1 year, then increase further during puberty, and subsequently decline over the lifespan (Vitalis et al., 2008). Similar
fluctuations in CB₁ expression during development have been observed in the *Maccaca mulatta* dorso-lateral prefrontal cortex (Eggan *et al.*, 2010). CB₁ levels are also high in rat white matter from embryonic day 14 until P1, after which CB₁ is undetectable (Eggan *et al.*, 2010). These findings, as well as our own, demonstrate that CB₁ expression is tissue- and developmental stage-specific. Going forward, we chose to focus on post-mitotic 7/7, 7/111, and 111/111 cells that modelled adult MSNs with high CB₁ expression that was repressed in the presence of mHtt.

4.4 Cannabinoid Treatment Induced CB₁ Expression in the Presence of mHtt

4.4.1 Cannabinoid Treatment was Associated with Elevated CB₁ Promoter Activity, mRNA and Protein Levels

We found that treatment of post-mitotic 7/7, 7/111, and 111/111 cells with direct CB₁ agonists (ACEA, mAEA, AEA) or indirect CB₁ agonists (URB-597) induced CB₁ promoter activity and mRNA expression and elevated CB₁ receptor levels. Cannabinoid treatment has been shown to induce CB₁ mRNA expression in primary hepatocytes (Mukhopadhyay *et al.*, 2008), Jurkat and primary T cells (Borner *et al.*, 2007a), and colorectal carcinoma cells (Proto *et al.*, 2011), but this is the first observation of cannabinoid-dependent CB₁ mRNA induction in neuronal cells. ACEA is a potent and selective CB₁ receptor agonist (Pertwee *et al.*, 2010) that was chosen to ensure that a response would be observed if indeed cannabinoid agonism could affect CB₁ expression. URB-597, in contrast, is an indirect cannabinoid agonist that inhibits FAAH and thus increases cannabinoid tone (Pertwee *et al.*, 1999; Pertwee *et al.*, 2010). The observation that URB-597 induced CB₁ expression suggested this response was relatively sensitive to fluctuations in cannabinoid tone. This result is promising because treatment with potent CB₁ agonists is associated with reduced seizure threshold and hypothermia in animal models of HD (Dowie *et al.*, 2009), while treatment with endogenous or indirect cannabinoid
agonists is associated with improved cell viability and improved motor coordination in models of HD (Scotter et al., 2010; Dowie et al., 2009).

The magnitude of cannabinoid-mediated CB₁ induction was attenuated in the presence of mHtt. However, the fold-induction of response was not different in 7/7, 7/111, or 111/111 cells, which suggested that mHtt non-competitively inhibited cannabinoid-dependent induction of CB₁ expression. mHtt is known to inhibit transcription of genes by interacting with, and squelching the activity of, many gene-specific co-activators of transcription (Cui et al., 2006). mHtt has been shown to repress CB₁ at the level of transcription because the number of primary CB₁ mRNA transcripts is reduced in the presence of mHtt (McCaw et al., 2004). Based on this evidence we hypothesized that, in 7/111 and 111/111 cells, mHtt repressed CB₁ promoter activity not CB₁ receptor activity, thereby non-competitively inhibiting cannabinoid-mediated CB₁ mRNA induction.

We also found that ACEA treatment elevated CB₁ protein abundance in 7/7, 7/111, and 111/111 cells and the magnitude of this effect was attenuated in the presence of mHtt. Cannabinoid treatment is associated with a modest increase (3 – 5-fold) in CB₁ protein levels in cultured hepatocytes (Mukhopadhyay et al., 2008). Here, CB₁ mRNA levels were induced 4 – 5-fold, and protein levels were induced approximately 2-fold, following cannabinoid treatment. We concluded from this that cannabinoid-mediated CB₁ mRNA induction translated to an increase in CB₁ protein.

4.4.2 CB₁ Receptor Localization was Altered in the Presence of mHtt

While examining CB₁ protein abundance following cannabinoid treatment we asked whether cannabinoid treatment altered the localization and trafficking of CB₁ receptors. Using an in- and on-cell western approach, we found that CB₁ receptors were more abundant on the
plasma membrane of 7/111 and 111/111 cells than 7/7 cells. This may have been because the total pool of receptors was lower and therefore the relative fraction of receptors at the plasma membrane appeared higher in the presence of mHtt. Alternatively, CB$_1$ receptor trafficking and internalization may depend on wild-type Htt protein, which may facilitate receptor trafficking in dendrites and axons (Marcora et al., 2010), and was therefore impaired in mHtt-expressing cells in a mHtt dose-dependent manner (Zuccato et al., 2008). We explored this observation further using confocal microscopy and found that CB$_1$ receptors were internalized in response to ACEA and trafficked to the plasma membrane in response to O-2050 (CB$_1$ antagonist) in 7/7, 7/111, and 111/111 cells. Therefore, CB$_1$ receptor trafficking to and from the plasma membrane was not impaired in mHtt-expressing cells. We also observed CB$_1$ receptors within the nucleus of vehicle- and ACEA-treated 7/7 cells and ACEA-treated 7/111 cells. Our interpretation of these data was that CB$_1$ receptors were normally present in the nucleus and could be trafficked there in 7/111 cells, but not 111/111 cells, following ACEA treatment. CB$_1$ receptors have been observed in the nucleus and nuclear membrane of astrocytes and are actively trafficked along actin filaments following cannabinoid treatment (Osborne et al., 2009). Given the lipophilic nature of cannabinoid ligands, the nuclear localization of CB$_1$ may play an important regulatory role in the signal transduction mediated by these receptors (Osborne et al., 2009). In 7/111 and 111/111 cells this trafficking was impaired, which may have resulted from lost wild-type function (Zucatto et al., 2008; Marcora et al., 2010) because CB$_1$ receptors were still localized to the nucleus following cannabinoid treatment in heterozygous 7/111 cells. Importantly, these data affirmed our earlier findings that cannabinoids increased CB$_1$ levels and the magnitude of this increase was lower in the presence of mHtt.
4.4.3 Cannabinoid Treatment Induced CB₁ Expression Via Functional CB₁ Receptors

We wanted to determine how cannabinoid agonists induced CB₁ mRNA expression in 7/7, 7/111, and 111/111 cells. We found that CB₁ mRNA abundance was induced in a cannabinoid agonist dose-dependent manner in 7/7 cells treated with ACEA, mAEA, or AEA. The EC₅₀ and Eₘₐₓ values were not different for the dose-response curves observed for each drug. We also observed that simultaneous treatment with the cannabinoid antagonist O-2050 resulted in an antagonist dose-dependent shift of the dose-response curve to the right. ACEA and mAEA are potent, CB₁-selective, synthetic cannabinoids (Pertwee et al., 2010), while AEA is a less potent, less selective, endogenous cannabinoid (reviewed in Howlett et al., 1999). The observation that the responses to the three agonists were not different affirmed our hypothesis that cannabinoid-mediated CB₁ mRNA induction was relatively sensitive to fluctuating endocannabinoid tone. Further, the antagonist-dependent shift of the dose-response curve demonstrated the cannabinoid-mediated CB₁ mRNA induction required the activation of functional CB₁ receptors. Mukhopadhyay et al. (2008) demonstrated that CB₁ mRNA induction was mediated via CB₁ receptors in mouse primary hepatocytes because induction was blocked following treatment with the CB₁-selective inverse agonist AM-281. Similarly, Proto et al. (2011) demonstrated cannabinoid-dependent CB₁ mRNA induction occurs through activated CB₁ by blocking these receptors with SR141716 (rimonabant). In contrast, Borner et al. (2007a) demonstrated that cannabinoids mediate induction of CB₁ via CB₂ receptors, which are activated by JWH-018 and inhibited by AM-630. Here, we demonstrated that CB₁, not CB₂, receptor activation induced CB₁ mRNA expression. To our knowledge, this is the first dose-dependent pharmacological characterization of this phenomenon.
We went on to demonstrate that mHtt non-competitively inhibited cannabinoid-mediated CB₁ mRNA induction because the EC₅₀ of the dose-response curve was not different in 7/7, 7/111, and 111/111 cells and the Eₘₐₓ was reduced by approximately 50% in 7/111 and 111/111 cells. mHtt dysregulates transcription at many genes via interactions with co-activators of transcription (Gafni & Ellerby, 2002). Eukaryotic gene expression is regulated in a combinatorial manner that is dependent upon the activity and localization of multiple proteins. The probability that mHtt represses transcription of a gene depends on the number of mHtt-interacting proteins that regulate that gene and their localization to, or away from, that gene’s promoter (Hogel, 2011). Here, steady-state CB₁ mRNA levels were repressed in the presence of mHtt and this repression remained in cells treated with cannabinoid agonists. The maximal cannabinoid-mediated induction of CB₁ expression may have been lower in mHtt-expressing cells because the steady-state level of expression was repressed while the inducibility (i.e. fold-induction) was not affected.

We also examined the temporal nature of cannabinoid-mediated CB₁ induction and found that CB₁ mRNA abundance rose within 30 min of cannabinoid treatment, and continued to rise until 18 h post-treatment, after which CB₁ mRNA levels began to decline. The half-life of ACEA in cell culture is approximately 18 h (Pertwee et al., 1999). Thus, we propose that ACEA treatment produced a rapid increase in CB₁ expression, new CB₁ receptors were synthesized, and these new CB₁ receptors were activated by remaining ACEA to further increase CB₁ expression. Based on the reported half-life of 18 h for ACEA (Pertwee et al., 1999), ACEA concentration would have decreased by 50% at 18 h, which was the time that induction of CB₁ expression began to wane. During the period of time that we monitored CB₁ mRNA expression, our data do not indicate that negative feed-back or receptor desensitization, resulting in a decreased response
to ACEA, occurred. If cannabinoid tone regulates CB₁ level \textit{in vivo}, then the response of CB₁ levels to acute or chronic treatments may be highly dependent upon the potency and half-life of the cannabinoid and the frequency of treatment (Pacheco \textit{et al}., 2009; Dowie \textit{et al}., 2009).

\subsection*{4.4.4 CB₁ Promoter Activity was Induced by Akt-dependent Activation of NF-κB}

We found that cannabinoid treatment produced a dose-dependent increase in pERK2(Y204) in 7/7 cells but this response was attenuated in the presence of mHtt. Cannabinoid treatment also produced a dose-dependent increase in pAkt(S473) and this response was not changed in the presence of mHtt. ERK1/2-mediated signal transduction is inhibited in PC12 cells expressing mHtt and in YAC128 HD mice (Dowie \textit{et al}., 2009; Marcora \textit{et al}., 2010). Akt-mediated signal transduction, however, is unaffected by mHtt (Dowie \textit{et al}., 2009). The cannabinoid-dose-pERK2(Y204)-response curves and cannabinoid-dose CB₁ mRNA-response curves did not resemble each other (Fig. 30 & 31). pERK(Y204) induction was attenuated in cells expressing one copy of mHtt (7/111) and further attenuated in cells expressing two copies of mHtt (111/111), whereas CB₁ mRNA induction by cannabinoids was attenuated to the same extent in 7/111 and 111/111 cells. If pERK2(Y204) were upstream of CB₁ mRNA expression, than we would not expect CB₁ mRNA expression to be induced to ~50% of wild-type levels in 111/111 cells. Akt-mediated signal transduction, however, is unaffected by mHtt (Dowie \textit{et al}., 2009). We concluded that activated CB₁ receptors mediated CB₁ mRNA induction \textit{via} Akt and that downstream effectors of Akt were inhibited by mHtt.

Activated Akt phosphorylates many proteins that regulate transcription. Borner \textit{et al}.
\cite{2007a} demonstrated that cannabinoid-dependent CB₁ induction required binding of NF-κB to the CB₁ promoter. Other authors have demonstrated cannabinoid-mediated CB₁ mRNA induction depends upon RARα/γ or the estrogen receptor (Mukhopadhyay \textit{et al}., 2008; Proto \textit{et
al., 2011). Of these candidates, only NF-κB is activated downstream of Akt and only NF-κB-mediated transcription has been shown to be inhibited by mHtt (Marcora et al., 2010; Reijonen et al., 2010; Ghose et al., 2011). Therefore, we examined NF-κB-mediated promoter activation using an NF-κB promoter-firefly luciferase reporter and found that activity of this promoter increased in an ACEA dose-dependent manner and the response was inhibited by approximately 50% in the presence of mHtt. Three theories currently exist to explain how mHtt inhibits NF-κB activity. First, wild-type Htt may normally facilitate the trafficking of NF-κB from the dendrites to the nucleus to activate transcription (Marcora et al., 2010). Second, mHtt expression is associated with elevated calpain activity and calpain enzymes decrease NF-κB p65 protein abundance (Reijonen et al., 2010). Third, the expression of several microRNAs is elevated in the presence of mHtt and these microRNAs suppress expression of the RelA subunit of NF-κB (Ghose et al., 2011). Based on our data, we were unable to determine whether mHtt attenuated the NF-κB-mediated increase in promoter activity via transcriptional dysregulation of NF-κB genes or via decreased activity of the NF-κB protein. Given that transcriptional dysregulation occurs early in HD pathogenesis, CB₁ is one of the genes that is dysregulated early in HD, and NF-κB is a regulator of CB₁, the attenuated NF-κB response we observed may have resulted from mHtt-mediated repression of NF-κB genes. In summary, we observed that cannabinoids activated CB₁ receptors, which stimulated Akt phosphorylation, leading to NF-κB-mediated induction of CB₁ promoter activity and mRNA expression and the translation of CB₁ mRNA to produce new CB₁ receptors (Fig. 41).

4.5 Cannabinoid Treatment Improved Cellular Function

We had shown that cannabinoids could stimulate expression of their cognate receptors. But, if this stimulation conferred no functional benefit to the cells expressing mHtt, then this

121
Figure 41. Cannabinoid-mediated induction of CB₁ receptor expression in the presence of mHtt. We found that cannabinoids, such as ACEA, mAEA, and AEA, activated CB₁ receptors leading to the phosphorylation of Akt and activation of NF-κB-mediated transcription. NF-κB induced CB₁ promoter activity. Increased CB₁ promoter activity lead to elevated CB₁ mRNA and protein abundance. Elevated CB₁ levels may augment inhibition of Ca²⁺-dependent neurotransmitter release. In the presence of mHtt NF-κB-mediated activation of the promoter activity was reduced by approximately 50%.
observation would have limited utility for HD research. CB₁ receptors are considered neuroprotective because they enhance expression of pro-survival genes, inhibit Ca²⁺-dependent neurotransmitter release, and enhance synaptic plasticity (Fernandez-Ruiz et al., 2004). Moreover, cannabinoids display cannabinoid receptor-independent antioxidant properties (Pertwee et al., 1999). We hypothesized that cannabinoid treatment would improve general cellular viability in the presence of mHtt. Indeed, treatment with 1 μM ACEA increased esterase activity, and decreased membrane permeability. One micromolar ACEA treatment was also associated with elevated ATP levels, which are known to be decreased in the presence of mHtt (Trettel et al., 2000; Cui et al., 2006). It is unknown whether these effects were CB₁-dependent or –independent. CB₁ receptor activation could have induced pro-survival signalling to yield improved cellular viability (Fernandez-Ruiz et al., 2004). Alternatively, ACEA may have acted as an antioxidant and improved mitochondrial activity by absorbing excess reactive oxygen species or, as a lipid, altered the plasma membrane to alter membrane permeability (Pertwee et al., 1999).

We also found that treatment of cells with 1 μM ACEA restored expression of BDNF-2 and PGC1α, but not DARPP-32, in a cannabinoid dose-dependent manner. In accordance with this observation, PGC1α mRNA levels were lower in CB₁⁺/− mice than wild-type mice, yet DARPP-32 mRNA levels were unchanged. Based on these data we concluded that CB₁-mediated signal transduction regulates the expression of a subset of genes, including PGC1α and BDNF-2 and excluding DARPP-32. PGC1α and BDNF-2 mRNA levels were probably not induced via the same mechanism as CB₁ as the form of these dose-response curves does not resemble the responses observed for CB₁. Overall, cannabinoid treatment alters the expression of a subset of genes. Similarly, mHtt alters the expression of a subset of genes (Luthi-Carter et al., 2000).
Based on our observations we concluded that certain factors that are activated by CB₁-mediated signaling are also inhibited in the presence of mHtt, which yields an overlapping regulatory region in which CB₁, BDNF-2, and PGC1α co-exist (Luthi-Carter et al., 2000; Gafni & Ellerby, 2002; Pazos et al., 2008). The crux of these observations is that cannabinoid treatment was associated with normalized expression of two genes that are repressed early in HD pathogenesis.

### 4.6 Elevated CB₁ Levels Could Affect GPCR Signaling and Pharmacology

Cannabinoids induce expression of their cognate receptors in a cell culture model of ‘adult’ striatal neurons. Altered endocannabinoid tone could affect CB₁ receptor expression. CB₁ receptors are known to co-localize and dimerize with orexin, μ- and δ-opioid, and dopamine D₂ short receptors in the mammalian brain (Uriguen et al., 2009; Miller & Devi, 2011; Navarro et al., 2009; Bortolato et al., 2010). Thus, CB₁ abundance and trafficking could alter the localization and signaling of several other GPCRs depending on the tissue- and cell-specific importance of CB₁ receptors. If cannabinoid treatment can increase CB₁ expression in vivo, then cannabinoids may alter their own receptor pharmacology as well the dopaminergic and opiate-mediated signal transduction. In fact, injection of AEA into the mouse median forebrain elevates dopamine concentration and dopamine D₂ receptor binding (Khoury et al., 2012). The effect of cannabinoid treatment on the ECS may also be developmental stage-specific because expression of CB₁ fluctuates during developmental (Eggan et al., 2010). Cannabinoid treatment, or cannabis abuse, may be particularly potent during adolescence because CB₁ mRNA and protein levels peak in several regions of the brain during this stage (Eggan et al., 2010; Vitalis et al., 2008).
4.7 Cannabinoid-mediated Induction of CB₁ Receptors may Negatively Feedback onto Neurotransmitter Release

Elevated CB₁ receptor expression as a response to cannabinoids seems to represent a positive feedback loop, yet few biological systems operate through positive feedback. The role of acutely activated CB₁ receptors in the central nervous system is the inhibition of Ca²⁺-dependent neurotransmitter release (Fitzgerald et al., 2012). Therefore, a biological system whereby cannabinoids induce expression of their cognate receptors may represent a form of negative feedback on the release of neurotransmitter from the cell. Viewed from this context, elevated CB₁ receptor levels would enhance hypoactivity and analgesia, which are two commonly observed effects of cannabinoid treatment (Mallet et al., 2008).

4.8 Cannabinoid-mediated Induction of CB₁ may Hold Therapeutic Benefit for HD

Cannabinoid treatment elevated CB₁ receptor abundance in the presence of mHtt. Although CB₁ induction was attenuated by approximately 50% in 7/111 and 111/111 cells, CB₁ mRNA levels exceeded those observed in untreated wild-type 7/7 cells for all cannabinoid-treated cells. An important point is that this induction was mediated by NF-κB, which is an important factor in the inflammatory response (Borner et al., 2007b). CB₁ receptor activation may trigger certain components of the inflammatory response that may be of benefit and detriment depending on the context. Furthermore, cannabinoid treatment improved cellular function and viability. Therefore, although the toxic factor mediating HD pathogenesis, mHtt, was not altered by cannabinoid treatment, the function and viability of 7/111 and 111/111 cells were improved. CB₁ mRNA levels decline by approximately 50% early in HD pathogenesis in human patients and all animal models of HD tested to date (Denovan-Wright & Robertson, 2000; Pazos et al., 2008), and decreased CB₁ levels contribute to HD pathogenesis (Blazquez et al., 2011; Mievis et al., 2011).
Our data provide strong evidence for the utility of cannabinoids as a therapeutic treatment for HD because CB₁ receptor activation may ameliorate transcriptional dysregulation, decrease excitotoxicity, and improve motor coordination and synaptic plasticity (Fernandez-Ruiz et al., 2004; Pazos et al., 2008). Further, cannabinoids represent a pharmacologically tractable means of treatment for HD that can be administered orally, nasally, or by inhalation (El Khoury et al., 2012); whereas other putative therapeutics for HD, such as gangliosides (Di Pardo et al., 2012) and kinase inhibitors (Atwal et al., 2011) may be limited by their route of administration, bioavailability, and specificity. Other authors have explored cannabinoids as a therapeutic treatment for HD. Treatment of PC12 cells expressing mHtt with direct and indirect cannabinoid agonists improves cell survival (Scotter et al., 2010). Treatment of mice injected with quinolinic acid or 3-nitropropionic acid (models of HD striatal lesions) with cannabinoid agonists reduces striatal atrophy (Lastres-Becker et al., 2003; Lastres-Becker et al., 2002; Pintor et al., 2006). Short-term (2 week) treatment of R6/2 HD mice with THC is associated with decreased striatal atrophy, improved rotarod performance, and increased lifespan (Blazquez et al., 2011). However, chronic (10 week) treatment of R6/2 HD mice with THC lowers the threshold to seizure and does not alter striatal atrophy while AEA or inhibitors of FAAH did not alter seizure threshold or HD progression (Dowie et al., 2009). Our study is the first to our knowledge to demonstrate a cannabinoid-mediated induction of CB₁ receptor expression in the presence of mHtt. In light of this observation, the therapeutic benefit of cannabinoids in HD may depend upon the specific cannabinoid used, the dose and frequency of use.

4.9 Conclusions and Future Research

We observed that several components of the ECS, CB₁, CB₂, and FAAH, were dysregulated during HD pathogenesis. We found that treatment of models of adult striatal neurons with
cannabinoids induced expression of CB₁ in a CB₁ receptor-, Akt-, and NF-κB-dependent manner in the presence of mHtt and mHtt non-competitively inhibited this induction. To our knowledge, this is the first demonstration of cannabinoid-mediated CB₁ receptor induction in a neuronal cell model (Borner et al., 2007a, Mukhopadhyay et al., 2008; Proto et al., 2011). This research demonstrates that the pharmacology and expression of GPCRs can be altered by their cognate ligands. In HD therefore, the malleability of CB₁ expression is restricted by the presence of mHtt, but not so restricted that CB₁ expression could not be normalized by cannabinoid treatment. *In vivo*, cannabinoid-mediated induction of cannabinoid receptors may depend on the type of exposure to and potency of the ligand used. We propose that CB₁ agonists of limited potency (Dowie et al., 2009), indirect agonists (Kim & Alger, 2010), or allosteric modulators of CB₁ (Ahn et al., 2012) hold the most therapeutic potential for the treatment of HD because they appear to promote the desirable affects of cannabinoid treatment, such as improved motor control and reduced striatal atrophy, with fewer detrimental repercussions. The biological significance of our observations is that induction of CB₁ expression by cannabinoids may improve neuronal function in the population of neurons most severely affected by mHtt.

Our future research will explore three major facets of cannabinoid-mediated CB₁ induction. First, we will determine whether cannabinoid treatment affects other components of the ECS, such as CB₂ and FAAH expression, using the STHdh cell culture model of HD. Second, we will assess the effect of elevated CB₁ receptor levels on Ca^{2+}-dependent neurotransmitter release in STHdh cells. Finally, we will treat HD mice with cannabinoids, measure expression of several components of the ECS, and evaluate the progression of HD in animals treated with cannabinoids or untreated. Our hypothesis is that cannabinoid treatment will induce the
expression of CB₁ in HD mice and that the magnitude of response to cannabinoid will be dose-, drug-, and developmental stage-specific.
REFERENCES


ExPASYy (2012) [http://expasy.org/proteomics/protein_characterisation_and_function]


136


Schagat et al. (2007)


*Handb Clin Neurol* **100**: 83 – 100.


